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Abstract : 
The chicken is a well-established model for amniote (including human) skeletal muscle formation 
because the developmental anatomy of chicken skeletal muscle matches that of mammals. The 
accessibility of the chicken in the egg as well as the sequencing of its genome and novel molecular 
techniques have raised the profile of this model. Over the years, a number of regulatory and 
marker genes have been identified that are suited to monitor the progress of skeletal myogenesis 
both in wildtype and in experimental embryos. However, in the various studies, differing markers 
at different stages of development have been used. Moreover, contradictory results on the 
hierarchy of regulatory factors are now emerging, and clearly, factors need to be able to 
cooperate. Thus, a reference paper describing in detail and side-by-side the time course of marker 
gene expression during avian myogenesis is needed. We comparatively analysed onset and 
expression patterns of the key markers for the chicken immature paraxial mesoderm, for muscle-
competent cells, for cells committed to myogenesis and for cells entering terminal differentiation. 
We performed this analysis from stages when the first paraxial mesoderm is being laid down to 
the stage when mesoderm formation comes to a conclusion. Our data show that, although the 
sequence of marker gene expression is the same at the various stages of development, the timing 
of the expression onset is quite different. Moreover, marker gene expression in myogenic cells 
being deployed from the dorsomedial and ventrolateral lips of the dermomyotome is different 
from those being deployed from the rostrocaudal lips, suggesting different molecular programs. 
Furthermore, expression of Myosin Heavy Chain genes is overlapping but different along the 
length of a myotube. Finally, Mef2c is the most likely partner of Mrf proteins, and, in contrast to 
the mouse and more alike frog and zebrafish fish, chicken Mrf4 is co-expressed with MyoG as cells 
enter terminal differentiation.  
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The extraordinary capacity of regeneration exists in just certain species and tissue types. In 
vertebrates, the cells that regenerate tissues are called stem cells. 
During adulthood, damaged muscle tissue regenerates through Satellite stem cells that re-enter 
the cell cycle from a quiescent state, giving rise to new muscle tissue. During development, newly 
forming organisms build tissues through proliferating stem cells that renew the stem cell pool 
whilst generating myogenic stem cells which will eventually differentiate into muscle cells. For 
many years the Myogenic Regulatory Factors (Mrf) genes have been considered to be the main 
genes driving this proliferation in adult and fetal stages.  
Mrf genes have been shown to be capable of inducing non-myogenic cells to enter the myogenic 
lineage in vitro, but their role and capabilities in vivo have been less well characterised.    
Here we show, using the developing chicken model, that Mrf genes and related genes are not 
capable of prematurely upregulating terminal muscle differentiation before HH20. MyoD and 
other combinations of gene misexpression were however shown to be capable of inducing Myosin 
upregulation between HH20 and HH24 indicating the existence of a time-frame dependent 
protection of premature development. These results indicate that the Mrf genes have a reduced 
proficiency for inducing differentiation in vivo compared with in vitro likely due to the presence of 
currently unidentified additional factors. 
Our results demonstrate that the current understanding of the signals and cues of muscle stem 
cell differentiation are still insufficient to exploit the regenerative capabilities of muscle tissues 
towards regenerative therapies. The possible additional factors required for muscle stem cell 
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1.1 Regeneration of organs and body parts: the challenge for regenerative medicine 
The regeneration of organs is one of the most important aspect of the medical research. The 
capability of the body to regenerate new cells and substitute damaged cells is due to the presence 
of stem cells. Every organism has its own way to regenerate damaged cells. Flat worms such as 
planaria can replace any missing body part and can regenerate the whole body from just a little 
piece of the previous organism (1,2). The superclass of Tetrapoda comprises the first four-limbed 
vertebrates and their descendants, including amphibians, birds and fish. Tetrapods are very well 
known for their capacity to regenerate a missing body part, among them, salamanders display by 
far the highest regenerative capacity that includes the eyes, heart, tails and entire limbs (3–5).  
For more complex vertebrates, such as humans, the regeneration is much more complicated and 
requires a finely tuned system and communication between cells. A large network of signalling 
can drive the differentiation of cells and their behaviour (1). Sometimes the network doesn’t work 
or it can be interrupted and the cells lose their capacity to communicate with other cells thereby 
interrupting regeneration. This massive failure brings about catastrophic consequences such as 
organ or tissue collapse (6). Bad lifestyle such as poor dietary intake of protein and fat coupled 
with inadequate physical exercise can increase the instance of cardiac disease, one of the leading 
causes of death in the world. Of course, diseases that impact the heart and the liver require 
immediate attention and in extreme cases, the transplantation of a new organ.  
Genetic diseases represent another key factor that impact an organ's regeneration. Muscular 
Dystrophy (MD) is a group of genetic degenerative diseases that impact the structure of the 
muscle. In the last decade, a number of genes have been discovered to be part of Muscular 
Dystrophy diseases such as the gene Dystrophin  (7,8). Duchenne Muscular Dystrophy (DMD) is 
caused by a mutation in the Dystrophin gene (DMD) found on the X chromosome (7). The DMD 
gene is one of the longest in the Human genome which encodes the 427 kDa protein dystrophin 
(9). In the case of DMD, the surgical correction solution cannot be approached. The disease is not 
localised in just one area of the body but extends throughout the whole muscular mass.  
In each case, these diseases cause organ regeneration and the replacement of damaged tissues to 
fail. Regenerative medicine focuses on the of the natural behavior of stem cells, that represent 
the new frontier to fight incurable diseases (10). Stem cells in the adult body gradually resign their 
job of repair and maintenance with age, eventually causing tissue and organ failure. Based on the 
past decade of research, this occurs because stem cells become dormant in increasing numbers as 
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rising levels of age-related cellular damage change the mix of chemical signals propagating 
through tissues (11).  The manipulation and the understanding of stem cells represents an 
important step towards the regeneration of tissue and organs and a new hope for numerous 
patients.   
1.1.1 Regeneration in the animal kingdom 
Salamanders, Xenopus frogs and zebrafish have all been used for many years to observe the 
behaviours of stem cell regeneration in vertebrates (1,12,13). These three vertebrates have 
different mechanisms and capabilities to regenerate a missing limb or part of a damaged tissue. 
Xenopus can regenerate a missing tail when in their larval stage as a tadpole, during which their 
cells are still in a pluripotent state (1)  
Human tissues and organs have different ways to replace damaged cells (6). The skin for example 
is one of the more active tissues which replaces millions of cells every day (10). Organs like the 
liver can regenerate damaged hepatocytes or an entire damaged part of the organ (14). Muscle 
tissue is another part of the vertebrate body that can be regenerated after trauma. In this specific 
case the regeneration of the muscle is linked to a specific family of cells called Satellite cells, that 
after injuries are awaked from their dormant state and become active again (15).  
Trying to understand the mechanism of regeneration could help us to comprehend the 
development of diseases like Muscular Dystrophy and create new techniques to cure or treat 
their degeneration. Currently, the majority of the experiments are performed in vitro, trying to 
recreate a representative and functional environment in which we can observe how cells divide 
and create new tissue (10,16). In essence, the gold standard is to use/develop autologous cells 
from a patient as they would be compatible with the patient’s immune system. For organs that 
naturally have stem cells, these cells may be of direct use in therapy, provided they can be 
cultured and manipulated. Moreover, it may be possible to reprogram existing tissue-specific 
stem cells by making genes for alternative cell fates accessible. Likewise, with the discovery of 
protocols for the generation of induced pluripotent stem cells from adult, differentiated cells, 
possibilities have opened up to recapitulate developmental processes and derive desired 
precursor or stem cells in vitro prior to grafting them into a patient. Taken together, it appears 
that stem cell research may be the most promising route in regenerative medicine.  
1.2  Stem cells 
1.2.1 What is a stem cell? 
Stem cells are undifferentiated, mitosis-competent cells that simultaneously generate cells for 
progressing towards differentiation whilst self-renewing (17). The cellular basis for this is 
asymmetrical cell division, in which one daughter cell will again be a stem cell and the other will 
become recruited into differentiation to build functional tissues and organs. The differentiating 
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cell may progress through one or several precursor cell stages in which the cell pool may expand 
by symmetric cell division (Figure 1.1). These cells are also referred to as transit amplifying cells. 
However, after the cells differentiate, they are no longer able to participate in the future renewal 
of organ tissue hence, a constant pool of stem cells is necessary to maintain the continued 





Figure 1. 1: Renewal and differentiation of stem cells. 
Stem cells (A) and pre-differentiation progenitor cells (B) multiply by symmetrical cell division (1, 3). 
Asymmetrical division of a stem cell (3), provides cells the ability to build differentiated tissue, but at the 
same time provides a new stem cell to maintain the stem cell pool. The two cells obtain from the symmetric 
division of the cell (B), will now carry on differentiation (4) and they won’t be able to divide again but they 







1.2.2 Stem cells can be distinguished by their potency 
During embryo development, the potential of stem cells is gradually reduced. At the morula stage 
and early blastocyst, the stem cells are totipotent, meaning that they are able to give rise to any 
kind of tissue in the embryo (19).  
The pluripotent stem cells are embryonic stem cells (ES) which are derived from the late blastula, 
just before the onset of gastrulation (20). In mammals, they constitute the inner cell mass, located 
inside the primordial embryo which eventually gives rise to the structure of the fetus (21). The 
pluripotency of ES means that they are able to differentiate into any of the three germ layers: 
endoderm (giving rise to: interior stomach lining, gastrointestinal tract and the lungs), mesoderm 
(giving rise to: muscle, bone, blood and the urogenital tissues), or ectoderm (giving rise to: 
epidermal tissues and the nervous system) (22).  
The capability of the embryonic totipotent stem cells decreases during development reaching the 
unipotent adult stem cell stage in which proliferation occurs to maintain the tissue and replace 
the damaged cells (23). This means that adult stem cells can produce just the same cells found in 
that specific tissue. For example, the epidermis produces new cells to compensate for the high 
number of cells that are lost every day. There are many tissues in the Human body that have the 
same characteristics including: muscle stem cells, intestinal stem cells, and neural stem cells (24–
26). 
Embryonic stem cells are found just in the first stage of the generation of new tissue. At the final 
stages, these cells are replaced by satellite cells or adult stem cells. The embryonic stem cells 
express Mrf proteins in a specific order at specific stages of muscle development. The first marker 
expressed is Myf5 followed by MyoD, MyoG and Mrf4. Embryonic stem cells divide symmetrically 
then asymmetrically to produce two sister cells, one of which contributes to maintaining the stem 
cell pool whilst the other cell carries on differentiating. During this process a few of the cells will 
not express Mrf markers but they will keep expressing the pair box genes Pax3/Pax7 (27). These 
cells will form the adult satellite cells which will be in a dormant state until an eventual injury (28). 
The proliferation capabilities of unipotent cells decreases with aging of the organism leading to 
aged individuals with difficulties in healing wounds and with slower recovery time following 
trauma.   
 
1.2.3 Efforts to develop the use of stem cells for therapies 
The discovery of the stem cell developed a new theory of the possibility to reprogram cells and re-
create new tissues in the laboratory. The first engineered stem cells created in the laboratory 
were the induced pluripotent stem cells (iPSC). iPSCs are adult cells reprogrammed to be 
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pluripotent stem cells. These cells were developed for the first time in 2006 (Takahashi & 
Yamanaka, 2006). The first reprogramming was done in murine fibroblasts by viral overexpression 
of a specific set of pluripotency-associated genes; Oct4, Sox2, cMyc, Klf4.  
The discovery that murine and human fibroblasts can be converted into stable and fully functional 
embryonic stem-like cells (ESCs), has encouraged scientists to look beyond ESCs for regenerative 
medicine, as well as to re-evaluate the terminology ‘terminally differentiated state’ and the 
notion of cellular plasticity (30). Since the discovery of iPSC, researchers have attempted to 
directly convert various adult cells to different cell types, by avoiding the pluripotent state, using a 
unique combination of cell type-specific key master regulators. Several medically relevant cell 
types have been generated, including hematopoietic cells, different neuronal cells and 
cardiomyocytes (31). However, despite remarkable progress in characterising the reprogramming 
process and the resulting iPSCs and directly converted cells, it remains to be seen if these 
converted cells are safe and of sufficiently high quality to facilitate their immediate use in the 
clinic (32). Theoretically, iPSCs and directly converted cells are ideal for regenerative medicine and 
for disease modelling. In contrast to ESCs, their use does not involve ethical issues and, because 
they can be derived from patients, they should not be rejected by the host. However, rigorous 
functional assays in the mouse system showed that, unlike ESCs, which are relatively uniform in 
their differentiation capacity, the quality of iPSCs varies widely between different colonies, 
creating cells that can over proliferate and lose the control. This could potentially create 
dangerous effect if transplanted into human bodies. The use of iPSC have to be tested to ensure 
the quality of the cells themselves before applying them to humans (22,32–36). 
1.2.3.1 Tissue specific stem cells 
Surgery to repair and heal devastating injuries are based of the implantation of new tissue that 
will help the regeneration of the damaged tissue (37). The tissue can be produced in vitro but the 
negative impact of this procedure is the body's potential reaction to the foreign engineered tissue 
causing what is defined as rejection. If the immune system of the patient rejects the newly 
transplanted cells it will treat them as an extraneous part and it will attempt to eject the tissue 
(38). Tissue specific stem cells may be a safer option for stem-cell based therapies, since they are 
committed to regenerate specific cells or organs. This technique could use cells taken from the 
body of the patient and in this way the body and the immune system will recognise the cells as 
'self' with no rejection (38). An example of tissue specific stem cells are the bone marrow derived 
cells, used as a treatment for myocardial infarction (MI). Large improvements in myocardial 
function have been shown in the results of animal experiments and adult stem cell therapy clinical 
trials (39). Bone marrow-derived mesenchymal stem cells (MSCs) in particular present themselves 
as useful tools for cardiac repair following MI, due to their self-renewal and proliferation 
properties as well as their multiple lineages (40).  
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Another example of advances in stem cell therapy is the use of the olfactory epithelia cells as a 
treatment of spinal cord injuries. These specialised glial cells surrounding the olfactory sensory 
axons in the nose have been shown to have capabilities comparable to Schwann cells in 
supporting axon growth. Successful transplantation of olfactory ensheathing cells into mice with 
spinal cord injuries ranging from lesions to complete transection led to recovery of paw use and 
coordinated movements (41). However, no completely effective treatments have yet been 
developed for neurological repair following spinal cord injuries in humans.  
1.1.1.1 Muscle stem cells (MuSC) in the application of therapeutic treatment of muscular 
dystrophies and other types of muscle wasting diseases 
As explained in Section 1.1, Muscular Dystrophy is linked to the X chromosome and affects 1 in 
3500 male births. In recent years little information has been collected to clarify the cause and 
possible solutions to cure this disease. The Dystrophin gene is considered the main cause for the 
progression of the disease (9). Dystrophin is an important cytoskeletal protein and a major 
component of the dystrophin glycoprotein complex (DGC) whilst also being responsible for the 
maintenance of cell integrity, mediation of cytoplasmic signalling and muscle cell function. 
Without dystrophin, muscle cells cannot form the DGC and degenerate as a result of mechanical 
stress during contraction (9,16). 
A few murine models have been created to mimic the disruption caused by the absence of the 
Dystrophin protein (42). Attempts to cure the disease are separated into treatment via 
transplantation of autologous or allogenic cells. In the first case stem cells extracted from a 
patient afflicted with DMD were treated and genetically reprogrammed before replanting in the 
same patient. In the second case muscle stem cells taken from a healthy patient were 
transplanted into a DMD patient (9). One strategy used in gene therapy is for a healthy full-length 
dystrophin complementary DNA (cDNA) to be inserted into muscle precursor cells presenting 
muscular dystrophy. This can be achieved through the use of viral vectors, like the adeno 
associated virus (AAV) and lentiviral vectors. These vectors are used to insert a micro or mini-
dystrophin gene, a necessary approach given by the fact that the dystrophin gene itself is one of 
the biggest genes in the Human genome and would be too large in its entirety (43,44). Another 
possible strategy is the exon skipping technique utilising the adeno virus. Experimentally, this 
involves introducing a small RNA or DNA molecule into cells which can then interfere with the 
normal splicing of a gene and consequently cause one of the exons to be removed. This process is 
used to skip the exons that contain nonsense mutations so as to restore an open reading frame. In 
the mdx mouse, it has been proven that skipping exons can allow the myofibres to produce 
dystrophin lacking only the region encoded by exon 23 (45,46). 
The two techniques produced both positive and negative results. The first technique has the 
advantage that it does not cause any issues with rejection as the cells originate from the same 
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organism. The second technique allows the use of healthy cells without the need for 
reprogramming but carry the risk of being recognised as foreign by the patient's immune system 
and being rejected as the cells do not originate from the patient. Unfortunately, muscular 
dystrophy is not the only disease that can cause disruption, loss of muscle mass and function. 
Acquired immune deficiency syndrome (AIDS) is typically associated with 10 % loss of weight and 
muscle mass due to weakening of the body as well as changes in gene expression that bring about 
a loss of muscle control called disuse atrophy (47,48).  
Patients with Cancer or other chronic illnesses often suffer from unintended weight loss and 
muscle wasting referred to as Cancer anorexia-cachexia syndrome (CACS). This syndrone is 
characterised initially as inadequate oral intake and metabolic changes and subsequently 
anorexia, weight loss and muscle wasting (49). Natural aging is associated with progressive loss of 
neuromuscular function, loss of skeletal muscle mass and strength commonly referred to as 
sarcopenia (50). The major contributor to the development of sarcopenia is loss of skeletal muscle 
fibres as a result of reduced motor neurons but other associated factors include decreased 
physical activity, change in hormone levels and decreased calorie and protein intake (51). 
With a clear need for new and convincing strategies for transplanting muscle cells into patients, 
Cossu and colleagues described a variety of different techniques being trialled as well as the 
properties of satellite cells that lend themselves to be used for cell therapies (52). Satellite cells 
(SCs) are unipotent stem cells found under the basal lamina. They remain quiescent in adult 
individuals until they are activated following injury however, in patients with DMD this 
mechanism fails to work. Recent data demonstrated that SCs can be isolated pure and cultivated 
but unfortunately the cells lose their capacity to replicate if kept cultured for long periods (52).  
Similarly, human hematopoietic stem cells and mesenchymal stem cells lose their capability to 
regenerate when transferred to cell culture (37,52–54). The loss of regenerative capacity of 
cultured stem cells is therefore an important barrier to overcome.  
Evidence is accumulating that, in a healthy environment in vivo, the muscle stem cell state may be 
actively stabilised, therefore underlining the importance of in vivo format experiments (52,55,56).  
1.3  Anatomy, function, homeostasis and regeneration of adult skeletal muscle 
1.3.1 Muscle anatomy and function 
Muscles are responsible for all the movements of our body, voluntary and involuntary. They are 




The fibres are filled with contractile protein filaments, consisting of reiterated contractile units 
called sarcomeres (58). The muscle itself is surrounded by connective tissue and is anchored to 
the skeleton or skin via tendons.  
Sarcomeres are basic contractile units of the muscle, and are arranged in series to form myofibrils 
which are aligned along their longitudinal axis and constitute the largest component of the muscle 
fibre. Satellite cells are situated between the basement membrane and the sarcolemma  (Figure 
1.2) and the myonuclei are located at the periphery of the myofibres just underneath the 
sarcolemma itself (15).  
The sarcoplasmic reticulum is a network of flattened tubules around each myofibril and is 
responsible for the release and uptake of Ca2+ associated with muscle contraction. The function of 
the T-tubules is to transmit the action potential from the muscle fibre surface to its interior. Each 
mature myofibre is innervated by a single motor neuron that makes contact with the myofibre at 
the neuromuscular junction. Skeletal, cardiac and smooth cells all use the same molecular 
principle to generate force during the contraction (59,60). The energy for contraction is provided 
by ATP. The contraction mechanism involves the protein Myosin attaching to an Actin thin 
filament and pulling on it, causing Actin to slide past the Myosin thick filament (61). Myosin is a 
large protein of which the main body is composed of two heavy chains (62,63) and the head 
possesses ATPase activity and contains the Actin interaction site. The protein Actin forms a 
molecular rope that Myosin pulls on during contraction. Actin is synthesised as a globular protein 
(G-Actin) and then polymerised to form the (F-Actin) which contains two beadlike polymers 
braided in a helical confirmation (64,65). Actin expresses Myosin binding sites, but these must 
remain hidden until a signal to contract is received or else the muscle fibre may lock into a rigid 
state (rigor) (63). Access to the binding sites is controlled by Tropomyosin and Troponin, two 
regulatory proteins that lie in the grooves of the Actin helix near the binding site. Actin 






Figure 1. 2: Structure of the muscle. 
Skeletal muscle is voluntary muscle controlled by motor neurons which innervate every single muscle 
myofibre. Muscles are composed of a series of layers and specific cells that contribute to making the tissue 
functional and responsive for every movement. A single fasciculum is made of numerous myofibres. The 
main components of the myofibre are satellite cells, myonuclei and myofibrils. Satellite cells are situated 
under the basal lamina and they are responsible for the maintenance of the tissue in the case of injuries. 
These cells can re-enter the cell cycle and give rise to new muscle stem cells. Myonuclei are positioned at 
the border of the myofibres, under the sarcolemma. The sarcoplasmic reticulum is responsible for the 
release and uptake of the Ca
2+
. The single Myofibril represents the centre of the movement in a unit called 
the Sarcomere, made of Myosin and Actin filaments responsible for the muscle contraction and are Ca
2+
 





1.3.2 The muscle satellite cell, muscle homeostasis and regeneration 
Since their discovery, satellite cells (Mauro, 1961) have been the major candidate for the source 
of myogenic cells for muscle repair during injury-induced regeneration. (69,70). Transplantation of 
satellite cells into dystrophic muscle of a single muscle fibre generates plenty new myofibres and 
myofibre associated cells (17). Upon injury (or when muscle is explanted in vitro), satellite cells re-
enter the cell cycle in G1. Moreover, they express some premyogenic genes such as Pax7 in their 
quiescent state (Fig. 1.3), indicating that their cell cycle arrest is actively regulated (71–74).  
Upon injury or growth stimulus, activated satellite cells, express myogenic factors Myf5 and/or 
MyoD and begin extensive proliferation to generate the progenitors for muscle regeneration. The 
myoblasts later downregulate Pax7 expression and upregulate MyoG and Mrf4 expression before 
exiting the cell cycle towards differentiation and the formation of fully formed, fused myofibers 
(52). Depletion of Pax7-expressing satellite cells results in lack of adult muscle regeneration 
thereby demonstrating that this process is responsible for the regenerative capabilities of skeletal 
muscles (75). Quite often the embryonic myoblast has been defined as a stem cell but in reality 
the myoblast cannot divide asymmetrically but just symmetrically, producing two sister cells 
which both will differentiate into myocytes (76). 
As well as providing the progenitors for forming new myofibres, satellite cells also need to 
maintain the satellite cell pool through self-renewal (17,71). This balance between self-renewal 
and commitment is therefore important for the continued regenerative capability of skeletal 
muscle yet the dynamics of this process remain to be shown. A popular theory stipulates that the 
satellite cell pool is heterogeneously comprised of committed and non-committed cells that each 
have a predisposition for differentiation or self-renewal, respectively (77).  
Some satellite cells generate large numbers of daughter cells that eventually differentiate, and do 
not produce cells that efficiently re-populate that SC niche (18,73,78)(18,78,79). These cells 
behave like myoblasts (mitotically active cells, committed to muscle formation) and qualify as 
transit amplifying cells rather than genuine stem cells (80,81). There are many intrinsic and 
extrinsic factors that control satellite cell function. Previous experiments have shown that the 
regulation of the cell cycle represents one of the crucial routes for satellite cell control (73,82).  
The embryonic myogenic progenitors express the paired box proteins Pax3 and Pax7 after which 
their myogenic progression is controlled by a program of Mrf expression starting with Myf5 
and/or MyoD activation followed by MyoG and Mrf4 (83,84). During late stages of mouse 
development at around E16.5-18.5 (E-embryonic day) a subpopulation, hypothesised to form the 
future satellite cell population, avoid Mrf expression and maintain Pax3/Pax7 expression (55).  
Inactive adult satellite cells do not express MyoD however, Myf5 positive and negative cells can 
be distinguished in adult muscles. Moreover, approximately 10 % of satellite cells never express 
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Myf5 during development (85). This heterogeneity has been hypothesised to be the source of 
satellite cells with self-renewing capacity. Activated satellite cells expressing higher levels of Pax7 
are less likely to commit to differentiation compared with the cells that express low levels of Pax7. 
The paired box family members Pax3 and Pax7 are discussed further in Section 1.3.3. Careful 
observation of Satellite cells in culture show that reserve cells, i.e. self-renewed satellite cells, are 
not immediately present. Their emergence is linked to a phase when MyoD-negative, mitotically 
silent and MyoD-positive, dividing cells appear (86). This phenomenon was followed by another 
study that shows satellite cells must divide at least once, and this division must be asymmetric, to 
generate a renewed satellite cell as well as a differentiating daughter cell (73). This indicates that 
in principle, quiescent satellite cells are genuine muscle stem cells. Precise control of the 
activation of satellite cells is essential to the maintenance and survival of muscle fibres. This firm 
control was revealed by microarray analysis which noted that more than 500 genes are highly 
upregulated in quiescent satellite cells compared with cycling myoblasts (87). The importance of 







Figure 1. 3: Symmetrical and Asymmetrical division of satellite cells 
Once activated, Pax7-expressing satellite cells may undergo symmetrical division to facilitate the 
expansion of the stem cell population. Similarly, they may undergo asymmetrical division to generate 
a new population of myogenic progenitors whilst maintaining the stem cell pool. Alternatively, the 
satellite cells can commit to become myogenic progenitor cells expressing Pax7, Myf5 and MyoD. 
Myogenic progenitors can proliferate to give rise to committed myogenic progenitors or they can 






1.3.3 Pax7 is the universal marker for muscle stem cells 
After the initial discovery of satellite cells, it took almost 30 years to identify the transcription 
factor, Pax7, as a key marker for these cells. This discovery allowed the behaviour of satellite cells 
to be studied in more detail. Data of genetically traced Pax7 expressed in injured muscle cells 
showed that Satellite cells have to regenerate muscle fibres and produce new satellite cells at the 
same time (75). Moreover, when Pax7 expressing cells were ablated, muscle could not regenerate  
(88). 
The Pax family of paired box domain transcription factors play key roles during tissue specification 
and organ development. In the context of myogenesis, Pax3 and Pax7 are important upstream 
regulators (89). Pax3 is expressed in all myogenic progenitor cells in the embryo whilst Pax7 is 
mainly present in the central domain of the dermomyotome, in the absence of Pax3 it is this 
domain that survives (90). These Pax3/Pax7 positive cells provide the self-renewing reserve cell 
population for muscle growth (91). After birth, Pax7 mouse mutants lose their satellite cells and 
Pax3 cannot compensate the role of the missing Pax7, perhaps because the protein is present at 
too low a level or because of divergent Pax3 and Pax7 functions by this stage (92). The role of 
Pax7 in adult satellite cells has been controversial. Studies showed that  muscle regeneration is 
severely reduced when Pax7 is ablated in most satellite cells, preventing repopulation of the 
satellite cell pool (88,93). Consequently, in adults the satellite cell pool is not maintained, not due 
to cell death but probably because of premature differentiation at the expense of proliferation 
(93). 
 Artificial maintenance of Pax7 expression in myoblasts has been reported to delay differentiation 
(94,95). In this context, it has been proposed that Pax3 can promote satellite cell proliferation 
(96). As in the embryo, intervention by Pax7 gene is perhaps critical to maintaining the balance of 
self-renewal and differentiation. 
Pax7 has been shown to directly activate Id3, which encodes a HLH inhibitor of myogenic factor 
activity, potentially partnering together with Id2 and preventing the onset of Myogenesis in 
quiescent satellite cells (97). New insight into potential Pax7 targets in satellite cells comes from 
genome wide ChIP-seq and transcriptome analysis carried out on primary myoblasts derived from 
cultured satellite cells, in which a tagged Pax7 protein is expressed (92). This data revealed that 
Pax7 targets many genes implicated in satellite cell function including genes involved in cell 




1.3.4 Muscle stem cells facilitate fetal and juvenile muscle growth in amniotes and 
continuous muscle growth in anamniotes. 
The Pax7 gene is not only expressed in quiescent and activated adult muscle stem cells, but it is 
expressed in myogenic cells from embryonic stages (72). Ablation experiments in early stage 
mouse embryos show that in the absence of Pax7 positive cells, no fetal or juvenile muscle growth 
occurs and no adult muscle stem cells are ever organised (88). However, all studies agreed that 
the adult Pax7 expressing muscle stem cells (muscle satellite cells) are derived from the Pax7-
expressing embryonic muscle stem cells. Moreover, they agreed that the initial role of the muscle 
stem cells is to create the bulk of the musculature (55). 
In amniotes, after juvenile muscle masses have been laid down, adult muscle mass increases 
predominantly by filling muscle fibres with more contractile protein (muscle hypertrophy as 
opposed to muscle hyperplasia – increase in cell number) (98). However, in anamniotes such as 
the zebrafish, adult muscle still grows via hyperplasia similar to fetal and juvenile muscle in 
amniotes (12). This suggests that the basic role of muscle stem cells is to drive muscle growth. It 
also suggests that muscle stem cell quiescence is a special feature of amniotes.  
1.4 Origin of muscle and muscle stem cells 
1.4.1 All vertebrate skeletal muscle cells originate from the segmented paraxial 
mesoderm (the somites) 
Skeletal muscles originate embryonically from the paraxial mesoderm which is a subdivision of the 
mesoderm, one of the three germ layers formed during the process of gastrulation early in 
embryogenesis (99).  
Formation of mesodermal and endodermal organs takes place simultaneously with neural tube 
formation. The notochord forms between the base of the head and the tail with the neural tube 
above. Thick groups of mesodermal cells - referred to as the segmental plate in chickens and 
unsegmented plate in mammals - lie flanking the neural tube (66). Fate mapping experiments 
showed that the mesodermal cells which leave the primitive streak later on, settle anterior to the 
cells that leave the primitive streak earlier. As the primitive streak regresses its activity patterns 
the embryo in an anterior-to-posterior direction. After the complete regression of the primitive 
streak, new mesodermal cells are continuously added from the posterior by a mass of cells in the 
tail bud (100). Initially, the paraxial mesoderm is organised as mesenchymal tissue on either side 
of the axial midline. At this stage, the paraxial mesoderm is referred to as the segmental plate in 
chick and the presomitic mesoderm in mouse. Along the anterior-posterior axis, the paraxial 
mesoderm is later divided into segmented and nonsegmented mesoderm. The head paraxial 
mesoderm (which contributes to blood vessels, bones and muscles in the head) lies anterior to 
the otic vesicle and does not undergo segmentation. The paraxial mesoderm posterior to the otic 
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vesicle are segmented into reiterated units called somitomeres. These somitomeres compact and 
bind together encompassed by an epithelium which eventually separates from the segmental 
plate to form individual somites. A new pair of somites are formed every 30 minutes in the 
zebrafish, 90 minutes in the chick and 120 in the mouse (101). Despite being transient structures, 
somites are extremely important in organising the segmental pattern of vertebrate embryos. The 
somites eventually form the vertebrae and ribs, the dermis of the dorsal skin and the skeletal 
muscles of the back, body wall and limbs. Additionally, somites determine the migration paths of 
spinal nerve axons and neural crest cells (59). The important components of somitogenesis 
(somite formation) are periodicity, epithelialisation, specification, and differentiation. The first 
somite appears in the posterior portion of the trunk, and new somites emerge from the rostral 
end of the paraxial mesoderm at regular intervals (102).  
1.4.2 Periodic Notch-Delta signalling, overlaid by an Fgf8 maturation gradient regulates 
the formation of segments 
Somitogenesis has been shown to involve a molecular oscillator, the segmentation clock, which 
controls the periodicity of the expression of the genes involved in it. The genes are expressed 
rhythmically in the segmental plate. These genes belong to the Wnt and Notch pathway, in which 
the Wnt signalling lies upstream of Notch signalling. Axin2, an inhibitor of Wnts but directly 
activated by Wnt signalling, is a cyclic gene in the Wnt pathway (Fig. 1.4). The Notch related genes 
include members of the Hairy and Enhancer of split family of basic helix loop helix (bHLH) 
transcription factors that act downstream of Notch-Delta signalling, as well as the glycosyl 
transferase Notch signalling inhibitor, Lunatic fringe (101). Fibroblast growth factor 8 (Fgf8) 
signalling generates a moving front at which both segment boundary position and axial identity is 
established. Fgf8 is downregulated and the cyclic genes stop oscillating around the time of somite 
formation when the basic-loop-helix (bHLH) transcription factor Pax3 (103) is expressed. After a 
defined number of expression cycles, cyclic gene expression discontinues and resolves into a 




Figure 1. 4: The intricate network of genes and factors that are influencing the formation of the somite.  
The positions of different factors create a map and an orientation for cell migration. The cells of the young 
somite developing from the presomitic mesoderm (PSM) start migrating and form an organised structure. 
Migration is initially influenced by the Wnt and Shh signalling factors that guide the first step forming a full 
somite. The presence of these two factors contributes to the elongation of the somitic structure, giving rise 
to the Epaxial and Hypaxial sides. The paired box proteins Pax7 and Pax3 are expressed in the dorsal part of 
the somites until the formation of the first muscle stem cell whereupon Pax genes are downregulated and 
the first Mrf gene (Myf5) is expressed. Cells of the somite start migrating from the dorsal part of the 
dermomyotome and colonise the layer below called the myotome, whereupon they differentiate into 
muscle cells. The position of the somite dictates the fate of the cells that develop from within it. At the limb 
level, the Pax3 cells will migrate towards the limb bud to give rise to the muscle cells that colonise the area. 
The presence of Hepatocyte Growth Factor (HGF) contributes to the migration of Pax3-expressing cells, 




1.5 Gene regulatory networks controlling Myogenesis 
1.5.1 Tbx6 regulates the specification of the paraxial mesoderm 
T-box transcription factor (Tbx6) expression is essential for paraxial mesoderm development 
(107–109) whilst its paralog, Brachyury, is expressed in the axial mesoderm.  
Tbx6 mutations show patterning defects in the somites which lead to malformations of the axial 
skeleton (110,111). These defects arise from possible misidentity of the anterior somite 
compartment and/or its reduction (112). Tbx6 has also been shown to affect the expression of the 
Notch ligand, Delta 1 (Dl) by experiments in chick and mouse showing lowered DL expression 
levels upon lowered or knocked out Tbx6 expression (107,110,112). 
1.5.2 In amniotes, surface ectoderm derived signals upregulate Paraxis which controls 
somite epithelialisation 
Paraxis is considered a pre-myogenic gene which facilitates the formation of the epithelial 
somites (104). Wnt6 is known to be expressed in the ectoderm overlying the anterior segmental 
plate and early somites of the chick embryo (113–116).  
Wnt6 has been shown to promote the epithelial organisation of the segmental plate mesenchyme 
(117). Additionally, Wnt6 activity is thought to be mediated by a β-catenin-dependent pathway as 
blocking β-catenin or Lef1 activity in the dermomyotome depolarises somite cells and de-
epithelialises the dermomyotome (118). The extended expression of Paraxis has also been 
demonstrated as sufficient to reverse de-epithelialisation. There, it is established that the 
epithelial organisation of the somites requires β-catenin activity, which in turn is mediated by 
Wnt6, Fz7 (Frizzled 7) and Paraxis (114) although the mechanism by which Paraxis controls 
dermomyotome construction remains to be clarified.  
Interestingly, ectoderm Wnt genes regulate Paraxis and Pax3 in a similar manner indicating a 
close relationship between epithelialisation and cell differentiation processes. 
Paraxis has however been shown to be expressed in non-epithelial cells such as the sclerotome 
(119), indicating that its epithelialising function may be context dependant and require additional 
factors (105,118,119).  
1.5.3 Pax3 and Pax7, the master regulators of myogenesis in amniotes  
Pax3 transcription is downregulated in fetal muscle, upon which Pax7 becomes the dominant 
factor in all myogenic progenitor cells (92). In the limb, Pax7 is initially co-expressed with Pax3 and 
genetic tracing experiments show that all later Pax7 positive cells in the fetal limb are derived 
from cells that had expressed Pax3 (76). Postnatal and adult satellite cells are marked by Pax7 
expression, with continuing transcription of Pax3 in trunk muscles such as the diaphragm and 
some limb muscles (120). Pax7-negative satellite cells can initiate differentiation, probably due to 
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transcription of Myf5 in an increasing number of these cells from the perinatal period. Consistent 
with a role for Pax7 in the initiation of MyoD but not Myf5 transcription in most satellite cells in 
culture, introduction of dominant-negative Pax7 specifically abolishes MyoD but not Myf5 
expression or satellite cell differentiation (72). Pax3 and Pax7 are normally downregulated prior to 
activation of Myogenin, cell cycle exit and differentiation and artificial maintenance of their 
expression in myoblasts has been reported to disrupt differentiation. 
In this context, it has been proposed that Pax3 can promote satellite cell proliferation. Pax3 does 
not rescue the postnatal phenotypes of the Pax7 mutant mouse in muscles where both proteins 
are present in satellite cells. Functional differences between Pax3/Pax7 in postnatal versus 
prenatal Myogenesis may reflect post-translational modifications of the proteins and also 
association with different cofactors. During embryonic Myogenesis, Pax3 functions as a 
transcriptional activator (89); however, like other Pax proteins, it is a poor activator on its own, 
indicating the probable importance of co-activators. Pax7 has been shown to interact with the 
histone methyl transferase complex, which directs H3K4 histone modifications (121) in myoblasts 
from postnatal muscle. Pax7 mutant satellite cells show reduced heterochromatin condensation 
(93) pointing to a role in chromatin organisation, also recently suggested for Pax3 (122). Recent 
research begins to provide some insight, but mechanistically much remains to be understood 
about the function of Pax3 and Pax7 as transcription factors. 
1.5.4 In amniotes, the somites are extensively patterned before muscle is made  
The newly formed somites can be divided into two distinct parts, medial and lateral. The cells 
which are responsible for the formation of the two specific parts have different origins and they 
are fused together at the time of the gastrulation (123). The notochord and the floor plate of the 
neural tube produce and secrete the morphogen sonic hedgehog (Shh). The notochord also 
produces and secretes the bone morphogenetic protein (BMP) inhibitor, Noggin. Shh and Notch 
contribute to forming the ventral region of the medial somite as sclerotome, which is the origin of 
the ribs, vertebra, connective tissue and tendons. The sclerotomal progenitor located in the 
ventral region of the formed epithelial somite undergo SP ephitelia-to-mesenchymal transition 
(EMT) to form the new mesenchymal sclerotome (124,125). The dorsal part of the somites 
remained epithelia and the signalling from the Wnt and BMP from the dorsal neural tube and 
later, plate mesoderm, specified this region as epithelial dermomyotome (126). The 
dermomyotome later contributes to the formation of the trunk and limb muscles, dorsal dermis 
and the scapula (102). The influence from Wnt, BMP, Paraxis and Pax3, which were expressed in 
the segmental plate at the time of somite epithelialisation, become restricted to the newly 
formed dermomyotome (105,127). The neural tube and notochord together with the dorsal 
ectoderm overlying the somites influence the specification of the somitic cell fates.  
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1.5.5 The formation of the Dermomyotome in vertebrates 
The newly formed dermomyotome matures, it extends dorsomedially and ventrolaterally as a 
single layer of cells resting on the basement membrane (Fig. 1.5A). In the early stage of the 
formation of the dermomyotome, the cells in the somites form a cavity in their centre called a 
lumen which is eventually filled with migrating cells to form the advanced structure of the somites 
(Fig. 1.5B). The cells located at the borders of the dermomyotome flex inwards ventrally, forming 
the dermomyotome lips, dorsomedial lip (DML), ventrolateral lip (VLL); rostral and anterior lips 
and caudal or posterior lips. The structure of the dermomyotome eventually disappears due to 
cells migrating ventrally to form the myotome and dorsally to form the dermatome (102,128). The 
dorsomedial part of the dermomyotome and myotome is specified by the signal of Shh and 
Wnt1/Wnt3a. These genes can trigger Myogenesis in vitro (129). The development of the later 
part of the dermomyotome/myotome is influenced by BMP with Wnt4/Wnt6/Wnt7 coming from 
the surface ectoderm (130,131). The formation of myotomal cells involves the complex 
translocation of the migrating dermomyotomal cells causing a phenomena called delamination 
(132).  
1.5.6 The formation of the Myotome, the centre of muscle formation  
The formation of the myotome occurs with a sequence of “waves” which contribute to the 
migration of cells and the formation of the final structure of the myotome itself (Fig. 1.5C) 
(133,134). The first wave of post-mitotic myoblasts (called pioneer myoblasts) located in the DML 
migrate to the rostral or caudal lip, then differentiate into myofibres to reach the caudal or rostral 
lip (i.e grow in a rostro-caudal direction) to form the primary myotome (Fig. 1.5D) (135). The 
dorsomedial-to-ventrolateral growth and expansion of the myotome occurs when a second wave 
of post-mitotic cells translocates directly into the myotome from the rostral and caudal 
dermomyotome lips (Fig. 1.5E). These cells intercalate between the pre-existing myofibres of the 
primary myotome, which acts as a scaffold. Even the DML and the VLL contribute to the formation 
of the myotome, but cells derived from these lips may first move to the sublip domain and then to 
the rostral and caudal dermomyotome lips before forming unilaterally extending myofibres (135–
137). A study from Gros and colleagues showed that the cells derived from the DML or VLL do not 
migrate toward the rostral (or caudal) lip prior to differentiation, but they move to the myotome 
then elongate to reach the rostral and caudal lip (138). The second phase (or wave) combines the 
incremental growth at the DML and VLL and coherent growth at the rostro-caudal lips since the 
DML, VLL, rostral and caudal lips generate myoblasts to populate the myotome (138). In the third 
wave a population of mitotically active myoblasts enter the primary myotome from the rostral 
and caudal dermomyotomal lips (Fig. 1.5F) (139). At this point the myoblasts express the 
fibroblast growth factor receptor 4 (Fgfr4) (139). The dermomyotomal lips remain organised and 
continue to contribute to the myotome. The central dermomyotome will eventually de-
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epithelialise as cells in this region undergo EMT (epithelial-to mesenchymal transition) at this 
point the cells will form the myotome and the dermatome (140).  Recent studies show that when 
the central dermomyotyome de-epithelialises, the myotome experiences a massive flux of a final 
fourth wave of mitotically active, Fgfr4-expressing muscle precursors (141,142). In the adult 
muscle, the structure of the trunk is divided into two major groups: the epaxial and hypaxial 
muscle. The epaxial muscles are deep muscles of the back and these muscles have the important 
functions of maintaining posture as well as movement of the vertebral column and head. The 
hypaxial muscles form the limbs, the intercostal muscles and the body wall muscles that include 
the superficial back muscle and all lateral and ventral muscle. The hypaxial muscles are 













Figure 1. 5: Myotome formation and cell migration occurs in waves 
The somites are formed through a series of cell migrations called ‘waves’. Represented in the figure 
are the different stages of a developing chicken trunk, shown in transverse sections. The first two 
sections (A and B) show the early stages of development of the somites (green) whereupon the cells 
still express Pax7 and they are in a stem cell state. In B, the cells organise themselves for the 
formation of the dermomyotome upon which a cavity forms in the centre of the somites called a 
lumen (asterisk). The cells in the dermomyotome migrate to form a more organised structure whilst a 
selection of cells start to differentiate by expressing the first Mrfs, Myf5 and MyoD, giving rise to the 
first proliferating myoblasts (C, blue cells). The post-mitotic myoblasts migrate to the rostral or caudal 
lip and then differentiate into myofibres to reach the caudal or rostral lip to form the primary 
myotome (D, myotome in blue and dermomyotome in green). The expansion of the myotome occurs 
when post-mitotic cells migrate to the myotome from the rostral and caudal dermomyotome lips. 
These cells will form the scaffold of the myotome (E). The central dermomyotome (green) will start to 
de-epithelialise and will then undergo epithelial to mesenchymal transition (F). At this stage, the cells 




1.5.7 Anamniotes and the quick formation of muscle during the larva stage  
The formation of the muscle in anamniotes presents a few differences when compared with the 
formation of the muscle in amniotes. In xenopus, the first differentiated fibres in the vicinity of 
the notochord arise from the medial Myogenesis, whereas dorsomedial and ventrolateral groups 
that appear to continue growing at the tail bud stage arise from the lateral Myogenesis. The most 
lateral cells of the marginal zone were shown by cell tracing of the circumblastoporal gastrula cells 
to give rise to muscle fibres in the dorsal and ventral regions of somites (143). These experiments 
also showed that the most medial (dorsal) cells contribute to the association between the 
notochord in the head and trunk. 
After stage 26, a second wave of Myogenesis is generated from the dermomyotome (144,145). 
Comparison of embryonic Myogenesis of mice and xenopus reveals that the first median and 
lateral Myogenesis shown in the frog was lost in the mammal as all trunk and limb muscles arise 
from dermomyotome. Despite this, similarities between the second wave of xenopus Myogenesis 
and mammalian Myogenesis still remain. These include: the generation of epaxial and hypaxial 
myogenic cells from dermomyotome; initiation with Myf5 and strong MyoG expression (146), as 
well as concomitant expression of Mef2c expression in the intersomitic space (146,147). 
Similarly, the third wave of Myogenesis in xenopus is suggested to originate in the Pax3/Pax7 
expressing progenitors of the somites (142,148). This is corroborated by the observation of Pax7-
expressing muscle stem cells in the stage 46 xenopus myotome (149). It is thought that Myf5 
expressing cells could participate in plurinucleated cell formation in the third wave which takes 
place from stage 45 onwards (150).  
1.5.8 The Myogenic regulatory factor (Mrf) family of bHLH transcription factors control 
myogenic commitment and differentiation in amniotes 
Myogenic commitment and differentiation of muscle cells is driven by the expression of Myf5, 
MyoD, MyoG and Mrf4, a family of bHLH transcription factors known as myogenic regulatory 
factor (Mrfs). They bind to E-boxes (concensus sequence = CANNTG, N - any nucleotide) as 
heterodimers with the E2 protein. The Mrfs can activate the transcription of muscle-specific 
genes, even in non-muscle cell types (151). Myf5 and MyoD are the first of the Mrfs to be 
expressed in muscle precursor cells (myoblasts) in the DML and VLL, and the newly formed post-
mitotic myotome. However, they are not initially expressed in the same myoblasts during early 
Myogenesis (151,152). The epaxial myoblasts are the first to be generated in the DML and the 
dorsomedial wall of the dermomyotome (128). Myf5 is the first to be expressed in the epaxial 
myoblast where it activates the transcription of MyoD in these cells later in the post-mitotic 
primary myotome. The hypaxial myoblasts are generated in the VLL and express MyoD first 





lineages eventually meet and the expression of the Myf5 and MyoD becomes continuous in the 
primary myotome (151,152).  
In   Myf5  knockout   mice,   the   development   of   the   myotome   and subsequent expression of 
MyoD, MyoG, and MRF4 is delayed but there is no loss of muscle phenotype (153). Similarly, 
muscle also develops normally in MyoD mice, although elevated levels of Myf5 still persist into 
postnatal stages (154). However, homozygous Myf5 and MyoD double knockout mice die soon 
after birth due to a lack of any skeletal muscles (154).  
These results demonstrate that Myf5 and MyoD are required for specification of myoblasts, and 
they can compensate for each other (Fig. 1.6). However, unlike Myf5, MyoD also has a function in 
differentiation just like MyoG and Mrf4, which direct the terminal differentiation of myoblasts 
into myocytes, fusion of myocytes into myotubes and eventually the alignment of myotubes into 
bundles or myofibres. Consistent with this, they are expressed later, in differentiated muscles 
(151,152). Myf5 and MyoD activate the transcription of MyoG and Mrf4 in epaxial and hypaxial 
myoblasts (155). The Mrf genes do not act alone in the stimulation of proliferation and muscle 
differentiation but they cooperate with other genes, like Mefs and Six that are defined as co-
factors (Fig. 1.6). These genes cooperate with the Mrf genes during the various steps of the 
muscle formation.  
1.5.8.1 Mrf proteins structure and function  
The Mrf proteins are classified as transcription factors and they have a basic Helix Loop Helix 
(bHLH) domain structure.  
The bHLH domain is ∼60 amino acids long and it has a DNA-binding basic region, followed by two 
α-helices separated by an adjustable loop region (156,157). This domain is the site of 
dimerisation, allowing the formation of homodimeric or heterodimeric complexes between 
different family members. In this case, the Mrf proteins can dimerise with E proteins to form an 
important complex for myogenic activation. The two basic domains brought together through 
dimerisation bind specific hexameric DNA sequences referred to as “E Boxes” which have the 
consensus sequence (CANNTG). 
The bHLH proteins have been divided into four different groups: A, B, C and D. The most 
important group regarding this project are group A which includes tissue specific proteins such as 
the Mrf members (158). 
1.5.8.2 MyoD acts as a heterodimer with E12/E47 
There are three different genes of E-protein in the group A of the vertebrates species: TCF3/E2A, 
TCF4/E2-2 and TFC12/HEB. All of these proteins can heterodimerise with MyoD and other 
myogenic bHLH proteins to give rise to a functional transcription factor complex (159,160). The 
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single knockout of individual E-proteins in the skeletal muscle has been shown not to produce any 
specific muscle phenotype, indicating that expression of these proteins is redundant. 
The E2A gene produces alternatively spliced transcripts encoding E12 and E47, which differ by just 
the bHLH region (160). The E2A proteins are post-transcriptionally regulated, the most important 
example of which is in the case of E47, which is controlled by Notch signalling and MAP kinase 
activity (160). Notch signalling and the MAP kinase play an important role in skeletal muscle 






Figure 1. 6: Program of transcription factors that regulate myogenic progression 
The expression of transcription factors is regulated during the differentiation of the cells through the 
myogenic lineage. The embryonic progenitors leave the cell cycle and differentiate into myoblasts, while a 
small number of satellite cells return to the quiescent state. The expression of Six1/Six4 and Pax3/Pax7 
represents the master regulators of the early lineage specification, while Myf5 and MyoD commit cells to 
differentiate. The expression of MyoG and Mrf4 represent the last step of differentiation bringing the cell 




1.5.9 Sine oculis and Six4 type members of the Six family of homeoproteins, activated by 
Eya phosphatases, aid the onset and progression of myogenesis 
Six genes encode transcription factors belonging to the Orthodenticle subfamily of paired-type 
homeodomain proteins (reviewed in (161,162). In the vertebrate genome we can find 7 different 
Six genes, Six4-Six1-Six6, Six2-Six3 and Six5-Six. RNAseq data deposited in the Ensembl data base 
(S. Dietrich, unpublished observations) and expression data obtained from mouse, chicken and 
zebrafish expression (156,163–168) showed that, with the exception of Six9, the so and Six4-type 
genes are expressed in skeletal muscle whereas the optix genes are predominantly expressed in 
the developing nervous system (169).  
Six proteins carry two conserved domains. The first is the homeodomain that facilitates DNA 
binding of specific target sites. The second is the more N-terminally located Six domain (SD), 
which aids DNA binding and interacts with Groucho, Dach and Eya proteins. This interaction 
determines whether Six proteins act as transcriptional repressors or activators.  
Groucho/Grg/TLE proteins are transcriptional co-repressors. Vertebrates have 5 Groucho genes, 
all of which are expressed in the young somites albeit at different levels. Dach proteins are 
recruited to additional sites in the chromatin by other transcription factors such as Six proteins, 
but also Jun or Smad 4, in this context typically acting as transcriptional repressor. Vertebrates 
have 2 Dach paralogs (teleosts: 4), and both are expressed in the dermomyotome/somite (see 
RNAseq data in the Ensembl database and (165). 
Eya proteins carry a C-terminal 271 amino acid long Eya domain or ED that facilitates interaction 
with other proteins, most notably Six and Dach proteins. They also carry the two consensus 
sequences typical for the haloacid dehalogenase (HAD) family of phosphohydrolases. Thus, Eya 
proteins dephosphorylate tyrosines on target proteins in an Mg2+-dependent fashion. Eya-
mediated phosphorylation of Six or Six-Dach complexes allow the recruitment of the CBP co-
activator as well as RNA polymerase II for the activation of target genes. Thus, the presence of Eya 
proteins renders Six or Six-Dach complexes transcriptional activators (170,171); reviewed in (172).  
Vertebrates have 4 Eya genes, all of which are expressed in the somite and/or skeletal muscle 
(173,174) and S. Dietrich, unpublished observations). In mice, the expression of the closely related 
Eya1 and 2 genes and the more distantly related Eya4 first occurs in the dermomyotome and its 
dorsomedial and ventrolateral lips and later in the myotome. Eya3 is weakly expressed in the 
somites yet has been shown to cooperate with Ski and Six1 in the differentiation of C2C12 
myoblasts (174–177). Given that Eya proteins facilitate the activation of Six targets, it is not 
surprising that Six and Eya proteins synergise (165). Six1 mutant mice show correct initiation of 
Myogenesis with muscle fibres being diminished at E13.5 of development whilst Six4 mutants 
have no developmental defects (178). However, in Six1-Six4 double mutants, expression of MyoD 
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is reduced, that of MyoG and Mrf4 is abolished at E10.5, and most skeletal muscle is missing at 
E13.5 (164). Likewise, strong muscle phenotypes occur in an allelic series of Eya knockout mice 
only when Eya1 and Eya2 genes are inactivated together (174). However, the precise role of Six 
and Eya genes during skeletal muscle formation is complicated and controversial.  
Sine oculis and the Six4 type genes can bind to the promoters of MyoD and MyoG as well as the 
limb-specific enhancer of Myf5 and drive gene expression from them (179–181) . Therefore, Six 
and Eya genes, like Pax3/7 and Paraxis, have also been referred to as pre-myogenic genes. In the 
ventrolateral lips of the mouse dermomyotome, Pax3 expression is lost when Six and Eya genes 
are mutated, while in Pax3 mutant Splotch, ventrolateral Six and Eya expression is maintained 
(164,174). Thus, in this case, Six and Eya genes act upstream even of the Pax genes. Furthermore, 
Six binding to the MyoD promoter occurs in the context of Myf5 deficiency, which is also an 
artificial situation.  Six and Eya genes regulate the expression of enzymes and structural genes 
required for the establishment of the fast-twich, glycolytic muscle fibre type (182). Thus, Six-Eya 
genes display a key role far downstream in Myogenesis and their description as “pre-myogenic” 
genes may be somewhat misleading. Indeed, although Six1 is expressed in quiescent and 
activated satellite cells, it is not required for satellite cell maintenance or activation, nor for Myf5 
expression. However, it plays a role in MyoD and MyoG regulation as well as satellite cell 
differentiation and, via the upregulation of the Erk1/2 inhibitor Dusp6 (Pyst/ Mpk3), a role in the 
return of the remaining satellite cells to quiescence (183). 
Muscle differentiation requires cell cycle exit and the return of satellite cells to quiescence 
requires cell cycle pausing. It is curious that Six proteins are involved in this, given that in many 
cancer cell lines, Six-Eya proteins enhance transcription of Cyclin D1 during the G1 phase of cell 
cycle and of Cyclin A during late S phase, thereby promoting cell cycle. The role of Six-Eya proteins 
is highly context dependent and the link between muscle regulatory genes and cell cycle control 
will be explored in more detail in Chapter 10. 
1.5.10 The Mef2 family of MADS box transcription factors act as Mrf cofactors 
Mrf activity has been shown to be assisted by the myocyte enhancer factor 2 (Mef2) family of 
transcription factors in regulating the expression of muscle-specific genes (184). Mef2 proteins 
belong to the MADS (MCM1, agamous, deficiens, serum response factor) box-containing 
transcription factor family. The Mef2 family contains four members, Mef2a, b, c and d, all 
encoded by separate genes. In contrast to the Mrfs, Mef2 genes show widespread expression 
during development. Mef2 proteins specifically recognise A/T-rich DNA sequences common to the 
promoters of multiple muscle-specific genes (185). Mef2c transcripts are upregulated during 
Myogenesis in tissue culture and are induced in 10T1/2 fibroblasts by MyoG, suggesting that the 
Mef2c gene is a target for myogenic bHLH proteins. Mef2c transcripts appear for the first time in 
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myocytes, in the myotome of the somites between developmental days 8.5 and 9 with Mef2a and 
Mef2d expressed soon thereafter. Mef2c expression in the myotome initiates about one day later 
than the initial appearance of Myf5 transcripts and several hours later than the appearance of 
MyoG transcripts (186). 
In vitro, Mef2 expression in cell lines does not result in the reproduction of the myogenic cascade. 
Additionally, in vitro evidence shows Mef2 and MyoD directly interact to activate E box/Mef2 
binding site-driven reporters (representative of a muscle-specific cis-element (187)) suggesting 
that Mef2s may serve to support the Mrfs (188–190).  
Inactivation of the murine Mef2c gene resulted in lethal cardiac morphogenic defects however, 
the lack of defects observed in the skeletal muscle was attributed to the redundancy of the Mef2 
genes (191). The expression of the Mef2 family members in skeletal muscle is altered in response 
to the expression of MyoD and this reinforces the idea of a strong link between these proteins 
during muscle progenitor differentiation (192).  
1.5.11 MyoD, Mef2 and Six proteins interact with each other and with histone modifying 
enzymes to activate muscle structural genes 
As mentioned previously, the Mrf genes do not act alone in their activation and maintenance of 
skeletal muscle differentiation, but act in collaboration with other cofactors. Six1 and Mef2 
proteins present themselves as the most important for this essential collaboration as they are 
directly induced by MyoD and cooperate to activate muscle genes ((181) Fig. 1.7A). Interestingly, 
recruitment of a demethylase to the MyoG locus (193,194) along with Six1 upregulates Pax3, 
Myf5, MyoD and MyoG (164,181) as well as fast-twitch muscle-function genes (195). Six1 and Six4 
are essential for final muscle differentiation (164,196) and this function is in cooperation with the 
muscle regulatory factors (Mrfs) MyoD and MyoG in the activation of target gene transcription 
(196). Data revealed a strong correlation between Six binding and target gene activation during 
differentiation (196). MyoD targets chromatin remodelling complexes to the MyoG promoter 
which form a stable DNA-bound complex (197). The presence of MyoD facilitates the acetylation 
of histones at the MyoG promoter followed by the recruitment of Swi/Snf which bind MyoD and 
Mef2 factors. MyoD is consequently secured to the MyoG promoter with the help of HATa p300 
(Histone acetyltransferase) and PCAF. Subsequent rearrangement of the MyoG locus-containing 
chromatin exposes the E-boxes and binding sites of other factors such as Mef2 and Six, creating a 








Figure 1. 7: MyoG promoter activation by MyoD-targeted chromatin-remodelling. 
A) In the undifferentiated myoblast, a nucleosome (yellow) is expected to obscure the relevant binding sites 
of Mef2 and Six factors. Id proteins sequester E-proteins, preventing the formation of MyoD/E12/E47-
protein heterodimers. Mef2 and Six proteins are present but not bound to the MyoG promoter. At this 
stage, the chromatin is acetylated through a mechanism not yet fully understood. 
B) Decreasing Id levels facilitate MyoD/E-protein heterodimerisation that interact at the MyoG promoter to 
recruit HATs and the Swi/Snf complex which acetylate the histones and remodel the chromatin, 
respectively. Remodelling of the chromatin liberates the DNA for proteins to recognise their cognate sites. 






1.5.12 In parallel to the activation of muscle genes, differentiating cells must withdraw 
from the cell cycle 
The final stage of muscle fibre formation and differentiation requires the withdrawal from the cell 
cycle to allow differentiation into myocytes. Recent studies have shown that MyoD, Myf5 and 
MyoG have opposite roles in the control of the cell cycle. In fact both MyoD and Myf5 promote 
the expansion of the muscle progenitor population (81,199), while MyoG possesses an intrinsic 
activity that requires the exit from the cell cycle that consequently leads myoblasts to 
differentiate into myocytes (200). 
The Mrf proteins show different levels of expression during the cell cycle (201). Myf5 for example 
shows a spike in G0, decreasing again at the end of G1 where it remains stable through mitosis, 
meanwhile, MyoD has a low spike in the G1/S transition (202). Studies that observe the behaviour 
of satellite cells during injuries, have discovered that satellite cells can be in a G Alert state (Fig. 
1.8). This different group of Satellite cells have the capability to re-enter and conclude the first cell 
cycle faster than normal satellite cells. This allows the body to respond promptly to injury (203). 
The level of MyoD protein oscillates from a high spike in G1 and reduces in G1/S, increasing again 
between S and M phase of mitosis (201).  
The regulation of MyoD and Myf5 protein levels is regulated by post-translational modifications 
which target them for degradation. Specifically, Myf5 protein levels are modulated by its 
phosphoregulated degradation at mitosis (204,205). At late G1, MyoD is processed through the 
ubiquitin degradation pathway triggered by cyclin E/CDK2-dependent phosphorylation of MyoD at 
Ser200 (206,207). Cyclins are a group of proteins essential for the control of the cell cycle and 
they can control the transcriptional activity of the Mrf genes through phosphorylation. MyoD, for 
example can be phosphorylated by cyclin B/Cdc2 specifically at residues Ser5 and Ser200. 
Phoshorylation of these amino acids reduces the DNA binding activity and the capability to 
activate transcription (208).  
It is therefore evident that Myf5 and MyoD are closely linked to the cell cycle through regulation 
of their stability and activity. This is further corroborated by data demonstrating that MyoD and 
even Myf5 efficiently bind regulatory regions of cell cycle genes, establishing their own 
modulation of the cell cycle (209–211)(81). 
Additionally, mouse myoblasts lacking MyoD fail to exit the cell cycle (200) demonstrating the 
importance of MyoD for cell cycle function. The exit from the cell cycle induced by the expression 
of MyoG causes the activation of CDKN1 (p21cip) (94,212) and the upregulation of specific 
microRNAs. It has been shown that microRNAs can directly target the mRNA of the E2F proteins 
and inhibit their translation  (213,214). Therefore MyoG can indirectly downregulate E2F family 
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protein levels (215). The expression of MyoG represents a ‘point of no return’ upon which the Mrf 
genes initiate commitment to the program that leads the myoblasts to withdraw from the cell 
cycle (216). From this data, we can conclude that MyoD and Myf5 facilitate cell cycle progression 
whereas MyoG and Mrf4 induce exit from the cell cycle. The cell cycle and cyclins are discussed in 





Figure 1. 8: Intrinsic and extrinsic factors regulate the cell cycle of satellite cells 
The effect of intrinsic signals regulate the dormant state of satellite cells in a reversible G0 state. In case 
on injury, the Satellite cells re-enter the cell cycle or via the intermediate state “G-alert”. The satellite cells 
can return to quiescent state through the expression of Spry1 or Notch. Exit from cell cycle will force the 
satellite cells to differentiate into myoblasts and then myocytes, consequently upregulating the expression 
of the cell cycle inhibitors such as p21, p19 and p57 whilst downregulating the cell cycle genes. Image 
adapted from (87) 
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1.5.13 Differentiating muscle cells switch off the precursor/stem cell genes – a role for 
miRNAs 
The human genome contains thousands of non-coding RNAs of which the most studied are 
microRNAs (miRNAs). This group of RNAs regulate gene expression at the post-transcriptional 
level by suppressing the translation of mRNAs through the recognition of complementary 'seed' 
regions of one or more mRNAs, usually in the 3’UTR (217). Recognition of an mRNA target by a 
miRNA results in downregulation of the target through either blocking translation and/or the 
degradation of the target in a process called RNA interference (218). Many miRNAs are expressed 
in skeletal and cardiac muscle suggesting their specific role in the control of Myogenesis (219). 
The more common muscle-specific miRNAs are: miR-1, miR-133, miR-206 and miR-208, which 
appear to be under the control of MyoD and the bHLH transcription factor Twist which cooperate 
with Mef2 (220,221). Data extracted from chromatin immunoprecipitation followed by microarray 
(ChIP on chip) showed that MyoD and MyoG bind sequences upstream of miR-1 and mir-133 
(222).  
Analysis of mice deficient in Myf5 and MyoD revealed a specific requirement of Myf5 for miR-1 
and miR-206 (223). At early developmental stages, the expression of both miR-1 and miR-206 was 
almost entirely absent in the somites of Myf5-mutant embryos, whereas mouse embryos lacking 
MyoD showed an apparently normal expression of both miRNAs (224). Whilst miR-133 and miR-
206 are expressed from independent loci, miR-208 is derived from the intron of the α-myosin 
heavy chain (αMHC) mRNA (225). Some experiments suggest that miRNAs are strictly involved in 
myogenic differentiation as indicated by the absence of miR-1 and miR-133 in undifferentiated 
myoblasts which are conversely upregulated upon differentiation (226).  
The regulatory roles of miR-206, miR-486, and miR-27 for example are not just linked to the Mrf 
family genes but are involved with a wider number of genes such as Pax3 and Pax7 (227). miR-1 
and miR-206 have been shown to downregulate Pax3 during muscle differentiation (227,228). 
Similarly, Pax7 was described to be under the control of miR-1 and miR-206 (229,230). 
Consequently the feedback loop that amplifies MyoD-induced terminal muscle differentiation 
involves the transcriptional switch towards late factors such as Mef2c but also the epigenetic 
downregulation of muscle stem cell factors such as Pax3 and Pax7 (229). Given the roles that they 
play, it can be concluded that miRNAs are a key determinant in myogenic gene control therefore, 
efforts made to expand the understanding of these mechanisms would provide valuable 
information. However, current understanding of miRNAs functions remains contradictory due to 
issues with experimental strategies. Overexpression experiments in which the miRNAs are 
expressed at high levels may not be representative of the miRNAs expressed at endogenous 
levels. The presence of non-physiological levels of miRNAs might cause off target effects and 
therefore wrong conclusions about function as it has been shown for small interfering RNAs (231).  
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1.6 Intrinsic and extrinsic factors which could influence the possible protection of the 
muscle stem cell state in vivo  
The generation of muscle cells occurs by numerous steps that start from gastrulation and the 
formation of the germ layers before progressing to the formation of the primitive streak and the 
cell migrations to construct the immature paraxial mesoderm in chick. Later the tissue will then 
advance and generate the dermomyotome and then establish the myotome through 
epithelialisation, whereupon the cells that migrated from the dermomyotome will colonise the 
myotome and differentiate in the final stage of muscle cell formation. During this process, muscle 
stem cells are exposed to many different cell and tissue types which can affect the progression of 
differentiation through extrinsic factors. The intricate network of genes which drive myogenic 
progenitor differentiation coupled with extrinsic signals which are considered most important in 
muscle stem cell differentiation are therefore important to consider (87,232).  
1.6.1 Systemic factors involved in the control of muscle stem cells 
1.6.1.1 Oxytocin 
Muscle aging is characterised by a lower capacity to regenerate after injuries as well as muscle 
atrophy which together compromise the function of the muscle and is called sarcopenia (233). 
The satellite cells localised in the aged muscle can repair the damaged tissue but they are 
reversibly inhibited by the aged niche (234). Recent experiments identified the presence of 
numerous factors that influence the aging of cells such as TGF-β, Wnt and CCL11 chemokine 
which reduce neurogenesis, influencing cognition and memory (235–237). An important factor 
linked to satellite cell maintenance is Oxytocin, a nanopeptide produced by the hypothalamus 
(238). Oxytocin acts through its receptor which upon activation binds protein kinase C and 
induces intracellular calcium release which in turn acts as a second messenger to induce a cascade 
of intracellular changes (239). Oxytocin is required for muscle tissue regeneration and 
homeostasis, but during aging its levels in plasma decline, reducing its effects on the muscular 
tissue. Data shows that inhibition of oxytocin in young mice reduces muscle regeneration whilst 
genetic deletions of oxytocin cause no developmental defects in muscle but instead lead to 
premature sarcopenia (240). 
1.6.1.2 Diabetes and enhanced Tgf beta signalling 
The production of pancreatic β-cells is essential for the control of glucose homeostasis. 
Autoimmune and non-autoimmune diabetes cause depletion of pancreatic β-cells which result in 
mild and severe metabolic disorders along with increased blood glucose levels  (241,242). Förster 
and colleagues showed that the depletion of the β-cells caused by the injection of streptozotocin 
in vivo (a compound used to induce toxicity in β-cells) caused drastic changes in the regenerative 
response of muscle stem cells, measured by the ability to give rise to proliferating myoblasts. 
Regeneration competency quickly deteriorated in vivo and muscles fail to repair after injuries 
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(243). It was shown however, that the injection of insulin into diabetic mice restores muscle tissue 
regeneration (244). Streptozotocin inhibits satellite cell responses by inducing Myostatin/pSmad3 
signalling, and follistatin (a small molecule inhibitor of TGF-β receptor) which recover satellite cell 
response and improves muscle repair in the diabetic patients. Myostatin is discussed in more 
detail in Section 1.6.2.2. 
1.6.2 Local control by cell-cell communication 
1.6.2.1 Lateral inhibition involving Notch-Delta signalling 
Notch signalling mediates cell-cell communication by the interaction with the two ligands Delta 
and/or Serrate, thereby activating a signalling cascade (245). The role of Notch has been 
attributed to the regulation of embryonic and post-natal skeletal muscle  (246) and it has been 
shown that the forced activation of Notch in cultured myoblasts inhibits their differentiation 
(247). Later, this was shown to be true in vivo as well (132). Notch signalling is also involved in 
muscle stem cell proliferation and differentiation (248) and can influence somitogenesis (249). For 
this, Notch guides the formation of the somite structure by imposing somite borders as well as 
establishing anterior and posterior polarity (102,250). Delta null mice present prominent defects 
in skeletal muscle and dramatic hypotrophy of the muscle tissue. This defect seems to be caused 
by the premature differentiation of the muscle stem cells, followed by the loss of the Pax3/Pax7-
expressing myogenic progenitor cell pool (251). Myogenesis in Delta null mice is present in the 
early embryo but is prematurely terminated disallowing formation of normal musculature. This 
data confirm the role of Notch in the prevention of precocious differentiation and thereby the 
maintenance of progenitor pool expansion (252). 
1.6.2.2 Suppression of Tgf beta signal transduction 
Myostatin, a secreted factor of the TGF-β superfamily, is another important regulator of muscle 
growth. Deletion of Myostatin in animals creates a dramatic increase in muscle mass (253,254) 
whilst its overexpression in skeletal muscle induces a decrease in muscle mass (255). In recent 
years, Myostatin levels were revealed to correlate with muscular dystrophy as dowregulation of 
Myostatin improved the muscular mass in the context of various myopathies (256,257). Cultured 
myogenic cell lines of primary myoblasts used to investigate Myostatin function in vitro 
demonstrated inhibition of myoblast proliferation and cell cycle withdrawal through activation of 
the CDK inhibitor p21 (258,259), as well as simultaneously inhibiting myogenic differentiation 
(259). Myostatin is used to maintain the undifferentiated state of the satellite cells (260) however, 
this hypothesis has not yet been tested in vivo.  
The introduction of Myostatin protein-coated  microbeads into developing chick limb buds altered 
proliferation of Pax7-expressing cells as well as downregulating the genes: Myf5, MyoD and Pax3 
(253,261). This specific effect of Myostatin is reversible upon removal of the beads (262). In adult 
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satellite cells, myostatin signalling reverses quiescence and causes muscle progenitors to 
withdraw from differentiation (260). Additionally, overexpression of Myostatin in somites changes 
the balance between differentiated muscle cells and muscle progenitors in the favour of 
differentiated cells (262) 
1.6.2.3 Suppression of Fgf signal transduction 
Reversible quiescence is widely accepted to be a defining property of adult stem cells. This 
alternation between quiescence and activation is essential for the maintenance of tissue stem 
cells and the tissue as a whole (263). The mechanism by which satellite cells revert back to 
quiescence to renew the stem cell pool is only partially understood. A key component of 
regeneration processes and myogenic fate decision is Receptor Tyrosine Kinase (RTK) signalling 
(264,265). The ligands involved in RTK signalling such as FGF and HGF, are known to be proficient 
in activating satellite cells (266). Elevated levels of FGF, sourced principally from aged satellite 
cells results in loss of quiescence and depletion of the local stem cell pool which therefore reduce 
regenerative capacity (267). The consequences of aged stem cells is therefore their incapability to 
retain stem cells in a quiescent state (267). 
1.6.2.4 Ang1 signalling from nearby non-muscle cells return satellite cells to quiescence 
Several markers have been associated with murine quiescent satellite cells, such as M-cadherin 
(268,269), syndecan 3 and 4, CD34, calcitonin receptor (270), and Myf5. However, satellite cells 
have been shown to have greater proficiency in self-renewing when not expressing Myf5 (18). 
Many genes are involved in the regulation of myogenic cell proliferation and differentiation, but 
direct regulators of quiescence and self-renewal are scarcely known; p130 from the Rb family 
impedes cell cycle progression and differentiation in human cultures, thereby regulating the stem 
cell pool (271). Satellite cells in normal adult skeletal muscle are located close to capillaries (272). 
Ang1 and Tie2, expressed highly in quiescent and undifferentiated stem cells, bind each other to 
cause reversion to stem cell status. This was confirmed in vivo by loss- and gain of function 
experiments in skeletal muscle satellite cells (273). 
1.6.2.5 Wnt7a and the expansion of the stem cell pool by promoting symmetrical cell division 
Wnt signalling is very important in the paraxial mesoderm for embryonic myogenic induction  
(274,275), as well as in the control of differentiation during muscle fibre development. The Wnt 
planar cell polarity (PCP) pathway drives the orientation of myocyte growth in the developing 
myotome (276). Wnt signalling is required for activation of adult stem cells for the repair of 
damaged muscle tissue (277).  
Canonical Wnt/β-catenin signalling activates and recruits reserve myoblasts (278) as well as 
controlling myogenic lineage progression by limiting Notch signalling and thus promoting 
differentiation in satellite cells within adult muscle (279).  
65 
 
Wnt receptor Fzd7 has been shown to be markedly upregulated in quiescent satellite stem cells 
indicating involvement of non-canonical Wnt signalling. Wnt7a was later revealed to be expressed 
during muscle regeneration and enhances muscle regeneration through the induction of 
symmetric satellite stem cell division by acting via the Fzd7 and Vangl2 components of the planar 
cell polarity (PCP) pathway. The PCP pathway is thereby indicated to regulate the renewal of the 
stem cell pool during adult skeletal muscle regeneration (280). 
Elevated quantities of fibronectin (FN) in the microenvironment of committed satellite cells were 
discovered at the initial response to injury. Ligation of FN to the Fzd7/Sdc4 receptor complex is 
essential for the early stage expansion of the stem cell pool by Wnt7a as was shown by knock 
down of FN, consequently causing reduction of the satellite cell pool and the subsequent capacity 
of the muscle to regenerate (281).  
This auto-regulation of the FN content in satellite cells was shown to be an essential ability for 
correct maintenance of satellite cell pools. 
The FN content of satellite stem cells was demonstrated to be lower than in satellite myogenic 
cells (281) indicating that committed daughter cells of an asymmetrical division are capable of 
instructing the satellite cell to enhance its sensitivity to Wnt7a/Fzd7 signalling. This feedback 
between satellite myogenic and satellite stem cells is proposed to provide a means by which the 
size of the satellite cell pool and the ratio of its committed/non-committed components is 
controlled. 
Wnt7a–Fzd7 activation of the planar cell polarity pathway is completely independent of IGF-
receptor activation resulting in enhanced skeletal muscle repair. Wnt7a–Fzd7 therefore activates 
specific pathways at defined developmental stages during the progression of Myogenesis through 
a non-canonical anabolic signalling pathway in skeletal muscle (282). 
1.6.2.6 JAK-STAT signalling stimulates symmetrical division of satellite cells  
The regenerative capacity of skeletal muscle diminishes with age which is characterised in mice as 
a reduction of satellite cell contribution to regeneration and self-renewal. Analysis of gene 
expression in relatively older mice identified increased JAK-STAT signalling (283). Investigation 
with JAK2/STAT3 knockdown in cultured myofibres significantly stimulated satellite stem cell 
division. Moreover, genetic knockdown of JAK2 or STAT3 in satellite cells transplanted into 
regenerating tibialis anterior muscle greatly enhanced repopulation capacity. Investigation into 
pharmacological inhibition of JAK2 and STAT3 produced similar expansion and engraftment 
results. Subsequent use of these drugs by intramuscular injection enhanced muscle repair and 
force generation following cardiotoxin injury. This shows promising prospects for future 
development of a therapy for tackling muscle wasting disease (284,285). 
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1.7 Aims of this study 
Previous reports showed that the Mrfs are sufficient to drive non-myogenic cells to become 
muscle cells in vitro. Currently, limited evidence exists to support that this is the case in vivo, 
whilst preliminary data indicates the contrary. Broadly, the aim of this project was to investigate 
this gap in knowledge. The use of embryonic muscle stem cells importantly allows us to 
characterise the behaviour of cells during muscle formation. This approach could help understand 
the pathologies associated with muscle degeneration and how muscle diseases could be detected 
in early development. As explained in section 1.3.2, satellite cells (adult muscle stem cells) are 
considered a heterogeneous group of muscle stem cells with different markers expressed 
compared to the embryonic myoblasts. It is therefore thought that future therapies utilising 
reprogrammed stem cells would be more easily developed by starting with embryonic myoblasts. 
The aims of this work will link together basic investigations to understand wild type myogenic 
differentiation with more applied investigations into how the genes involved in muscle 
development can be used to manipulate muscle generation. 
This study will specifically involve: 
1. Characterising the expression of known myogenic genes at a range of developmental 
stages to enable the compilation of a time course to inform future experiments. 
2. Misexpressing Mrfs and/or known cofactors in various early stage stem cell tissues and 
analysing the effects on gene expression by various molecular techniques such as in situ 
hybridisation and immunohistochemistry. 
3. Searching for gene misexpression conditions under which early stage stem cell tissues can 





2 Materials and Methods 
2.1 Stock solutions 
Unless otherwise stated, solutions used in RNAse sensitive protocols were treated with 0.05 % 
(v/v) DEPC and autoclaved. Water double distilled/deionised (ddH2O) in a water purification unit 
was sterilised by subsequent autoclaving. All the other stock solutions were sterilised by 
autoclaving. 
2.1.1 In Situ Hybridisation (ISH) and Immunohistochemistry (IHC) stock solutions   
10 % BBR  Boehringer 's  blocking  reagent  (Roche)  dissolved  in MAB by autoclaving 
   and stored in 10 ml aliquots at -20°C. 
 
Bleaching solution  5 % Formamide (Sigma) 0.5 × SSC pH 4.5 
   10 % H2O2 (Sigma) 
    
2 % Cysteine  4 g cysteine (Sigma) 150 ml 0.1 M MBS 
   10 pellets of concentrated NaOH 
   5 M NaOH was added to bring the solution to pH 8.0 
 
Detergent mix  1 % lgepal (Sigma), 1 % SDS, 0.5 % Sodium Deoxycholate (Sigma), 50 mM 
   Tris-HCl pH 8.2, 1 mM EDTA and 150 mM NaCI (Fisher) in DEPC-ddH2O.  
 
Glycerol  Glycerol (Fisher) diluted in DEPC-PBS to 20 %, 50 % and 80 %. 
Goat Serum  Goat serum (Sigma), heat inactivated at 56 °C for 30 min and stored in  
   aliquots of 10 ml at -20 °C. 
 
Hybridisation mix 50 % Formamide (Sigma), 5 x SSC pH 4.5, 2 % SOS, 2 % BBR, 250 µg/ml  
   tRNA (Roche), 100 µg/ml heparin (Sigma) in DEPC-ddH2O. 
 
1M Levamisole  Levamisole (Sigma) dissolved in ddH2O and stored in aliquots of 1 ml at  
   -20 °C. 
 
MAB pH 7.5  100 mM Maleic acid (Sigma), 150 mM NaCI in ddH2O, ddH2O treated and 
   autoclaved. 
 
MABT   MAB with 0.1 % Tween-20 (Sigma)  
MBS    (Modify Barth’s Saline) 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 15 mM  
   HEPES-NaOH pH 7.6, 0.3 mM Ca(NO3)2, 0.41 mM CaCl2,  0.82 mM MgSO4, 
   50 mg/ml Gentamycin. 
  
MEMFA  0.1 M MOPS pH 7.5 2 ml 0.5 M 
   2 mM EGTA pH 8 40 µl 0.5 M 
   1 mM Mg2SO4   20 µl 0.5 M 




NTMT with azide 100 mM NaCI, 100 mM Tris-HCI pH 9.5, 50 mM MgCl2, 1% Tween-20,  
   2mM Levamisole, 0.02 % Sodium azide (Sigma) in ddH2O. 
 
NBT   Stock 100 mg/ml in demethylformamide (Boehringer) 
BCIP   Stock 50 mg/ml in demethylformamide (Boehringer)    
1 x PBS   Phosphate buffered saline tablets (Sigma) dissolved in ddH2O according  
   to manufacturer’s instructions, DEPC treated and autoclaved. 
 
PBT   PBS with 0.1 % Tween-20. 
4 % (w/v) PFA  Paraformaldehyde (Sigma) dissolved in PBS with stirring and, heating at  
   60 °C. 10 ml aliquots were stored at -20°C. 
 
20 % SDS  Sodium dodecyl sulphate (Sigma) dissolved in DEPC-ddH2O. 
20 x SSC pH 4.5  3 M NaCI, 0.3 M sodium citrate (Sigma) dissolved in DEPC-ddH2O.  
pH adjusted to 4.5 with 1 M citric acid. 
 
Solution X  50 % Formamide, 2 x SSC pH 4.5 and 1 % SDS in ddH2O. 
Solution 1  50 % de-ionised formamide, 5 × SSC pH 4.5, 1 % SDS in ddH2O 
Solution 2  5 M NaCl, 1 M Tris pH 7.5, Tween 20 in ddH2O 
Solution 3  50 % formamide, 2 × SSC pH 4.5 
Tris-HCI pH7.5, 8.2, 9.5 Trizma base (Sigma) dissolved in DEPC-ddH2O, pH adjusted with   
   concentrated hydrochloric acid (HCI). 
 
Triton X-100  4-(1,1,3,3-Tetramethylbutyl ) phenyl-polyethylene glycol (Sigma). 
Tween-20   Polyoxyethilene sorbitan monolaurate (Sigma) 
2.1.2 Molecular Biology solutions  
1.5 % LB Agar  Agar (Sigma) mixed in LB medium. 
LB medium  1 litre Luria-Bertani medium: 10 g tryptone (Sigma), 5 g yeast extract,  
   10 g NaCI in ddH2O. pH adjusted to 7.5 with sodium hydroxide and  
   autoclaved. 
 
50 x TAE  242 g Tris base (Sigma), 57.1 ml glacial acetic acid, 100 ml 0.5 M EDTA  
   (pH 8), in ddH2O to 500 ml. 
 
2.1.3 Albumin Petri dishes culture solutions  
35 mm Petri dishes (Fisher). 
50 ml Falcon tubes (Fisher). 
10 ml pipettes 
120 ml of thin albumen, collected from 2 dozen incubated eggs. 
120 ml of simple saline, autoclaved (7.19g NaCl/ 1 l distilled water). 





2.1.4 β-galactosidase  
50 mM K4Fe(CN)6  
   50 mM K3Fe(CN)6 
   1 M MgCl2 
   10 % NP40 
   40 mg/ml X-Gal (Euromedex) in formamide  
   40 mg/ml Red-Gal (Sigma) in formamide 
   PBS/MgCl2 :1 × PBS containing 2 mM MgCl2 
 
 
2.2 Molecular Biology 
Unless otherwise stated, a benchtop centrifuge (Heraeus instruments PICO 21) at 13000 rpm 
(17900 x g) was used for all centrifugation steps. 
2.2.1 Plasmid Vector and bacterial strain 
The general cloning vector was pCAB-GFP conferring ampicillin resistance. This was used for 
cloning all the genes used in chicken models. The vector is 5770 bp and it has a cytomegalovirus 
(CMV) enhancer and chicken beta actin promoter. More details are described in Chapter 4 (Fig. 
4.5). The vector pCS2+ was used to clone Mrf and mouse MyoD constructs genes for producing 
mRNA used in Xenopus injections. Contains a strong enhancer/promoter (simian CMV IE94) 
followed by a polylinker and the SV40 late polyadenlyation site. An SP6 promoter is present in the 
5' untranslated region of the mRNA from the sCMV promoter, allowing in vitro RNA synthesis of 
sequences cloned into the polylinker. A T7 promoter in reverse orientation between the 
polylinker and the SV40 polyA site allows probe synthesis, as well as a second polylinker after the 
SV40 polyA site to provide several possible sites to linearise the vector for SP6 RNA transcription. 
The vector backbone is from pBluescript II KS+ and includes the ampicillin resistance gene. α-
select Chemically Competent cells (Silver Efficiency) (Bioline) were used for the transformation 
step.  
2.2.2 Transformation of competent cells 
Frozen 10 µI aliquots of competent α-cells were thawed on ice, mixed in a 1.5 ml micro-centrifuge 
tube with 0.5 µg of plasmid DNA, and kept on ice for 5 minutes. The DNA was forced into the cells 
by heat shocking the bacteria at 42 °C for 45 seconds, then placed on ice for a further 2 minutes. 
Following this, 900 µl of pre-warmed SOC medium was added to the tube. The cells were then 
plated onto pre-warmed LB agar plates containing 100 µg/ml ampicillin to select for transformed 





2.2.3 Bacterial Stock 
Bacterial stocks were prepared by re-suspending 200 µl of homogenised bacteria, cultured 
overnight at 37 °C, in 800 µl glycerol. The mixture was quickly frozen in liquid nitrogen and then 
stored at -80 °C. 
2.2.4 Ligation 
DNA fragment/insert of interest was isolated by gel eletrophoresis and purified by gel extraction 
kit (section 2.2.10). Both the insert and the desired vector were digested with the same restriction 
enzymes, again isolated and purified by the same methods. T4 DNA ligase in the DNA rapid 
ligation kit (Roche) was used to ligate the insert and vector at room temperature for 5 minutes. 
Once complete, the ligated product was directly transformed into bacteria. 
2.2.5 Screening for transformants and PCR 
Successfully ligated transformants were screened by PCR with the following conditions: 95°C tor 1 
minute, then denatured, annealed and extended at (95°C tor 15 seconds, 65°C tor 15 seconds, 
72°C tor 2 minutes) for 5 cycles; (95°C tor 15 seconds, 50°C tor 15 seconds, 72°C tor 2 minutes) for 
25 cycles, and then at 72°C for 6 minutes. Individual colonies from the original LB plate with 
transformants were dipped into a free grid cell on a replica LB plate and then dipped into the 
corresponding PCR tube/well. The replica plate was incubated at 37°C overnight. The 
transformants containing the insert of interest was cultured in LB medium overnight tor mini-
preparation, and confirmed by restriction enzyme digest and DNA sequencing. 
2.2.6 Mini-preparation of plasmid DNA 
A single colony of transformed E.coli cells was inoculated into 5ml of LB medium with 1OOµg/ml 
ampicillin and cultured overnight at 37°C shaking at 250 rpm in an IKA KS 4000 I control orbital 
incubator. The cells were homogenised by brief vortexing and pelleted by centrifugation for 5 
minutes. The Qiagen miniprep kit was used to extract DNA according to the manufacturers' 
instructions. Briefly, the pelleted cells were resuspended in Buffer P1 to which RNaseA had been 
added to a final concentration of 1OOµg/ml. The cells were lysed by adding Buffer P2 to the 
suspension and mixed by inverting the tube. The lysis reaction was neutralised with Buffer N3, 
which precipitates genomic DNA and proteins. The solution was mixed thoroughly by inverting the 
tube, and then centrifuged tor 1O minutes. The supernatant containing the plasmid DNA was 
applied to the QIAprep spin column and centrifuged for 1 minute. The DNA bound to the column 
was washed with Buffer PE and eluted with 50 µl ddH2O by centrifugation, again tor 1 minute. The 
miniprep DNA was stored at-20°C. 
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2.2.7 Maxi preparation of plasmid DNA 
Ali centrifugations in this process were performed in a Heppendorf 5804R at 4°C. A single colony 
of transformed E.coli cells was inoculated into 250ml LB medium with 25Oµg/ml ampicillin, 
cultured overnight at 37°C with shaking at 250 rpm. The overnight culture was divided into 50ml 
polypropylene centrifuge tubes and centrifuged. The cell pellets were combined into a single 50ml 
polypropylene centrifuge tube before proceeding with the Qiagen Maxi Kit protocol. 
2.2.8 Agarose gel electrophoresis 
DNA and RNA were routinely analysed by gel electrophoresis with 1 % (w/v) agarose gels in 1 × 
TAE buffer. Typically 1 g of agarose (Sigma) was dissolved in 100 ml TAE buffer by heating in a 
microwave. The molten gel was cooled and ethidium bromide (Sigma) was added to a final 
concentration of 0.5 µg/ml before pouring. The gel was run at 70 V in an electrophoresis tank 
(Bio-Rad) using TAE as the running buffer. DNA was visualised under ultraviolet illumination. A 1 
kb or a 100 bp DNA ladder (Promega) was run alongside the samples as a marker to determine 
the size of the DNA fragments. 
2.2.9 Restriction analysis  
Plasmid DNA was digested using restriction enzymes and buffers provided by New England 
Biolabs (NEB), Promega or Roche. A typical reaction mixture consisted of up to 2µg of plasmid 
DNA, 1 µI of the appropriate restriction enzyme (final activity, 0.2-0.5 units/µI), 5 µl of the 
corresponding buffer and sterile ddH2O added to a total volume of 50 µl. The digest was 
incubated for 3-12 hours at 37 °C. Specific DNA fragments and linearised plasmid DNA were 
purified using gel extraction techniques. 
2.2.10 Gel extraction and purification 
Following a double restriction digest or a polymerase chain reaction (PCR), a specific DNA 
fragment was purified using the Machenery-Nagel (NucleoSpin Gel and PCR Clean-up) gel 
extraction kit. The DNA was first separated on an agarose gel using eletrophoresis. The fragment 
was excised under UV illumination and weighed. Three volumes of Buffer NTI were added to 1 
volume of gel (assuming that 10 µl-100 mg) and the gel was melted at 50 °C for 10 minutes. One 
gel volume of isopropanol was added to the sample, mixed, then applied to a spin column and 
centrifuged tor 1 minute. Buffer NT3 containing ethanol was used to wash the bound DNA in the 
column by centrifugation. The column was then transferred to a fresh 1.5 ml microcentrifuge tube 
and the DNA was eluted with 50 µl of ddH2O, again by centrifugation. 
2.2.11 NTP/CAP 
The PCR template the mMESSAGE mMACHINE Kit is designed to function best with templates that 
code for RNA transcripts in the 0.3 to 5 kb range. The kit can be used to produce shorter, or longer 
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RNA. 4 µl of water was mixed with 10 µl NTP/CAP, 10 µl 10 x reaction buffer, 1-2 µl DNA (1 µg) 
and 2 µl of Enzyme mix. The mixture was incubated for 2 hrs at 37 °C. 1 µl Turbo DNAse was then 
added to the mixture and incubated for a further 15 mins at 37 °C.  
2.2.12 NanoDrop  
All nucleic acids produced for the experiments were analysed at the NanoDrop 2000c (UV-Vis 
spectrophotometer) to verify the absorbance and the initial analysis for the purity.  
2.2.13 DNA sequencing  
DNA sequencing was conducted offsite by DNA sequencing service provided by Source 
Biosciences, Cambridge. DNA and primers were diluted in ddH2O to a final concentration specified 
by the provider. lnserts cloned into pCAB-GFP vector were sequenced with the universal M13 
forward (5' - CCAGGGTTTTCCAGTC ACG - 3') and the M13 reverse (5' - TCACACAGGAAACAGCTATG 
- 3') primers or with pCAB-F forward (5'- CTACAGCTCCTGGGCAACGTGC - 3') and pCAB-R reverse 
(5' – GCTGAACTIGTGGCCGTTIAC - 3') primers. Different primers were used to sequences the 
constructs cloned in pCS2+. Sp6pCS2+ (5’-ATTTAGGTGACACTATAGAAGAGAAGC-3’) and T3pCS2+ 
(5’-AATTAACCCTCACTAAAGGGAGAAAAAG-3’). 
 
2.3 Subcloning Mrf constructs into pCS2+ vector for preparing mRNA 
The chicken Mrfs (Myf5, MyoD, MyoG and Mrf4) and three different mouse MyoD were cloned in 
pSC2+ vector. The constructs were digested with Cla1 and EcoR1 to cut the ORF with the 
restriction digestion analysis. The fragments were ligate in the pSC2 (see 2.3.4) and transform in 
competent cells. Colonies were verified and test with PCR and run in agarose gel. Colonies were 
chose and used for the mini prep and incubate overnight. The mini prep were digested and run in 
the gel to verify the exact size of the fragment. One verified the mini prep were linearised with 
Not1. The DNA of the constructs was treated with transcription reaction using (Fisher mMessage 
mMachine KiT) using a NTP/CAP. This transcription mixture allows the single step production of 
5’-prime capped mRNA. The RNA was nanodrop for measuring the concentration and to verify the 
initial assessment of the purity. Few problems came out with the MyoG constructs and we could 
to not cloned it pSC2 via subcloning therefore another an alternative strategy was used. The ORF 
was PCR-amplified using a Forward primer (ATTTAGGTGACACTATAGAAGAGAAGC) incorporating 
an upstream SP6 promoter and the Reverse primer (AATTAACCCTCACTAAAGGGAGAAAAAG). 
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2.4 Manipulation of embryos  
2.4.1 Chicken embryos  
Fertilised chicken eggs were obtained from Henry Stewart and Co (Peterborough, UK). They were 
incubated at 38 °C for the required stage (4.5 hours per stage). The embryo was harvested by 
cracking the egg open into a glass dish. The embryo was removed from the yolk by cutting into 
the yolk sac and putting the embryo into PBS using a spatula to wash. The vitelline membrane was 
removed and for embryos HH14 onwards the amnion was removed over the top of the rostral 
region. Embryos were then put into fixative. 
For embryos HH9 to around HH14, the embryos were staged by counting somites. However not all 
somites are the same within a given HH embryos, since the earlier formed anterior somites are 
developmentally more mature than later formed posterior somites. Thus, the developmental age 
or flank/trunk somites (S) was determinate according to Christ and Ordahl 1995 (128), modified 
by Pourquie’ in 1999 (286) , which takes into consideration both the maturation of the somites 
and HH of the embryos. For older stages embryos HH20/23/24 staged according to the 
morphological features described by Hamburger and Hamilton (287). 
 
2.4.1.1 Fixing embryos 
Chicken embryos fixed in 4 % PFA/PBS were left overnight and then stored long term in PBS. 
Xenopus embryos were fixed in MEMFA for 30-40 minutes, followed by two 30 minute methanol 
washes and then stored long term in methanol. All embryos were stored at 4 °C. 
2.4.1.2 Filter rings culture (ES) 
Heat a water bath to 49 °C. Add the saline to a sterile 500 ml flask and bring it to boiling, using a 
hot plate/stirrer. Add the agar and stir until it is dissolved. While the agar is dissolving, collect the 
thin albumen in a sterile Falcon tube (50 ml) or similar container. Place the tubes into the water 
bath at 49 °C. Once the agar is dissolved, put the flask into the water bath. Allow the liquid to 
equilibrate at 49 °C. On a flat surface, lay the sterile Petri dishes with their lids removed. Add the 
albumen to the flask containing the dissolved agar, and mix by swirling for 30–60 sec. Also add the 
penicillin/streptomycin to this mixture, 5 U/ml. Using a sterile 10 ml pipette or similar device, 
aliquot 2.5 ml of the mixture per Petri dish. Once the aliquoting is complete, replace the lids of 
the Petri dishes and leave the dishes for several hours or overnight at room temperature to dry. 
Store them at 4 °C. After the 21 hr of incubation to reach HH4 according to Hamburger and 
Hamilton (287) eggs were spray with ethanol 70 % and let cold down on the bench for 30 minutes. 
Eggs were opened in a glass petri dish and the thin albumin was removed using pieces of tissue 
paper. A piece of filter paper with a central aperture was placed gently onto the vitelline 
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membranes, such that the embryo is framed in the centre. Using scissors, cut through the vitelline 
membranes around the filter paper, taking care to cut completely around its perimeter. With 
forceps, gently pull the filter paper away from the yolk in an oblique direction. Place the embryo 
in the petri dish with the albumin and place the plate under the microscope and remove the 
excess of the yolk with saline using a pastette. Keep the embryos in box keeping the moist with 
wet paper. 
2.4.1.3 Dil labelling  
Fluorescent vital dyes Dil (lnvitrogen) was diluted in ethanol to 0.5 % Dii. The dye was injected 
into the primitive streak of the HH4, 5 and 6 embryos as showed in the chapter 5 (Fig. 5.1). The 
labelling was performed under a Zeiss Stemi SV11 fluorescent stereomicroscope. And analysed 
under the Zeiss Axioskop 2 plus after the amount of time necessary to allow the embryos to reach 
the desired HH10. 
2.4.2 Xenopus embryos manipulation 
Xenopus laevis embryos were de-jellied in 2 % cysteine to separate the embryos, and were 
carefully washed in 1 × MBS to remove the cysteine. The embryos were then transferred into 
0.1 × MBS and no more than 50 embryos were placed into a large Petri dish. The embryos were 
incubated at 14, 18 or 23 °C for the required stage (288). Once the embryos reached the required 
stage they were then into fixative. Embryos were staged according to Nieuwkoop and Faber (289).  
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2.5 Electroporation  
2.5.1 In ovo electroporation 
Fertilised chicken eggs were incubated until HH16. The eggs were sprayed with ethanol to prevent 
contamination and sellotape was placed over the top of eggs. Using a sterile needle (Fisher), a 
hole was placed at one end of the egg and 2-2.5 ml of albumin was removed. Another hole was 
placed, slightly off centre at the top of the egg, through the sellotape. A window was cut into the 
shell using curved scissors to expose the live embryo. 2- 3 drops of PBS + ampicillin were added to 
prevent the embryos drying out. 1 µl of fast green (Sigma) was added to 5 µl of expression 
construct in a 1.5 ml reaction tube and a small quantity was transferred to a fine glass needle and 
placed into a micromanipulator. 
The vitelline membrane was removed from above the embryo with fine forceps. The injection 
needle was placed inside the caudal somites and the construct was injected into the lumen of the 
somites. The platinum cathode (set up on micromanipulator) was placed into the neural tube and 
the tungsten cathode (hand-held) was used to give pulsed to the somites (Fig.2.1). The fine 
microsurgical electrode was used to pierce the somites and allow the construct to migrate 
towards the positive electrode. 3 pulses of 15 V with 50 ms width, 50 ms delay and 50 Hz 
frequency was applied and the electrodes were then removed. A further 1-2 drops of PBS were 
applied to the embryo; the lid of the egg was replaced and sealed with sellotape. The embryos 















   
Figure 2. 1: Electroporation in somites 
Schematic view of the electroporation in ovo. The somites were electroporated injecting 
the lumen of the somites with a microsurgical needles. The negative electrode was place 
in the centre of the neural tube and the positive electrode was moved close to the 






2.5.2 Electroporation in EC 
Electroporation was performed in EC culture with the embryo facing ventral side up, HH4. The 
embryos was place in a custom made chamber in an electrode build in the center of it. A small 
volume of saline was put on the top of the embedded electrode to avoid the embryos to stick to 
the bottom of the chamber and increase the conductibility. The embryos were transferred from 
the petri dish to the chamber and saline was add on top to the embryos to avoid fiscal contact 
between the electrode and the tissue. DNA at 1 mg/ml was mixed with fast green to allow 
visualization of the injection and injected into the primitive streak using an Eppendorf Fem- 
microinjector capillary needles (Fig. 2.2). Electrodes were made from 1 mm diameter platinum 
wires flame sharped. These were placed above the area to be electroporated and five pulsed of 
50 V, 50 ms width, 50 ms delay and 50 Hz were delivered using an Intra-cell TSS20 Dual Pulse 







Figure 2. 2: Electroporation of HH4-5 embryos in EC culture 
The embryos were electroporated ventral side up. The HH4 embryos were placed on 
custom made chamber and the embryos was placed on the top of the electrode 
imbedded in the chamber and moved to reach the desire position with the Hansen’s 
node and the neural plate on the electrode (dashed black circle). The embryos was 
electroporated on the primitive streak (Dashed blue circle). The HH5 embryos 
showed the first appearance of the notochord. In this case the primitive streak 
appear shorter and the neural plate appeared bigger (dashed back circle). The 
embryos was electroporated in the primitive streak (dashed blue circle) and pulses 





2.5.3 Fixation after electroporation  
Embryos electroporated at HH4 were harvested after 12 hrs of incubation. The embryos were 
taken out of the albumin plates and put in trays and covered with PBS. Using sharp scissors, the 
filter ring around the embryos was removed as well as the excessive tissue around the embryos. 
The head was freed from vitelline membrane and the forebrain was subsequently pierced to 
improve the quality of the IHC and ISH staining. Using a spatula, the embryos were placed 
carefully in a petri dish and covered with 4 % PFA.  
Embryos harvested at HH20/24 were taken out from the egg with a spatula and put in a petri dish 
with PBS. The embryos were dissected using sharp forceps and scissors and the amnion and 
allantois were removed. Once the embryos were freed from all membranes, punctures were 
made in the telencephalon and the mesencephalon. This important step was included to facilitate 
the unhindered movement of the IHC and ISH solutions thus allowing the reduction of background 
signal.  
2.6 Immunohistodetection of proteins in whole mount  
Embryos fixed in 4 % PFA/PBS were already stored in PBS so were ready to use. As embryos fixed 
in MEMFA and were stored in methanol, they needed to be rehydrated from 75 % MeOH to 25 % 
MeOH and then placed in PBS. Chick embryos were prepared by opening up the hindbrain roof 
plate and making a cut between the telencephalon vesicles, to improve penetration of the 
antibody into the tissue.  
2.6.1 Use of the primary antibody  
Embryos were placed into individual wells in a 24-well dish, in which all washes were performed 
at 4 °C on a shaking platform. The pigmentation of the Xenopus embryos was removed in an 
additional bleaching step. Bleaching solution was added to the embryos and placed on a light box 
for approximately 20 minutes until the embryos were white. The bleaching solution was removed 
by washing three times with PBS. Three 1 hour washes with PBS removed any excess fixative or 
bleaching solution, followed by PBS/5 % serum/1 % Triton X-100/0.1 % H2O2 that was left 
overnight at 4 °C. Goat serum (Sigma) was used to block non-specific protein binding. Triton X-100 
was used as it is a non-ionic detergent and allows cell permeabilisation and PBS (Phosphate 
Buffered Saline) was used as it ensures the pH of the solutions remain constant. 
The H2O2 solution was washed off with three 1 hour washes of PBS/5 % serum/1 % Triton X-100. 
The primary antibody was then added at the relevant concentration (Table 2.1) to the following 
solution: PBS/10 % serum/1 % Triton X-100/0.02 % Na-azide. This solution was left on the 
embryos for 3-4 nights at 4 °C to allow the antibody to diffuse throughout the embryo and bind to 
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its appropriate antigen. The addition of Na-azide allows the primary antibody solution to be 
preserved and used again. 
2.6.2 Use of the secondary antibody 
Any unbound primary antibody was washed off with three 1 hour washes of PBS/1 % serum/1 % 
Triton X-100, followed by the addition of the secondary antibody at the relevant concentration 
(Table 2.2) with the following solution: PBS/5 % serum/1 % Triton X-100. The secondary antibody 
solution was left on overnight at 4 °C. If a fluorescent antibody was used the embryos were kept 
in the dark. Any unbound secondary antibody was then washed off with three 1 hour washes of 
PBS/1 % serum/1 % Triton X-100. 
2.6.3 DAB (3,3'-Diaminobenzidine) labelling with HRP (horseradish peroxidase) conjugated 
antibody  
HRP conjugated antibodies were washed twice with 100 mM Tris-HCl pH 7.5 for 30 minutes and 
incubated with inactive DAB solution (filtered) for 3 hours. Active DAB stain (3 µl H2O2 per 1 ml 
DAB) was added to the embryos for up to 15 minutes (no longer than 1 hour) until the somites 
and the heart were clearly labelled. To stop the reaction the embryos were rinsed with ddH2O 
three times, followed by three 30 minute PBS washes. The embryos were fixed with 4 % PFA/PBS 
overnight and then put into 80 % glycerol for long term storage. 
2.6.4 Fluorescence immunostaining  
For fluorescently labelled antibodies, the embryos were washed with PBS for 30 minutes followed 
by fixing with 4 % PFA/PBS for 1 hour. The embryos were then put into long term storage with 
80 % glycerol. 
2.6.4.1 Double-labelling immunohistochemistry 
The basic protocol (Sections 2.7.1 and 2.7.2) was followed but two different primary antibodies 
that were raised in different species (rabbit and mouse) were used. Both the primary and 
secondary antibodies were added to the solutions at the same time. The secondary antibodies 
used were conjugated to different colour fluorescent dyes so they could be individually detected 
and distinguished by exciting at different wavelengths. 
2.7 Immunohistofluorescence detection of proteins in OCT treated sections 
2.7.1 Cryostat sections and antigen retrieval 
Chicken embryos were used for immunohistochemistry on cryosection slices. The embryos store 
in 4 % PFA in PSB were rise 5 times in PBS. The whole embryos was dissected to extract the 
central part of the truck that contained the electroporated somites and washed in 10 % sucrose in 
PBS overnight. Then wash in 20 % sucrose in PBS 6 hrs. Embedding standard wells (VWR) were 
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used to embed the embryos in OCT. A volume of OCT was placed in the well to fill the bottom 
then a pastette was used to transfer the embryos in to the well. The embryos were moved to be 
in a correct vertically straight position. The block was left in dry ice for a few minutes to make 
sure that the OCT and the embryos were thoroughly frozen and then transferred to be stored at 
-80 °C. 
The block was then mounted onto the cryo-block using OCT in the cryostat machine (HM525 NX). 
The block was trimmed using a razor blade and left in the machine to reach the stable 
temperature of -22 °C. The sections that were cut were between 10-15 µm. The sections were 
positioned on adhesion microscope slides (MARIENFELD) ready to use and store in a box 
overnight at 4 °C and then moved to -80 °C. 
2.7.2 Use of the primary antibody 
The slices were positioned in a tray were we could manipulate them without any problems. The 
slices were first fix in 4 % PFA in PBS using 400 µl per slide, spreading over the sections and using a 
blue tips held at a shallow angle. We decided to don’t use the bucket to avoid the loss of the 
slices. The slices were wash 3 times for 3 min with PBS and then left one hr in 5 % serum in PBS. 
The primary antibody was added in 5 % serum in PBS and left over night at 4 °C. To keep the 
antibody to don’t dry out we placed a small cover slips made from clear parafilm. The slide was 
positioned carefully with forceps and removed the day after. Antibodies used in the immunos are 
all collected in Table 2.1. 
2.7.3 Use of the secondary antibody 
After the overnight incubation slices were wash 5 times with PBS for 3 min each. The secondary 
antibody was added in 5 % serum in PBS and left incubate for 2 hr room temperature. After the 
incubation the slices were washed 3 time in PBS and fixed for 5 minutes in 4 % PFA in PBS. The 
PFA was rinsed away in two PBS washes.  
2.7.4 Dapi staining 
10 µl Dapi/Hoechst in 12 ml PBS was incubated on the slides for 5 min. The Dapi was washed 
away with PBS and then rinsed with H2O. The slices were left to dry and then covered with 125 µl 




Table 2. 1: Primary and secondary antibodies used in this work 
Primary antibodies (red heading) are listed by the name, supplier, antigen determinant, type, antigen 
retrieval and dilution. The same order is used for the secondary antibodies (yellow heading). 
Primary antibodies Supplier Antigenic determinant Type Antigen 
retrieval 
Dilution 
anti-Desmin Dako human Desmin purified 
from skeletal muscle, 













light Meromyosin from 
chicken pectoralis 






anti-Myh7 Sigma partial human Myh7 








anti-Myh15 Sigma partial human Myh15 










Sigma partial human Tnni1 





































mouse IgG and IgM and 
light chains of other 
mouse Ig 
goat - 1:200 
anti-mouse IgG 
(H+L)- 
Alexa fluor 594 
Jackson 
Immuno 
whole mouse IgG goat - 1:200 
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anti-rabbit IgG (H+L)- 
Alexa Fluor 488 
Invitrogen/ 
Jackson 
whole rabbit IgG donkey - 1:200 
anti-mouse IgG1 
Alexa fluo 488 
Jackson 
immuno 









2.8 Whole mount in situ hybridisation 
2.8.1 DNA template synthesis 
The DNA template for the probes required for analysis by in situ hybridisation was amplified using 
PCR (Section 2.2.5).  
The following reagents were mixed in a 0.2 ml PCR tube: 21.5 µl dH2O, 25 µl 2 × BioMix Red 
(Bioline), 2 µl DMSO, 0.5 µl M13 (100 µm) F-primer, 0.5 µl M13 (100 µm) R-primer, 0.5 µl Plasmid.  
The programme used was: 1 minute at 95 °C, 5 × (95 °C for 15 seconds, 65 °C for 15 seconds, 72 °C 
for 2 minutes), 25 × (95 °C for 15 seconds, 50 °C for 15 seconds, 72 °C for 4 minutes) and a final 
step of 72 °C for 8 minutes. 
2.8.2 RNA probe synthesis 
A reaction mixture containing 37.5 µl dH2O, 5 µl 10 × transcription buffer (Roche), 2 µl RNA 
labelling mix (DIG or Fluorescein, Roche), 0.5 µl RNase inhibitor (Roche), 3 µl PCR template 
(Section 2.3.2) and 2 µl RNA polymerase (T3, T7 or SP6, depending on the template, Roche) was 
put into a 1.5 ml reaction tube. The reaction was incubated for 2 hours at 37 °C and 2 µl of the 
reaction was run on a gel to check the probe had been synthesised correctly. 2 µl RNase-free 
DNaseI (Roche) was added to the reaction and incubated for 15 minutes at 37 °C. This was then 
purified with post reaction clean up columns (Sigma) and the probe was stored at -20 °C. All the 
probes used are displayed in Table 2.2. 
2.8.3 Preparation of the embryos 
Chicken embryos fixed in 4 % PFA/PBS were prepared by cutting between the telencephalic 
vesicles and opening the hindbrain roof. The embryos were dehydrated then stored in methanol 
at -20 °C overnight or longer. This allows the membranes to become permeable and enhance 
staining. 
2.8.4 Hybridisation of the embryos 
Embryos were placed into individual wells in a 24-well dish, rehydrated and bleached with 6 % 
H2O2/MeOH, followed by two 5 minute PBT washes to remove any remaining methanol. The 
embryos were washed three times in detergent mix for 20 minutes, for 20 minutes and again 
followed by PBT washes. The detergent mix washes were different between the stages. We 
realised that the use of the 3 washes in detergent mix were making the HH4, 8 and 10 embryos 
very permeable and fragile, so we decided to reduce the number of washes to just 3 for 5 
minutes. The standard washes were kept for the HH13 to 24. The embryos were then put into 4 % 
PFA/PBT for 20 minutes and then washed 3 times for 5 mins in PBS. The pre-hybridisation mix was 
pre-warmed to 70 °C and pre-incubated with the embryos for 1 hour. The hybridisation mix, 
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which contains 5 µl of probe per 1 ml pre-hybridisation mix was added to the embryos and 
incubated overnight at 70 °C.  
2.8.5 Detection of the probe using alkaline phosphatase (AP)-conjugated antibodies 
Solution X was pre-warmed to 70 °C and used to wash the embryos four times for 30 minutes 
each, removing the hybridisation mix and any unbound probe. MABT was then used to remove 
the Solution X with two 30 minute washes at room temperature. MABT/2 % BBR/20 % serum 
bleaching solution was added to the embryos for 1 hour. AP-conjugated anti-digoxigenin antibody 
(1:2000, Roche) was added to the MABT/2 % BBR/20 % serum solution and incubated with the 
embryos for 3 nights at 4 °C. The antibody was then washed off with seven 1 hour MABT washes 
and then one overnight wash at 4 °C.  
To avoid a back ground embryos were sometime treated with RNAse. After the one night 
incubation with probes embryos were washed with the pre-warmed Solution 1 3 time for 30 
minutes at 70 °C. Than 1/10 Solution 1/Solution 2 for 10 min at 70 °C and washed 3 times for 5 
minutes with the Solution 2. 100 µg/ml RNAse A was add at the Solution 2 and incubated for 30 
minute at 37 °C for two washed. The embryos were washed twice with the pre-warmed Solution 2 
at 70 °C and we carry on with the same protocol with MABT washes.  
2.8.6 Staining reaction 
To stain the embryos they were first washed with NTMT (pH 9.5) for 10 minutes. The substrate 
solution was made with 10-20 µl of NBT/BCIP (Roche) per 10 ml NTMT. The substrate solution was 
removed from the embryos and washed with NTMT for 5 minutes and replaced with fresh 
substrate solution every time that the substrate changed to a pink colour. The substrate solution 
was left on the embryos for hours or days to allow staining. Once staining was finished, the 
embryos were washed in NTMT and then PBT for 10 minutes each. The embryos were finally fixed 
in 4 % PFA/PBS overnight and then put either into 80 % glycerol for long-term storage or PBS for 
double-labelling with immunohistochemistry. 
2.9 β-galactosidase staining  
β-galactosidase mRNA was injected into the blastomeres with a total amount of 250 pg in a 
volume of 9.2 nl. Embryos were fixed for 20 minutes in MEMFA, followed by 5 washes for 5 
minutes in PBS/MgCl2. Subsequently, embryos were stained for 2 h at 37 °C by using fresh Fe/Na-
phosphate solution containing 0.1 % Triton X-100 and 0.027 % X-gal (5-bromo-4-chloro-3-indolyl-
β-d-galactopyranoside), refixed for 1 h in MEMFA (0.1 M MOPS, 2 mM EGTA, 1 mM MgSO4, 3.7 % 





Table 2. 2 Antisense probes for in situ hybridisation:  
Probes used for whole mount in situ hybridisation (ISH). Cloning of inserts into the vectors pMK-RQ and 





Genes expressed in the gastrulating and immature trunk paraxial mesoderm 
Tbx6 RT- PCR fragment obtained from HH13-17 cDNA 
using the primers 
F: 5’- CCTGCTGGTGAGCAGGGAG-3’ 
RT7: 5’-TAATACGACTCACTATAGGGAGA- 
CTGCATGATCCACAGCCGCG-3’ 
The fragment was verified by sequencing. 
597 
Trunk premyogenic genes 
Paraxis gift from E. Olson(Šošic et al., 1997) 717 
Pax3 gift from P. Gruss (Goulding et al., 1993) 660 
Pax7 gift from P. Gruss (Goulding et al., 1993) 582 
Six1 gift from C. Tabin (Heanue et al., 1999) 700 
Eya1 gift from A. Streit (Christophorou et al., 2009) 1000 
Myogenic regulatory factor genes 
Myf5 open reading frame, synthesised and cloned into 
pMK-RQ 
785 
MyoD open reading frame, synthesised and cloned into 
pMK-RQ 
909 
MyoG open reading frame, synthesised and cloned into 
pMK-RQ 
694 




Mef2a-probe 1 EST clone WTSIp6101M23667Q 730 
Mef2a-probe 2 open reading frame, synthesised and cloned into 
pMK-RQ 
1647 
Mef2c probe 1 gift from T. Schultheiss (Alsan and Schultheiss, 2002) 500 
Mef2c probe 2 open reading frame, synthesised and cloned into 
pMK-RQ 
1431 
Mef2d RT- PCR fragment obtained from HH13-17 cDNA 




The fragment was verified by sequencing. 
450 
Mef2b RT- PCR fragment obtained from HH13-17 cDNA 




The fragment was verified by sequencing. 
414 
Genes labelling myogenic cells generated from the rostro-caudal edges of the dermomyotome 
Follistatin gift from A. Graham (Graham and Lumsden, 1996) 800 
Pitx3 gift from T. Ogura (unpublished PCR fragment, 3’ half 1000 
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of open reading frame) 
Genes encoding proteins facilitating cell adhesion and muscle contraction 
Cdh4 = Cadherin 4 = R-
Cadherin 
gift from C. Redies (unpublished PCR fragment) 900 
Des = Desmin 3’ half of the open reading frame, synthesised and 
cloned into pMK-RQ 
747 
Troponin I 1 (Tnni 1)  RT- PCR fragment obtained from HH13-17 cDNA 




The fragment was verified by sequencing. 
921 
Myh15 position 1168-2388 of the open reading frame, 
synthesised and cloned into pMA-T 
1224 
Myh7 position 2173-3138 of the open reading frame, 
synthesised and cloned into pMA-T 
966 
Genes involved in cell cycle control 
 Cyclins  
CcnA1 open reading frame, synthesized and cloned into 
pMA-T 
507 
CcnA2 open reading frame, synthesized and cloned into 
pMK-RQ 
492 
Ccn B2 gift of F. Pituello 1310 
CcnB3 open reading frame, synthesized and cloned into 
pMK-RQ 
1309 
Ccn D1 gift of F. Pituello 878  
Ccn D2 gift of F. Pituello 877  
Ccn D3 gift of F. Pituello 879 
Ccn E gift of F. Pituello 1226 
Ccn E2 gift of F. Pituello 509 
CcnO open reading frame, synthesized and cloned into 
pMK-RQ 
924 
Cyclin dependent kinases 
Cdk1 gift of F. Pituello 689 










open reading frame, synthesized and cloned into 
pMK 
738 
Cdk6 gift of F. Pituello 721 
Cdk activators 
Cdc25a gift of F. Pituello 723 
Cdc25b gift of F. Pituello 1029 
 Cyclin dependent kinase inhibitors  
Cdkn1a  open reading frame, synthesized and cloned into 
pMK-RQ 
465 





Cdkn1d (need to 
confirm identity) 





open reading frame, synthesized and cloned into 
pMK-RQ 
435  
Gg Cdkn2a-ARF open reading frame, synthesized and cloned into 192  
Cdkn2b = Ink4b=p15, 
probe 1 
gift of F. Pituello 1749 
Gg Cdkn2b, probe 2 open reading frame, synthesized and cloned into 
pMK-RQ 
429  
Gg Cdkn2c open reading frame, synthesized and cloned into 
pMK-RQ 
513  
Gg Cdkn3 open reading frame, synthesized and cloned into 
pMK-RQ 
633 





2.10.1 Gelatine embedding 
The embryos stored in 4 % PFA/PBS were washed 3 times for 1 hr in PBS. The embryos were 
sectioned and just the trunk with the electroporated somites was left in the well. The PBS was 
replaced with 1 ml of 20 % gelatine/PBS pre-warmed to 50 °C. The gelatine-suspended embryos 
were returned to the water bath at 50 °C to allow the gelatine to settle. The gelatine-suspended 
embryos were then transferred to the embedding moulds. The embryos were orientated in the 
desired position and a second layer of gelatine overlaid and allowed to settle. The embryos were 
then moved to the fridge at 4 °C to allow the gelatine to set. Once the gelatine was set the block 
was removed from the mould using the blunt end of a scalpel blade and neatly trimmed whilst the 
block was still cold. The block was then fixed in approximately 10-fold volume of 4 % PFA/PBS for 
several days at 4 °C. 
2.10.2 Vibratome sectioning  
The fixed block of gelatine in 4 % PFA/PBS was dried on a piece of blue towel and transferred onto 
a vibratome mounting stand. The block was fixed in place with super glue in the centre of the 
vibratome mounting stand, in the correct orientation. The vibratome mounting stand was placed 
in the centre of the tank submerged in PBS. The vibratome (Leica VT1000S) was set to cut 50 µm 
slices. The slices were collected with a fine brush and transferred to adhesion microscope slides 
(MARIENFELD). The slides were carefully dried and covered with 120 µl of glycerol/DABCO. 
2.11 Microscopy 
2.11.1 Stereomicroscopy 
Whole embryos at HH10 were mounted on a slide dorsal up and stage HH16 up to HH24 with the 
right side facing up. To improve the visibility of somitic expression patterns for older specimens, 
embryos were split midsagitally, and the neural tube and underlying mesenchymal tissue were 
removed using flame-sharpened tungsten needles. The embryos were examined under a Zeiss 
Axioskop2 microscope using Nomarski optics or fluorescence; digital images were captured using 
a Zeiss AxioCam digital camera (lmaging Associates). 
The same conditions were used to photograph sections. Images were assembled and edited using 
Adobe Photoshop 9. 
2.11.2 Compound microscopy using fluorescence and Nomarski optics 
The electroporated embryos were mounted on a slide dorsal side up or right side facing up for 
older stages. The embryos were analysed with the Zeiss AxioCAm digital camera fluorescence 
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microscope. The Normaski and the fluorescence images were mounted and analysed with Adobe 
Photoshop 9. 
2.11.3 Confocal microscopy 
Whole embryos and sections treated with immunohistochemistry with fluorescently-labelled 
antibodies were analysed with a Zeiss LSM 710 confocal microscope. The confocal was set for the 
use of multiple lasers to detect different dyes; 488 nm (Green), 561 nm (Red), 405 nm (blue) 
excitation wavelengths were used. The confocal microscope was focussed for optimal signal and 
Z-Stack pictures were taken. The confocal was set manually for the desired starting point and end 
point of the picture with the best focus. 35 pictures were taken starting from the distal point to 
the proximal point building up a 3D picture to allow the best images of the trunk of the embryos 
or the sections. The stacks were set at 0.50 µm intervals.  




3 Introduction  
3.1 Markers to monitor myogenic progression in the avian model 
In this study, we planned to explore whether and how the immature, pre-somitic paraxial 
mesoderm and the embryonic muscle stem cells developing in the dermomyotome of the somite 
could be forced out of their precursor or stem cell state, respectively, and into myogenic 
differentiation. Owing to its versatility and size, we planned on using the chicken as model; for 
more details on the choice of the approach and model, see chapter 4. The interpretation of 
phenotypes would rely on changes in marker gene expression. We therefore had to consider, 
which markers would be informative. 
In the introduction to this thesis, the key players in the gene regulatory network controlling 
myogenesis have been discussed. These players are candidate marker genes. However, it has 
been highlighted already that for example the sequence of somatic Mrf expression differs 
between zebrafish, Xenopus and mouse, and specifically the onset of Mrf4 expression is not 
known for the chicken (145,290,291). It also has been outlined that in all model organisms, the 
programs controlling myogenesis during the embryonic phases of somitic myogenesis, in the 
fetus/ juvenile and in the adult show slight variations (102,292). Additional variations on the 
theme of myogenesis are used by migratory muscle precursors or precursors of craniofacial 
muscles (293). To perform the planned work, we required certainty as to when marker gene 
would be expressed in chicken somites. 
A growing number of gene expression patterns are being deposited in the GEISHA (Gallus 
Expression in situ Hybridization Analysis) database (http://geisha.arizona.edu). Yet, astonishingly, 
myogenic gene expression has not been systematically analysed. For example, where 
premyogenic and myogenic gene expression may overlap, and which of the four Mef2 genes 
might be the most prominent partner of Mrfs in the chicken myotome is not known. In functional 
studies, Myf5, MyoD and sarcomeric Myosin expression have all been used as indicators for 
myogenic differentiation, even though Myf5 and MyoD expression is associated with proliferating 
myoblasts and the expression of sarcomeric Myosins with contractile myotubes or myofibres 
(294,295). This makes the comparison of the various experimental data difficult. To avoid this 
problem for our work, we decided to establish in detail the status of marker gene expression at 
the stages we planned to use for our experiments.  
To target the immature paraxial mesoderm, we planned to electroporate expression constructs 
into the primitive streak of young embryos; it has been suggested that construct expression is 
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detectable after 6 hours (296), and we planned to analyse the embryos after an overnight 
incubation, i.e. 18 hours after electroporation. Thus, we needed to establish marker gene 
expression at stages HH4-5, HH8, HH10. To target the embryonic muscle stem cells in the 
dermomyotome, we planned to electroporate the flank somites of embryos at HH15-16, the 
construct would be expressed at HH16-17, and after an overnight incubation, the embryos would 
have reached stages HH19-20 (287) Given the rapid progression of development between HH10 
and 15/16, we decided that we should include stage HH13/14 in our analysis. Thus, our analysis 
would cover the stages when the prospective somitic mesoderm is being laid down, when the first 
somites emerge, when the primary and secondary myotome form, to the stage when almost all of 
the 50 chicken somites have been generated and when embryonic muscle stem cells get ready to 
populate the myotome in the third wave of myogenesis.  
Our comparative expression analysis encompassed markers suggested to be instrumental for 
formation of the immature paraxial mesoderm (Tbx6;(108)), for muscle-competent cells 
(premyogenic genes including the stem cell marker Pax7, (297)), for cells committed to 
myogenesis and for cells entering terminal differentiation (Mrf genes, Mef2 genes, Cadherin4 and 
muscle structural genes; (298–300)). Gene expression was monitored by in situ hybridisation; to 
detect sarcomeric proteins, in addition antibody stainings were performed. The onset of gene 
expression is shown side-by-side for HH4/5 (Fig. 3.1), HH8 (Fig. 3.2), HH10 (Fig. 3.3), HH14 (Fig. 
3.4), HH16 (Fig. 3.5). Expression in mature flank somites of HH19-20 embryos is shown side-by-
side in Fig. 3.6; additional, detailed marker comparisons at HH19-20 are displayed in Fig. 3.7-3.9. 
The developmental age of somites was determined as in (McGrew and Pourquie, 1998), counting 
the condensing somite as somite 0, the first fully formed somite as somite 1, the next as somite 2 
etc. Results are summarised in Table 3.1. The work was carried out in collaboration with Júlia 






Figure 3. 1: Myogenic regulatory network 
The main genes involved in muscle differentiation and their roles are summarised. Initially, Id sequesters the E12/E47 proteins to avoid them binding to MyoD and stimulating 
differentiation prematurely (top left). Pax7 (top left) is important for the maintenance of the muscle stem cell state and collaborates with Six1, which is considered to be involved in the 
early stages of development but is essential for the activation of MyoD for muscle differentiation as well. Pax7 indirectly activates the Mrf genes and keeps Cdk1b inactivated. At the 
same time, Pax7 is controlled by miRs which are important in keeping the Mrf genes repressed in order to not prematurely activate differentiation. Mrfs (centre), especially MyoD are 
redundant and self-activating as indicated by the cyclical arrow. The activation of the Mrfs will upregulate miR which in turn, downregulate Pax7. Activated Six1 along with Mef2c will 
contribute to the progression of differentiation (top right). Mrf activation of Cdk1b (bottom) forces the cells to withdraw from the cell cycle. Delta signal along with Notch keeps the cell 





Table 3. 1: Maturation age of the paraxial mesoderm expressing a gene at selected stages of 
development 
stage HH4/5 HH8 HH10 HH14 HH16 HH19/20 comments 
key feature 
fully extended 
primitive streak - 
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Our data reveal a set sequence of gene expression, yet the timing of expression onset was quite 
different at different stages of development (summarised in Fig. 3.10). Moreover, marker gene 
expression in myogenic cells being deployed from the dorsomedial and ventrolateral lips of the 
dermomyotome was different from those being deployed from the rostrocaudal lips, suggesting 
different molecular programs. Furthermore, expression of Myosin Heavy Chain genes was 
overlapping but different along the length of a myotube. Finally, our work revealed that Mef2c is 
the most likely partner of Mrfs, and, in contrast to the mouse and more akin to the frog and 
zebrafish fish models, chicken Mrf4 did not show an expression phase prior to that of MyoD, and 
instead, was co-expressed with MyoG as cells enter terminal differentiation. Our data are 
consistent with those of (301) which was published back-to-back with ours.  
3.2 Results 
3.2.1 Expression of Tbx6 
Initial expression of Tbx6 was first detected in the primitive streak in cells destined to become 
paraxial mesoderm (Fig. 3.1A). At HH8 (Fig. 3.2A), expression was localised to the rostral primitive 
streak. Cells that leave the streak to settle as paraxial mesoderm continue expressing Tbx6, these 
cells constitute the tissue known as segmental plate or pre-somitic mesoderm. Notably, while 
Tbx6 is thought to label pre-somitic tissues only (302), expression could still be detected in the 
condensing somite (Fig.3.2A). At HH10 (Fig. 3.3A), a similar expression pattern was seen; in 
strongly stained specimen, Tbx6 expression was detectable up to the somite 2/3, labelling the 
medial-rostral edge of the somite most intensely. At HH14 (Fig.3.4A) and HH16 (Fig.3.5A), Tbx6 
labelled the paraxial mesodermal cells emerging from the tail bud. As before, expression 
continued in the segmental plate and the youngest somites. At HH19-20, mesoderm formation is 
almost complete. As increasingly fewer cells are being contributed by the tailbud, the process of 
somite formation consumes the segmental plate; hence the youngest somites are located close to 
the tail bud. At this point, intense Tbx6 expression was observed in the tailbud with lower 
expression levels in the youngest two somites (Fig. 3.6A and 3.7A). 
3.2.2 Expression of Paraxis 
Paraxis expression was observed in the prospective somitic mesoderm as early as HH4 (Fig. 3.1B). 
At HH8 (Fig. 3.2B), expression was located in the rostral segmental plate, continuing in somites as 
they segregated from the segmental plate. The same pattern was observed at HH10 (Fig. 3.3B), 
HH14 (Fig. 3.4B), HH16 (Fig. 3.5B) and HH19-20 (not shown). As somites matured, Paraxis 
expression became confined to the somitic dermomyotome and sclerotome. The strongest 
expression was found in the dorsomedial (epaxial) portion of the dermomyotome (Fig. 3.6B and 
Bi). Thus, Paraxis expression partially overlapped with that of Tbx6, but continued to be expressed 








Figure 3. 2: Marker gene expression at HH4-5. 
Dorsal views of primitive streak stage chicken embryos at stages HH4 (extended primitive streak) or HH5 
(head process visible), rostral to the top. Markers are shown on top of each individual image; in (B) the 
node is additionally stained for Chordin expression in red. Tbx6 and, more weakly, Mef2a and Pax7 label 
prospective paraxial mesoderm cells in the primitive streak; Paraxis labels the cells preparing to form 
somites (arrowhead). Other genes are not expressed, or are expressed in tissues not contributing to somite 
development with Six1 labelling non-somitic head mesoderm, Pax3 the embryonic epiblast, Pax7 the neural 
plate border. 








3.2.3 Expression of Pax3 and Pax7 
3.2.3.1 Pax3 
Pax3 showed a complex expression pattern, and at HH4-5 was expressed in the epiblast and along 
the primitive streak (Fig. 3.1C). This expression continued at HH8 (Fig. 3.2C), but additional 
expression could be seen in the lateral aspect of the condensing somites and the overlying edge 
of the neural plate (the neural folds). At HH10 (Fig. 3.3C), Pax3 expression was similarly present in 
the remaining epiblast flanking the remnant of the primitive streak whilst again being found in the 
neural folds/dorsal neural tube and the condensing as well as well-formed somites. At HH14 (Fig. 
3.4C), HH16 (Fig. 3.5C) and HH19-20 (Fig. 3.6C and Ci), Pax3 was expressed in the tail bud, the 
dorsal neural tube, the lateral aspect of the condensing paraxial mesoderm and the somites. As 
somites matured, expression became confined to the dermomyotome, with relatively low levels 
in the dermomyotomal centre and comparatively strong expression in the dorsomedial and 
ventrolateral lips (Fig. 3.6C and Ci). Thus, Pax3 expression tightly overlapped with that of Paraxis, 
but distinct areas of elevated expression levels were observed. 
3.2.3.2 Pax7 
Overall, the expression pattern of Pax7 was very similar to its paralog Pax3 (Fig. 3.2-3.6 D and Di). 
At gastrulation stages, however, Pax7 did not show prominent expression in the epiblast or tail 
bud and instead showed weak expression in the primitive streak, Hensen’s node and the 
emerging notochord cells. Moreover, the developing neural plate border from which neural crest 
cells will develop showed staining (Fig. 3.1D). From HH8 onwards, Pax7 strongly labelled the 
migrating cranial neural crest cells (Fig. 3.2D and 3.3D, ncc). Expression in the paraxial mesoderm 
began in the rostral segmental plate as seen for Pax3. The HH19-20 mature somite showed 
strongest expression in the dermomyotomal centre, occupying a dorsoventrally wider region than 
Paraxis (Fig. 3.6 D and Di). 
3.2.4 Expression of Six1 
Six genes evolved from an ancestral Six1/2/9/sine oculis gene, a Six4/5 gene and a Six3/6/7optix 
gene, with Six4/5 and optix-related genes possibly having arisen from an earlier, common 
ancestor (161). Mammals and birds only have Six1/2, Six4/5 and Six3/6, of which Six1/Six2 and 
Six4/5 are co-expressed in the newly formed somite, the developing dermomyotome, eventually 
becoming confined to the dermomyotomal lips and the myotome; other Six genes do not show 
prominent expression in the somite (163–168). Single Six1, but not Six4 or Six5 mutations cause 
somitic phenotypes, indicating Six1 to have a more prominent role in myogenesis (164). We 
therefore focused on Six1 in this study. At HH4-5, Six1 was expressed in the non-somitic head 
mesoderm and the pre-placodal ectoderm (Fig. 3.1E). At HH8 (Fig. 3.2E) and HH10 (Fig. 3.3E), 
expression was also seen in the pre-chordal plate and the developing somites. At HH14 (Fig. 3.4E) 
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and HH16 (Fig. 3.5E) expression in the rostral segmental plate and somites was also evident. 
Differentiating somites maintained strong Six1 expression in the dermomyotome, thus 
overlapping with the expression of Paraxis, Pax3 and Pax7 (not shown). In contrast, in mature 
somites such as the flank somites at HH19-20, strongest Six1 expression was found in the 
dorsomedial and ventrolateral lips of the dermomyotome and the underlying myotome (Fig. 3.6E 
and Ei). Thus, developing embryonic muscle stem cells do not express Six1, cells contributing to 
the myotome do. 
3.2.5 Expression of Eya1 
Eya family proteins are protein tyrosine phosphatases which have multiple roles including the 
conversion of Six proteins into strong transcriptional activators (Li et al., 2003; Tootle et al., 2003); 
reviewed in (172) . Vertebrates have four Eya genes. In the mouse, the closely related Eya1 and 
Eya2 genes and the more distantly related Eya4 are all co-expressed initially in the 
dermomyotome and its dorsomedial and ventrolateral lips and later in the myotome. These Eya 
genes have functionally overlapping roles. Eya3 is weakly expressed in the somites only and is 
known to cooperate with Ski and Six1 in the differentiation of C2C12 myoblasts  
(174,176,177,303). Expression of chicken Eya2 has been described (165) and matches that of the 
mouse, hence we focused on Eya1. No expression was observed for Eya1 at HH4-5 (Fig. 3.1F), but 
later stages of development showed very similar expression to that of Six1 at stages HH8, HH10, 
HH14 and HH16 (Fig. 3.2F, 3.3F, 3.4F and 3.5F, respectively). The strongest expression observed in 
HH19-20 mature somites was found in the dorsomedial and ventrolateral lips of the 
dermomyotome and in the myotome (Fig. 3.6F and Fi). This suggests that throughout somite 
development, Eya1 is available to convert Six1 into a transactivator that can activate myogenic 










Figure 3. 3: Marker gene expression at HH8. 
Dorsal views (Q-S: ventral views) of chicken embryos with 3-5 somites, rostral to the top. Markers are 
shown on top of each individual image; in (B,C) the notochord is additionally stained for Chordin expression 
in red. Note the overlapping expression of Tbx6 and the pre-myogenic genes in the rostral segmental plate 
and most recently formed somite (s1). Mrf genes are not yet expressed. Mef2c and 2d display some somitic 
expression. However, the main expression of Mef2 genes, and of Tnni1, Myh15, Myh7 is in heart precursors 
(ht). 
Abbreviations as in Fig.1 and:  hm, head mesoderm; ht, cardiac precursors; nf, neural folds; not, notochord; 









3.2.6 Expression of Mrf genes 
3.2.6.1 Myf5 
Myf5 has been described as the earliest Mrf gene to be expressed. Even though embryos at HH7-8 
have 1-4 somites, Myf5 expression was not detectable (Fig. 3.2G). We initially found a somewhat 
diffuse signal in condensing and newly formed somites at HH10, with somite 4/5 to somite 10 
showing expression in their medial wall (Fig. 3.3G). This is the region from which the cells building 
the primary myotome arise (135). At HH14 (Fig. 3.4G) and HH16 (Fig. 3.5G), a similar pattern was 
observed. From somite 9 onwards, Myf5 expression began to spread laterally, coinciding with the 
establishment of the myotomal scaffold. In mature somites at HH19-20 (Fig. 3.6G and Gi; Fig. 3.9A 
and Ai), Myf5 expression was detected in the sub-lip domain of both the dorsomedial as well as 
the ventrolateral lip, overlapping with myogenic cell production from both lips (304–306). 
Moreover, robust expression was seen throughout the myotome. However, the immediate sub-lip 
domains of the rostral and caudal lips that also contribute to the myotome (Kahane et al., 1998a), 
did not express Myf5 (Fig. 3.9A and Aii). Nevertheless, at a relatively short distance from these 
lips, individual Myf5-postive cells were observed (Fig. 3.9A, arrows), suggesting that after the 
entry into the myotome, cells derived from the rostrocaudal lips quickly activated Myf5. 
3.2.6.2 MyoD 
MyoD expression was not detected at stages HH4-10 of development (Fig. 3.1H, 3.2H and 3.3H). 
At HH14, expression was observed in the dorsomedial region of somites 4/5 and older, as seen for 
Myf5 (Fig. 3.4H); at HH16, this expression was already seen in somites 1/2 (Fig. 3.5H). Expression 
then expanded laterally as seen for Myf5, but this expansion lagged behind by 1-2 somites. At 
HH19-20, MyoD expression in mature somites was nearly indistinguishable from that of Myf5 (Fig. 
3.6H and Hi). However, the immediate dorsomedial and ventrolateral sub-lip domains showed no 
staining, and expression appeared more intersperse than that of Myf5, suggesting that not all 
cells expressed MyoD. 
3.2.6.3 MyoG 
MyoG expression was first detected at HH13-14, i.e. in animals with a total of 19-22 somites, 
commencing in somite 9/10 (Fig. 3.4I). As was the case for Myf5 and MyoD, expression spread 
laterally in older somites. Notably, at HH16, expression was already visible from somite 6/7 
onwards (Fig. 3.5I), and at HH19-20, expression was already present in the 5th youngest somite 
(Fig. 3.7B), suggesting that the progress of somite maturation speeds up as development 
progresses. At HH19-20, MyoG expression in mature somites appeared throughout the myotome 






Figure 3. 4: Marker gene expression at HH10. 
Dorsal views (P-T: ventral views), rostral to the top. Markers are indicated on top of each individual image 
as before. Tbx6 and the pre-myogenic genes show overlapping expression in the rostral segmental plate 
and most recently formed somite. The pre-myogenic genes label the condensing as well as fully formed, 
epithelial somites. Of the Mrf genes, Myf5 is expressed weakly in the condensing somite, and more robustly 
in the medial wall of the epithelial somites. Similar to HH8, Mef2c and 2d display some weak somitic 
expression, but the main expression of the Mef2 genes, of Tnni1 and the Myosins remains in heart (ht). 
Abbreviations as in Fig.1,2 and: bi, blood islands; ncc, neural crest cells; nt, neural tube; the position of the 














Figure 3. 5: Marker gene expression at HH14. 
Dorsal views of the caudal region of HH14 chicken embryos, rostral to the top. Similar to earlier stages, Tbx6 
expression and the expression of pre-myogenic genes and of Myf5 overlaps in the rostral segmental plate 
and youngest somite. More mature somites sequentially express MyoD, Mef2c, Mef2d, Cdh4, MyoG, Mrf4, 
Tnni1, Desmin and the Myosins (exception: Myh7; not yet expressed).  
Abbreviations as in Fig.2,3 and: im, intermediate mesoderm; lm, lateral mesoderm; tb, tail bud; the position 











Figure 3. 6: Marker gene expression at HH16. 
Dorsal views of the caudal region of HH16 chicken embryos, rostral to the top. Expression patterns are 
similar to those at HH14; however, expression of MyoD, MyoG, Mrf4, Mef2c, Mef2d and the muscle 
structural genes begins earlier. Myh7 is now also expressed; elevated expression in the myotome of somite 






Mrf4 expression commenced in somites 9/10 at HH13-14, roughly following the expression of 
MyoG (Fig. 3.4J). At HH16, somites 8/9 were the earliest in which staining was visible (Fig. 3.5J), 
whereas at HH19-20, the earliest somites that were stained were 6-7 (not shown). Compared to 
the other Mrf genes, Mrf4 expression levels were low. Expression of Mrf4 in mature somites was 
detected in the myotome but no staining was detected in the sub-lip domains of the 
dermomytome (Fig. 3.6J and Ji). Expression was concentrated in the centre of the myotome, with 
stronger staining in the epaxial domain and weaker staining in the hypaxial domain. Expression 
appeared even more intersperse than that of MyoD or MyoG, indicating that only a fraction of 
cells in the myotome expressed the gene. 
 
3.2.7 Expression of Mef2 genes 
Vertebrates have retained the four Mef2 genes that were generated during their two rounds of 
genome duplication (307). Of these, Mef2a and Mef2c are thought to have arisen from one of the 
ancestral genes generated in the first duplication event, and the genes have since remained 
relatively unchanged. Mef2b and Mef2d are thought to have stemmed from the other ancestral 
gene; yet, Mef2b appears to have diverged more extensively. The genes are displayed according 
to their similarity to Mef2a.  
3.2.7.1 Mef2a 
Mef2a was already weakly expressed in the primitive streak at HH4-5 (Fig. 3.1K). From stages 
HH7-8 and onwards, low-level widespread staining was observed, with the strongest expression 
seen in the precursors of the primitive heart (Fig. 3.2K and 3.3K; ht). The early heart, blood island 
and the notochord showed prominent expression at HH14 (Fig. 3.4K), and from this stage 
onwards, the somites also showed Mef2a expression (Fig. 3.4K and 3.5K). At HH16 (Fig. 3.5K) and 
HH19-20 (Fig. 3.6K and Ki), mature somites showed elevated expression in the myotome in a 
pattern similar to that of MyoG and Mrf4. 
3.2.7.2 Mef2c 
Mef2c expression coincided with Mef2a expression in the cardiac precursors of HH7-8 embryos 
and the primitive heart of HH10 embryos (Fig. 3.2L and 3.3L; ht). At these stages, weak, diffuse 
staining could also be seen in the somites. At HH14, prominent somitic expression was seen in 
somites 5/6 onwards, labelling the dorsomedial region as seen for MyoD (Fig. 3.4L). At HH16, 
somites 3/4 were already Mef2c-positive (Fig. 3.5L), with expression spreading laterally as 
observed for the Mrf genes. At HH19-20, mature somites showed robust expression in the 
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myotome, with elevated expression in the myotomal centre (Fig. 3.6L and Li). Notably, Mef2c 
expression at that stage also showed strong staining in the region beneath the rostral and caudal 
lips of the dermomytome (Fig. 3.9B and Bii, arrowheads). 
3.2.7.3 Mef2d 
Overall, Mef2d showed low expression levels with weak staining scarcely detectable in cardiac 
precursors at HH7-8 and the primitive heart at HH10 (Fig. 3.2M and 3.3M). At HH14, expression in 
the medial aspect of the somites was detectable from somite 6-8 onwards. A similar range was 
displayed at HH16 (Fig. 3.4M and 3.5M) whereas at HH19-20, staining was seen in somites 3/4 
onwards. Mef2d expression in the mature somites of the flank was confined to the myotome. 
3.2.7.4 Mef2b 
Mef2b showed widespread expression in all germ layers, with strongest staining in the primitive 
streak, neural plate, cardiac precursors and the somites at HH7-8 (Fig. 3.2N). Similar expression 
was seen at HH10; however, the staining appeared weaker in the somites when compared with 
the staining for the neural tube and primitive streak (Fig. 3.3N). Widespread expression was also 
seen at stages HH14, HH16 and HH19-20 (Fig. 3.4N, 3.5N and 3.6N). Cross sections revealed that 
the expression was located to the myotome as was the case with the other Mef2s, but the 
sclerotome was also stained (Fig. 3.6Ni). 
 
3.2.8 Expression of Cadherin 4 (R-Cadherin, Cdh4) 
Cdh4 has been shown to be expressed in the developing myotome, and its ability to support cell 
adhesion in epithelia suggests it has a role in myogenic cell alignment and cohesion (308,309) We 
observed initial Cdh4 expression in the developing notochord at HH7-8 and 9-10 (Fig. 3.2O and 
3.3O). At HH14 (Fig. 3.4O), a complex expression pattern encompassing the notochord and the 
intermediate mesoderm-derived nephric duct was observed. Weak expression was seen in the 
condensing somite as well as the first 1-3 newly formed somites. However, more robust 
expression was found in the medial region of somites 7-9. In further rostral somites, the 
expression was spread more laterally, concomitant with the developing myotome as observed for 
the Mrf genes. Notably, 9-10 somites rostral to the somite expressing the gene first, a new 
expression domain emerged in the lateral lip and sub-lip domain of the dermomyotome. At HH16 
(Fig. 3.5O) and HH19-20 (Fig. 3.6O), a similar expression pattern was seen. Cross sections of HH19-
20 flank somites confirmed that Cdh4 was expressedf in the myotome and throughout the 






Figure 3. 7: Marker gene expression in the flank of embryos at HH19-20. 
(A)Schematic representation of the images displayed in B-T (lateral view of flank somites on the right of the 
embryo, rostral to the top, lateral to the right) and Bi-Ti (cross section to flank somites, dorsal to the top, 
lateral to the right; section (Si) is from the forelimb- flank boundary as indicated in S). Markers are indicated 
as before. 
Paraxis, Pax3 and Pax7 show distinct areas of elevated expression in the dermomyotome (B,Bi-D,Di; 
arrowheads). Their expression overlaps in dorsomedial and ventrolateral lips with that of Six1, Eya1 and 
Myf5; in the ventrolateral lip, expression overlaps also with that of Cdh4. The Mrf genes, the Mef2 genes 
and the genes encoding cell adhesion and muscle structural proteins show overlapping expression in the 
myotome, with the late commencing markers still being confined to the more medial territories. 
Abbreviations as in Fig.1-4 and: da, dorsal aorta; dm, dermomyotome; dml, dorsomedial lip of 
dermomyotome; ect, surface ectoderm; fl, fore limb; hl, hind limb; m, myotome; scl, sclerotome; vll, 




3.2.9 Expression of muscle structural genes 
Desmin, Tnni1 (Troponin I 1), Myh15 (Myosin Heavy Chain 15 or ventricular Myosin Heavy Chain) 
and Myh7 (Myosin Heavy Chain, slow/cardiac or atrial Myosin Heavy Chain) are components of 
the functional sarcomere and have been reported to be expressed early on in the developing 
embryo (http://geisha.arizona.edu). We therefore included these muscle structural genes in our 
analysis. To monitor the availability of Myosins independent of individual contributing genes, we 
used the MF20 antibody to detect pan-sarcomeric Myosin. To evaluate the levels of protein 
production, whole mount antibody staining of HH21 embryos were performed with antibodies 
known (Desmin) or predicted (Tnni1, Myh17, Myh7) to recognise the avian proteins. 
3.2.9.1 Desmin 
Desmin mRNA was first detected at HH13-14, with somites 10-12 and older showing staining (Fig. 
3.4P). Similar expression was seen at HH16, (Fig. 3.5P) but at HH19-20, expression was already 
detected from somites 7/8 onwards (not shown). Expression was found in the centre of the 
myotome which contains the myonuclei (Fig. 3.6P and Pi). Overall, somitic Desmin transcription 
was low, whereas the staining was more prominent in the heart. Notably, Desmin protein was 
more readily detectable (Fig. 3.8H), suggesting that rate of production and/or half-life is greater 
for the protein than for the mRNA. In contrast to the mRNA, the protein was found throughout 
the myotube, suggesting an active distribution mechanism. 
3.2.9.2 Tnni1 
At HH4-5, weak expression of Tnni1 mRNA was found in the rostral primitive streak and the lateral 
mesoderm which contributes to the heart (Fig. 3.1Q). At HH7-8, this expression strengthened, and 
throughout the developmental stages analysed here, the cardiac precursors and the heart 
showed the most prominent Tnni1 expression (see Fig. 3.2Q and 3.3Q; ht). At HH14, somites 9/10 
showed Tnni1 expression (Fig. 3.4Q), whilst at HH16 and HH19-20, expression started already in 
somites 5/6 (Fig. 3.5Q) and 4/5 (Fig. 3.7C), respectively. Tnni1 mRNA was readily detectable, as 
was the Tnni1 protein (Fig. 3.8I), and was found to label the myotome throughout (Fig. 3.6Q and 
Qi).  
3.2.9.3 Myh15 
Myh15 expression was detected from HH7-8 onwards in the cardiac precursors and subsequently 
the heart (Fig. 3.2R and 3.3R; ht; (Bisaha and Bader, 1991)). Myogenic expression was first found 
in somites 20/21 at HH14, i.e. the two oldest somites (Fig. 3.4R). At HH16, earlier expression was 
seen in somites 14/15, labelling the myotomal centre (Fig. 3.5R and 3.8A). At HH19/20, expression 
appeared already in somites 11/12. Expression was confined to the developing myotubes, but the 
strongest expression was located in their rostral and caudal extremities (Fig. 3.6R and Ri; Fig. 3.8B-
D, arrows). Protein detection was comparatively less robust than mRNA detection; however, at 
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HH21, Myh15 protein was enriched along the rostral and caudal edges of the myotome, similar to 








Figure 3. 8: Expression of selected markers at the caudal end of HH19-20 embryos. 
Dorsolateral views of the caudal end of HH19-20 embryos, the position of the tail bud (tb) is indicated. Marker genes are indicated above the individual images as 
before. Similar to earlier stages, Tbx6 expression still continues in the recently formed somites. However, the onset of MyoG, Tnni1 and sarcomeric Myosins 




Myh7 expression levels were low, lower than those of Myh15, which is consistent with reports 
from Oana (310). At HH7-8 Myh7 was expressed in cardiac precursors, and from HH9/10 onwards, 
expression was found in the atrium of the heart (Fig. 3.2-3.5S; ht). At HH16, somites 19/20 
showed expression (Fig. 3.5S) whilst at HH19-20, expression was visible from somites 11-13 
onwards (Fig. 3.6S). Expression was confined to the developing myotubes, with the strongest 
expression found in their centre (Fig. 3.8E-G, arrow). Myh7 protein was not easy to detect, but 
also showed enrichment in the myotomal centre (Fig. 3.8K). 
3.2.9.5 Pan-sarcomeric Myosin detection 
The MF20 antibody recognises the rod-like tail of all sarcomeric Myosins and therefore generally 
detects terminally differentiated cardiac and skeletal muscle independent of the individual 
contributing Myosin gene (311). Initially, the antibody detected only the developing heart (Fig. 
3.3T, ht). At HH14, the antibody also stained somites 16/17 and older (Fig. 3.4T). At HH16, somites 
14-16 and older were stained (Fig. 3.5T), and at HH19/20, somites 8-9 showed staining (Fig. 3.7D). 
The expression was found to be confined to myotubes (Fig. 3.6T and Ti; Fig. 3.8L). 
3.2.10 Comparative analysis of Myf5, Mef2c, Follistatin and Pitx3 along the four 
dermomyotomal lips 
Myf5 and pre-myogenic genes shown here presented overlapping expression, occurring first in 
the dorsomedial and then in the ventrolateral lip of the dermomytome. Expression of MyoD, 
MyoG, Mef2 genes and Cdh4 overlapped with that of Myf5 in the dorsomedial and ventrolateral 
sublip regions. In contrast, Mef2c expression was also found along the rostrocaudal 
dermomyotomal lips (compare Fig. 3.9A, Ai, Aii and B, Bi, Bii). We screened our embryo collection 
for additional markers present in this region. We found that the gene encoding the TGF 
(transforming growth factor beta) inhibitor Follistatin was expressed from HH6 onwards in 
condensing and newly formed somites (Bothe et al., 2011). Expression continued in the 
dermomyotome, where upregulated expression was seen along all four dermomyotomal lips (not 
shown). At HH19/20, mature somites of the flank showed expression in these lips as well as in the 
myotome (Fig. 3.9C, Ci and Cii). Pitx3 expression was initially found in the lens of the eye. At HH16 
(not shown) and 19/20 (Fig. 3.9D, Di and Dii), expression was seen in the mature somitic 
myotomes. Notably, the strongest expression was seen along the rostrocaudal edges of the 









Figure 3. 9: Comparison of Myh15 and Myh7 expression at HH16, 20 and 21. 
(A-D) Myh15 mRNA expression in the somites of the HH16 neck (A) and the HH20 neck (B), fore limb-flank 
border (C) and the flank (D). (E-G) Myh7 mRNA expression in the HH20 neck (E), at fore limb levels (F) and in 
the flank (G). Anterior is to the top in all, dorsal to the left. Arrowheads mark the same somites in (C,D) and 
(F,G),respectively. Note that at HH16, Myh15 expression is strongest in the centre of the developing 
myotubes; at HH20 expression is strongest at the rostro-caudal ends (arrows) while Myh7 labels the centres 
of the myotubes (arrows).  
(H-L) Flattened confocal z-stacks of HH21 flank somites, stained with antibodies detecting the proteins 
indicated on the top of the panel. Lateral views, dorsal to the top, anterior to the right. Note that Myh15 
protein accumulated more strongly along the rostro-caudal edges of the myotome, while Myh7 protein is 
more concentrated in the centre (arrowheads). 





Figure 3. 10: Comparison of markers labelling myogenic cells from the dorsomedial-ventrolateral and 
rostrocaudal lips of the dermomyotome. 
 (A-D) Lateral views of flank somites on the right of the embryo, rostral to the right, dorsal to the top. (Ai-Di) 
Cross sections of these somites, with (Ai, Bi) leading through the centre and (Ci, Di) sectioned along the 
caudal edge of the somite as indicated by the vertical lines. (Aii-Dii) Frontal sections, medial to the top, 
rostral to the right. Individual cells along the rostrocaudal sublip domain of the myotome express Myf5 (A, 
arrows). In contrast, robust and widespread expression in this domain is found for Mef2c, Follistatin and 







Aim of this part of the study was to perform in the chicken embryo a side-by-side analysis of the 
key markers associated with the progression from an immature state of the paraxial mesoderm to 
myogenic commitment and, eventually, to myogenic differentiation. This was needed to ensure 
that data obtained from our functional studies would be interpreted correctly. Yet our study also 
provided novel insight into the process of skeletal muscle formation. Our key findings are 
summarised in Fig.3.10. 
3.3.1 Myf5 is the first gene to indicate myogenic commitment. 
Mrf genes are thought be the drivers of myogenesis, with Myf5 and MyoD playing similar roles in 
the still mitosis-competent myoblast (reviewed in (Aziz et al., 2010; Fong and Tapscott, 2013). We 
found, however, that Myf5 was always the first Mrf being expressed, with initial diffuse 
expression in the epithelialising somite, followed by robust expression in the medial wall of a 
newly formed somite, the dorsomedial lip of the dermomyotome and the expanding myotome. 
Later on, additional mirroring expression in the ventrolateral aspect of the somite was seen. 
Following Myf5, MyoD expression was activated in the dorsomedial and ventrolateral sublip 
domains of the dermomyotome, not the dermomyotomal lips themselves. This suggests that 
Myf5 is a marker for myogenic commitment, whereas MyoD marks cells that are ready to enter 
differentiation. Significantly, no myogenic differentiation was observed at the start of Myf5 
expression. Thus, in vivo, Myf5 may not be as proficient in driving myogenesis as in vitro. 
However, the continued expression of genes associated with an immature state such as Tbx6 may 
present a suitable explanation for this. Furthermore, it was shown that in quiescent satellite cells, 
the Myf5 mRNA is sequestered in mRNP granules together with miR31, preventing Myf5 
translation (Crist et al., 2012), and this mechanism may also operate in the embryo. Interestingly, 
an expression profile similar to that of Myf5 has recently been shown for avian Rgm genes, of 
which the functional relationship is yet to be shown (312) .  
3.3.2 In contrast to the mouse, Mrf4 (Myf6) is the last Mrf to be expressed. 
During all of the stages investigated, Myf5 expression was always followed by expression of 
MyoD, and subsequently followed by the expression of MyoG and Mrf4; an early onset of Mrf4 
expression as shown in the mouse (Summerbell et al., 2002) was not observed. It is not clear 
whether the murine expression pattern is representative of all mammals; yet the avian sequence 
of Mrf gene expression is comparable to that shown for Xenopus and zebrafish, suggesting that 
this is the general configuration for jawed vertebrates. MyoG is known to promote exit from the 
cell cycle and terminal differentiation (reviewed in (193,313) , yet MyoD, MyoG and Mrf4 were 
eventually all co-expressed in the dorsomedial and ventrolateral sublip regions of the myotome. 
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This indicates that cells entering the myotome via these lips may withdraw from the cell cycle in 
the sublip domain and begin differentiation within this compartment before being displaced to a 
position away from the lips by the next cells entering from the dermomyotome. 
3.3.3 Mef2c is the likely partner for Mrf proteins in somitic myogenesis. 
Mrf genes are important regulators of myogenic commitment and differentiation, yet their 
proficiency in target gene activation relies upon their interaction with Six/Eya and Mef2 proteins 
(reviewed in (193,313) . Our analysis suggests that Six and Eya proteins are constantly available to 
Mrf proteins since their expression was seen in epithelialising somites, the early dermomyotome, 
and then the dorsomedial and ventrolateral dermomyotomal lips as well as the myotome. Of the 
Mef2 genes, only Mef2c showed strong expression in the developing somites, highlighting Mef2c 
as a likely partner of Mrf proteins. Mef2c expression followed that of MyoD and therefore may 
explain the fact that terminal differentiation does not occur prior to the onset of MyoD 
expression. 
3.3.4 All cells in the amniote somite have a history of pre-myogenic gene expression. 
Our study showed that the immature chicken paraxial mesoderm invariably expresses Tbx6. When 
the tissue condenses and epithelial somites form, Tbx6 expression is gradually replaced with the 
expression of the pre-myogenic genes (Paraxis, Pax3, Pax7, Six1, Eya1). The pre-myogenic genes 
are all expressed throughout the developing somite before becoming confined to the 
dermomyotome (Paraxis, Pax3, Pax7) or the dorsomedial and ventrolateral dermomyotomal lips 
and the myotome (Six1, Eya1). The same sequence of gene expression has been reported for the 
mouse (104,314). This suggests that in amniotes, the trunk paraxial mesoderm adopts a specific 
pre-myogenic state before cells are being released into differentiation. Interestingly, in Xenopus 
and zebrafish, expression of Mrf genes begins concomitant or prior to somite formation; 
differentiation of functional skeletal muscle occurs shortly thereafter (145,300). Expression of 
Pax7 appears later and is associated with the formation of muscle stem cells and the emergence 
of the dermomyotome (90,315). Moreover, in Xenopus, the area delivering the Pax7 expressing 
cells initially expressed MyoD. Thus, in anamniotes, functional muscle that allows the larvae to 
swim is made quickly whereas cells with muscle stem cell features arrive later. 
 This furthermore suggests that the anamniote embryo is geared up towards myogenesis, while in 
amniotes, myogenesis is held back.  
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3.3.5 The pre-myogenic genes may have distinct roles in the myogenic programme. 
Our study showed that the pre-myogenic genes are initially expressed throughout the young 
somite and later, their expression overlaps with that of the Mrf genes in the dorsomedial and 
ventrolateral dermomyotomal lips of the dermomyotome. All the pre-myogenic genes have 
previously been demonstrated to be activators of MyoD, at least in the context of a Myf5 knock-
out (121). This therefore suggests that they all act upstream of the Mrf cascade for similar effect. 
However, the postmitotic cells of both the primary and secondary myotome show no expression 
of Paraxis, Pax3 and Pax7; in the mature somite; Pax7 expression appears in the myotome only 
when the mitotically active embryonic muscle precursor come in at E3.5, thereby forming the 
tertiary myotome (316). This suggests that in the context of a naturally developing amniote 
somite, the Paraxis/Pax3/Pax7 gene set may control the expansion of the precursor/stem cell 
pool and establish the myogenic fate. However, the genes do not immediately initiate myogenic 
differentiation. This idea is corroborated by studies in which wildtype and dominant negative 
forms of Pax3 and Pax7 were misexpressed in vitro. These studies showed that Pax3 and Pax7 
keep the myogenic cells mitotically active while impeding immediate differentiation (317,318). 
Moreover, Pax7, while co-expressed with Myf5 or MyoD at the time when the cells commit to 
myogenesis, is shut down by MyoG when the cells enter terminal differentiation (319). 
In contrast to Paraxis and Pax3/7, we found that Six1 and Eya1 expression eventually declined in 
the dermomyotome but continued in the differentiating cells of the myotome. Notably, Six and 
Eya proteins have been shown to accumulate in the nuclei of human myotomal cells at the time 
that MyoG is expressed, not before, indicating a role in the activation of genes required for 
muscle differentiation (173) . Six1 has also been shown to be an activator of MyoG and of genes 
encoding proteins required for muscle contraction, particularly proteins for glycolytic, fast-twitch 
contraction (181). Six1 is therefore a myogenic gene more than a pre-myogenic gene. This theory 
is corroborated by Pax3/7 double knock-out mice which were seen to struggle with forming a 
myotome whereas Six1/4 mice form a myotome which fails to develop further (164,297) 
In the early somite, Six and Eya genes are expressed along with Dach and Groucho/TLE co-
repressor genes, whereas in the myotome, some Groucho gene expression remains but Dach gene 
expression is shut down (165,245). The relative levels of Six, Dach, Groucho and Eya proteins may 
determine whether Six-Groucho and Six-Dach complexes repress their respective target genes, or 
whether Six-Eya or Six-Eya-Dach complexes act as transcriptional activators. It has yet to be 
confirmed that Six and Eya proteins can be localised to the nucleus in young somites (173); 
however, the presence of some protein at the promoters of target genes cannot be excluded. 
Thus, it is feasible that Six proteins play a role in the early somite, but likely as a temporary 
repressor of the myogenic program. Studies on Six4, MyoD and Mef2d binding to DNA revealed 
that these proteins create a poised promoter that is loaded with the transcriptional machinery 
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but require further input before transcription is fully activated (reviewed by (193). Thus, it is 
plausible that the distinct pre-myogenic role of Six proteins is to prepare promoters of muscle 
genes for activation. 
3.3.6 Expression of the first muscle structural genes is concomitant with that of MyoG. 
Our study revealed that at a given stage in development, the exact beginning of gene expression 
varied somewhat, most likely because the embryos were in a different phase of segmentation and 
epithelial somite formation. Furthermore, the extended time needed for the staining reaction 
when analysing weakly expressed genes (up to two weeks) led to somewhat divergent results. 
However, we found that the order of marker gene expression was in agreement at all stages 
investigated, with Myf5 showing expression before MyoD, followed by the onset of Mef2c. This 
was subsequently followed by the expression of MyoG and the first muscle structural gene, Tnni1, 
and ultimately the expression of sarcomeric Myosin genes (Fig. 3.10). The approximately 
coinciding expression of MyoG and Tnni1, followed by the expression of other structural genes is 
in line with suggestions that MyoG is involved in the initiation of terminal differentiation and the 
activation of late muscle genes (210). However, at HH15 and HH19/20 Tnni1 expression appeared 
to occur prior to that of MyoG. This may be within the assay margin of error but a double in situ 
hybridisation assay would be required to clarify this point. MyoD and MyoG recognise similar DNA 
sequence elements but also have unique protein-protein interaction domains which allow MyoD 
and MyoG each to target a subset of distinct promoters independent of their protein-DNA 
interaction sites. MyoD recognises alone a few structural genes such as Tnni1, Myosin heavy 
chain, Myosin light chain and Desmin (320). Using ChIP essays Bergstrom showed that in vivo 
MyoD is recruited in the early stages of myogenesis. However late MyoD targets such as Desmin 
was not detected until 24 hr after the induction of MyoD. This is shows that MyoD action is 
delayed until the proper key time of activation and the binding of MyoD was prevented entirely at 
E boxes in genes not expressed in the skeletal muscle. Bergstrom demonstrated that the 
promoter-specific regulation of MyoD binding is a critical mechanism for patterning gene 
expression (320).  MyoD starts the histone modifications and alone is enough for the expression 
of early genes but requires to be combined with MyoG at late stages. In culture MyoG does not 
substantially activate muscle gene expression in the absence of MyoD. This could be explain by 
the fact that MyoG needs MyoD to permit the histone modifications, critical to form a stable DNA 




Figure 3. 11: Summary 
Progression of marker gene expression from HH10-HH19/20, focusing on the onset of the most strongly 
expressed genes as their onset can be determined most precisely. At all times, the expression of Tbx6, of 
pre-myogenic genes and of Myf5 overlaps. As development proceeds, the onset of markers associated with 
myogenic progression and terminal differentiation occurs earlier, indicating that the process accelerates in 





3.3.7 Differentiation catches up with somitogenesis. 
At the early stages of development, the markers for differentiation initiation were not yet 
expressed (HH10) or were expressed at a distance away from the segmental plate (HH14). As 
development progressed, this distance decreased (HH16, HH19/20), suggesting that the process 
of differentiation catches up with the process of somitogenesis, and may ultimately contribute to 
the consumption of immature cells in the tail bud of the embryo. The decline of Wnt and Fgf 
signalling in the tail bud, combined with increased retinoic acid levels as a result of Raldh2 
expression, has been attributed to controlling the cessation of somite formation and body 
elongation (321,322). However, these changes occur after the time period considered here, 
suggesting that additional contributing factors are involved in the acceleration of somite 
differentiation. 
3.3.8 Distinct combinations of gene expression distinguish cells from the dorsomedial, 
ventrolateral and rostrocaudal dermomyotomal lips. 
Myf5 expression was tightly associated with cells in the dorsomedial and ventrolateral lips of the 
dermomyotome and the linked sublip regions, which accounts for the incremental growth of the 
myotome (304–306,323). The rostrocaudal lips themselves are a further source of myogenic cells 
and are considered the driver of the myotomal centre expansion (Kahane et al., 1998a). Yet, while 
Mef2c and Follistatin expression is shown in cells emerging from all dermomyotomal lips, this was 
not the case for Mrf. Moreover, the rostrocaudal lips but not the dorsomedial or ventrolateral lips 
expressed Pitx3, suggesting that distinct myogenic cascades exist in the four lips. However, Myf5 
was expressed in cells nearby the rostrocaudal lips, indicating that ultimately, all cells express Mrf 
and the cascades converge.  
3.3.9 Gene products are differentially distributed along the rostrocaudal length of the 
myotube. 
Skeletal muscle (myofibrils) is constructed out of distinct repetitive arrangements of contractile 
protein complexes called sarcomeres (324). It is therefore interesting to note that Myh15 and 
Myh7 gene expression, although initially being present in the myotomal centre, became 
differentially distributed in the mature myotome, with Myh15 mRNA and protein being enriched 
at the rostrocaudal extremes and Myh7 gene products in the centre. Given that Myh7 expression 
is staggered after that of Myh15, it is feasible that Myh7 expression may become similarly 
redistributed as for Myh15. However, it is also possible that the contractile specifications vary 
along the length of a myotube. Many Fgf signalling molecules have been reported to be 
specifically expressed in the myotomal centre where they control the release of the embryonic 
muscle stem cells from the overlying dermomyotome (325,326). Future exploration into these 




4 Design and validation of Mrf expression constructs 
4.1  Introduction  
In the previous chapter, we described, how the basis of the study was laid, analysing a palette of 
genes that could serve as marker genes to monitor myogenic progression. In this chapter, it will 
be described, how the experimental approach to test muscle stem cell protection was developed, 
and which steps were undertaken to ascertain that this approach would work. 
4.1.1  The working hypothesis of this project: suppression of premature differentiation 
ensures the in vivo maintenance of the muscle stem cell state.  
Muscle stem cells cultured in vitro quickly lose their stem cell characteristics and their ability to 
efficiently differentiate into muscle (15). In a healthy organism in vivo, however, a pool of muscle 
stem cells persists throughout life; in fact, muscle stem cells can even be collected from a recently 
deceased (327). This suggests that in a healthy individual, mechanisms exit that protect the 
muscle stem cell state. 
In the introduction to this thesis, possible factors that contribute to the stem cell niche and the 
maintenance of the stem cell pool were discussed, and efforts are being made to recapitulate 
these conditions when culturing muscle stem cells in vitro. However, eventually, extrinsic cues 
have to be molecularly integrated inside the cell, and hence, intrinsic mechanism must exist, too. 
This idea is reinforced by the observation that muscle stem cells can be recovered from a cadaver 
where the environment of the muscle stem cells ceased to support the stem cell. Yet the intrinsic 
mechanism of stem cell protection is not known.  
The previous expression analysis showed that in amniotes, the naïve paraxial mesoderm 
sequentially expresses a series of marker genes until markers associated with a muscle stem cell 
state - the pre-myogenic genes - are established in the somite. Cells then have the choice to retain 
stem cells features or to enter the differentiation program for muscle. The may also contribute to 
the dorsal dermis or the axial skeleton and connective tissue (328). However, the somite evolved 
as a structure to provide muscle for locomotion before the ability to generate cartilage and bone 
was acquired (135). Moreover, in anamniote vertebrates that develop via free-feeding juvenile 
stages, the paraxial mesoderm rapidly lays down skeletal muscle (329). We thus hypothesised 
that the main protection muscle stem cells require is a protection from premature differentiation 
since this guarantees a balance between muscle formation and maintenance of the stem cell pool. 
This idea is supported by the fact that pre-myogenic genes – though possibly at different steps - 
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are involved in the acquisition of myogenic competence and the activation of myogenic genes. Yet 
differentiation does not immediately occur when the pre-myogenic genes are expressed; in fact, 
prolonged expression of specifically Pax3 and Pax7 delays differentiation, and these genes are 
shut off during the differentiation process (318).  
4.1.2 The experimental approach: in vivo misexpression of Mrf genes 
Entry into myogenesis is marked by the sequential expression of Six/Eya, Mrf and Mef2 genes, 
followed by the activation of muscle structural genes ((330)) and this study). Phylogenetic studies 
established that members of the gnathostome Six, Eya, Mrf and Mef2 gene families arose during 
the whole genome duplications that occurred early during the evolution of this group of 
vertebrates (161,307,331). Therefore, it was not surprising that paralogous genes had some 
functional redundancy, and in loss-of-function experiments, several had to be inactivated 
simultaneously to show that these genes are required for myogenesis. However, gain-of-function 
experiments showed that of the Six/Eya, Mrf and Mef2 genes, only the Mrf genes are sufficient to 
drive myogenesis: when misexpressed in vitro, they can force myogenic as well as non-myogenic 
cell lines into myogenic differentiation (186,332,333). Moreover, when prematurely expressed in 
blastula-stage Xenopus embryos, Mrf can force non-myogenic cells into muscle differentiation 
(334–336). Furthermore, when misexpressed in the chicken neural tube/neural crest cells, Mrf 
can trigger expression of sarcomeric Myosins (albeit with very low efficiency; (337). Therefore, it 
was concluded that the Mrf genes are master regulators of myogenesis. Consequently, we chose 
as our first experimental series an Mrf misexpression approach in live muscle stem cells in vivo. 
4.1.3 The experimental model for in vivo misexpression: the chicken embryo 
Biomedical research aims at developing muscle stem cells for therapy in a patient. Hence, 
research will have to deliver the knowledge and understanding to manipulate adult muscle stem 
cells. The majority of these cells, at least in amniotes, are held in a quiescent state (77). Therefore, 
return to quiescence is typically interpreted as a sign that a muscle stem cell retained stem cell 
features and self-renewed. As explored in the introduction, muscle stem cell quiescence 
represents a specialised form of stem cell behaviour. Moreover, suspension in the G0 phase of the 
cell cycle is not per se a sign of stem cell properties. Yet it is difficult to experimentally separate 
the maintenance of generic muscle stem cell features (being muscle-competent, but 
undifferentiated and self-renewing) from a return to quiescence. Thus, we turned to a model 
where muscle stem cells quiescence is not an issue, namely embryonic muscle stem cells. 
Embryonic muscle stem cells are held in the somitic dermomyotome until released to populate 
the myotome (139). Thus, muscle stem cells can be selectively targeted. The chicken embryo is 
the ideal model to do so since it is accessible in the egg, the largest of all vertebrate models, and 
protocols to introduce molecular constructs into the dermomyotome are well established (338–
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340). The mouse embryo develops in utero and hence, is not accessible for transient assays. 
Instead, costly transgenic mouse lines that allow gene misexpression selectively in the 
dermomyotome would have to be created. Xenopus and zebrafish embryos are accessible but 
small. Constructs are typically delivered at the 1- or 2-cell stage, and hence early phenotypes arise 
before the desired stage of development is reached. The generation of transgenic fish and frog 
lines are options, but this would render the work as costly as for the mouse. Moreover, as will be 
discussed below, we suspected that in the anamniote models, rapid myogenesis is promoted, not 
suppressed. Hence, the chicken, being an amniote like mammals, remained the preferred choice 
of model. Consequently, we had to optimise the misexpression approach for the chicken. 
4.1.4 Criteria to generate appropriate Mrf constructs 
Structure and function of Mrf proteins has been investigated in numerous studies. However, 
these studies differed in the choice of expression vector, details of the molecular construct, use of 
autologous or heterologous Mrf genes and the use of proteins tags. We will below consider these 
differences and explain the criteria we used to create the, we hoped, most potent chicken Mrf 
expression constructs. 
4.1.4.1  Selection of a strong promoter/ enhancer 
To fully explore the potency of Mrf in enforcing myogenic differentiation of muscle precursor and 
stem cells in vivo, it was important to generate constructs with optimal molecular properties. In 
vivo, gene transcription is controlled by chromatin remodelling proteins, transcription factors and 
the protein complex facilitating RNA synthesis (trans-regulatory elements) which act on gene 
specific enhancer and promoter sequences (cis-regulatory elements; (341)). The interplay 
between trans- and cis-acting factors is a product of genome evolution, and the level of 
transcription of an endogenous gene may not be high (342,343). Yet misexpression studies in vitro 
showed that MyoD-driven myogenic conversion was more efficient when construct expression 
was driven from a strong promoter such as the human cytomegalovirus (CMV) or Rous sarcoma 
virus (RSV) promoter, and less efficient when driven from the in comparison weaker Simian 
vacuolating virus 40 (SV40) promoter (332,344). Thus, the expression vector of choice should also 
contain this promoter/ enhancer. 
4.1.4.2 Inclusion of a Kozak sequence for strong translation 
The Kozak sequence was identified as a consensus sequence for the initiation of translation from 
vertebrate mRNAs (345). It is recognised by the ribosome and facilitates the use of the ATG 
included in this sequences as translation initiation site. The most conserved position in this motif 
is the purine (R) in position -3 (three nucleotides upstream from the ATG codon) which occurs in 
97% of vertebrates mRNA (346). Mrf coding sequences do not necessarily have a full Kozak 
consensus at the translation initiation site, and hence, translation levels may vary. All the 
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constructs designed for use in this study were appended with the Kozak sequence and therefore, 
all construct mRNAs will have translation initiated at equally high rates. This allows us to 
standardise experimental conditions.  
4.1.4.2.1 Factors that affect translational control 
mRNA translation is affected by the RNA processing steps. It has been shown that correct removal 
of introns by splicing as well as processing of poly A signals can stabilise a primary mRNA and 
ensure that it is not prematurely degraded (347). During translation, the progress of the ribosome 
is affected by RNA secondary structure and codon usage. Areas of strong RNA structure or 
including rare codons with low abundance cognate tRNAs, cause the ribosome to progress at a 
slower rate and thus affect the overall equilibrium of protein concentrations within the proteome 
(348). 
4.1.4.3  Use of autologous versus heterologous Mrf proteins 
Mrf expression constructs have been used extensively, and misexpression studies have been 
performed in cells of many different species in vitro but also in vivo. In some studies, heterologous 
Mrf genes were misexpressed since this allows to discriminate transgene and endogenous gene 
expression. An example is the study by Delfini and Duprez (2004), in which mouse Myf5 and 
MyoD were misexpressed in the chicken neural tube and neural crest cells (224,337). In other 
studies, the autologous genes were used as these genes should be evolutionarily optimised for 
the chosen experimental model. An example is the study by Sweetman et al. (2008), in which 
tagged versions of chicken Mrf were expressed in the chicken neural tube and neural crest cells 
(224,337); for an evaluation of tags, see below). Unfortunately, the efficiency of heterologous Mrf 
driven from otherwise identical constructs has not systematically been explored. We therefore 
undertook a detailed comparison of vertebrate Mrf protein sequences to establish, how much 
proteins may differ between species and whether it would be advisable to use chicken Mrf. This 
comparison will be shown in the results section below. 
4.1.4.4  Avoidance of tags that might interfere with Mrf protein function 
Epitope fusion tags are a widely employed strategy for detecting protein expression due to their 
simple application. The tag is a short peptide sequence that is recognised by a commercially 
available monoclonal antibody. When fused to a protein of interest, the proteins can be detected 
even if no antibody for this specific protein currently exists. Yet some recent reports have shown 
that epitope tags can influence the function of the proteins they are fused to. Positioning a tag N- 
or C-terminally can influence the protein's affinity with its binding partner if positioned close to a 
binding site, and if positioned internally could affect the folding of the protein itself (349). Z. 
Shevtsova et al. compared the function of tagged and untagged Enhanced Green Fluorescent 
Protein (EGFP) and found that the migration pattern of EGFP on SDS-PAGE gels differed, 
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depending on whether an HA-tag was fused to either the amino or the carboxy terminus of the 
protein. Intriguingly, all HA-tagged EGFP proteins also showed considerably reduced fluorescence 
when compared to EGFP alone or to EGFP fused to other epitope tags (350).  
Previous studies on the sequence and structure of Mrf proteins revealed that these transcription 
factors have a highly conserved basic domain linked to a helix-loop-helix domain, required for 
nuclear localisation, DNA binding and interaction with their E-protein partners. These domains are 
located in the N-terminal half of the proteins. The proteins also carry a conserved, Myc-like C-
terminal domain involved in gene transactivation, this domain is longer in Myf5 and MyoD where 
it is referred to as a Myf5-domain. Work by Tapscott et al. (1988) and Bergstrom et al. (2001) 
showed that in Myf5 and MyoD, the ultimate C-terminus is also conserved and functionally 
relevant (157,351). We investigated more closely the conservation of Mrf protein termini, to 
decide whether or not the use of tags would be advisable (see below). We found no site that 
would allow to safely place an epitope tag without the risk of compromising protein function, and 
for this reason we decided to not add any epitope tags to the proteins sequences.  
4.1.5 Test systems to validate the constructs  
Our hypothesis is that the Mrf constructs are not sufficient to enforce premature myogenesis in 
amniote muscle stem cells. If this were to be correct, then misexpression of Mrf in the chicken 
embryo would not lead to the premature and ectopic expression of sarcomeric Myosins in the 
dermomyotome. A result like this however would be indistinguishable from results obtained by 
non-functional constructs. We therefore needed a positive control to confirm the activity of the 
constructs before inferring biological relevance from negative results. 
As will be shown below, our comparative bioinformatics analysis of Mrf proteins suggested that 
the use of untagged, chicken-specific Mrf proteins would be advisable to generate constructs best 
suited for misexpression in the chicken embryo. Detection of translation of the misexpression 
constructs would therefore rely on antibodies specific to the individual protein. However, these 
do not currently exist and it was considered too time consuming and costly to generate these 
antibodies for this project. Therefore, we planned a series of experiments to validate the activity 
of our constructs.  
To confirm the generation of biologically active Mrf proteins, we decided to replicate the 
experiments of Ludolph in 1994 (334), where they injected Xenopus embryos at the 1 or 2-cell 
stage or the early blastula stage with Xenopus MyoD or Myf5 mRNAs. They showed that on the 
injected side, non-myogenic cells were recruited into myogenesis. When injected at the 2 cell 
stage, cells underwent myogenic differentiation even before gastrulating, such that almost the 
entire half of the embryos expressed sarcomeric Myosin. We expected that our own constructs 
would lead to similar phenotypes when fully functional.  
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As will be shown below, we largely obtained the expected results. We therefore, as the last of our 
preparatory experiments, established in the chicken, when exactly after electroporation cells 
would be exposed to the products of our misexpression constructs, i.e. from which time point 
onwards phenotypes might emerge. 
4.2 Results 
4.2.1 Determination of the desired sequences 
4.2.1.1 Phylogenetic tree of Mrf proteins 
The data collected from Dr. Dietrich synteny analysis allowed us to allocate Mrf sequences to the 
four Mrf paralog groups. To further corroborate this allocation, a phylogenetic analysis of Mrf 
protein sequences was carried out. Mrf genes have been found in not only in jawed vertebrates, 
but also in agnathans and in invertebrates. In Drosophila melanogaster, an insect and hence 
belonging to the ecdysozoan branch of protostome animals, the mrf gene is known as nautilus 
(352). To carry out a meaningful phylogenetic analysis, we strived to identify Mrf protein 
sequences across bilateria, performing protein and cDNA database searches using the 
BLAT/BLAST algorithm as before. The complete list of animals searched and their phylogenetic 
relationship is provided in Annex Table 3.A. The protein sequences were aligned in Bioedit using 
ClustalW. The alignments were manually adjusted where ClustalW failed to align similar sequence 
stretches owing to different sequence length. The alignments were trimmed and phylogenetic 
unrooted and rooted trees were constructed by F. Schubert, using MPhyl3. Trees were then 
constructed using iTol (Fig.4.1) (353). The first trees (Fig.4.1 A, B) contained the Drosophila and 
red flour beetle nautilus sequences, and these were used as outgroups to root the tree. However, 
as the protostome sequences were very divergent, the relationship of the deuterostome 
sequences was not resolved well. We therefore generated a second set of trees with the 
protostome sequences excluded. To root this deuterostome Mrf tree, the echinoderm sequences 
were used as outgroups (Fig.4.1 C, D).  
In the tree analyses, gnathostome Myf5, MyoD, MyoG and Mrf4 protein sequences formed 
distinct subgroups. Moreover, the teleost proteins belonging to the conserved MyoD locus and to 
the more divergent MyoD locus were grouped separately, the latter with a bootstrap value of 
100. This indicates that our previous allocation of Mrf proteins to paralog groups was correct. The 
grouping of proteins within a paralog group largely followed the known animal phylogeny, with 
sarcopterygian sequences being grouped away from actinopterygian and condrichthyan 
sequences. Exceptions were Latimeria Mrf4 that was equidistant from sarcopterygian and 
actinopterygian Mrf4 proteins, elephant shark MyoG that grouped with the sarcopterygian 
sequences, and Human, Xenopus and elephant shark MyoD that grouped with the actinopterygian 
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MyoDs (see Fig.4.1 D). However, bootstrap values for these allocations were low, indicating that 
the grouping is not robust. Additional analyses using additional phylogenetic algorithms will solve 
this problem (354). 
Interestingly, in all trees, Myf5 and MyoD formed one metagroup, and MyoG and Mrf4 formed a 
second. Moreover, the invertebrate sequences fell between the Myf5/MyoD and the MyoG/Mrf4 
subgroups, respectively. This suggests also in the lineage leading to vertebrates, once an ancestral 
Mrf gene existed that combined properties of the current gnathostome Mrfs. It also suggests that 
after the first genome duplication, Myf5-MyoD arose from one ancestral gene, and MyoG-Mrf4 
from another ancestral gene, in line with (355). Unexpectedly, the hagfish Mrf sequence which we 
had expected to also lie between the Myf5-MyoD and MyoG-Mrf4 group, instead grouped with 
the Myf5-MyoD set. However, agnathan sequence information was limited and the sequence 
used here may not have been representative.  
Moreover, the first round of vertebrate genome duplication may have occurred before the 
agnathan-gnasthostome split (356–358), and hence the existence of a further agnathan Mrf gene/ 









4.1: Phylogenetic trees of vertebrate Mrf proteins 
(A) Unrooted and (B) rooted phylogentic trees for deuterostome Mrf proteins as well as Drosophila and Trilobium castaneum nautilus proteins. In (B), the tree was rooted with the insect 
sequences. (C) Unrooted and (D) rooted phylogentic trees for deuterostome Mrf proteins; in (D), the tree was rooted with the echinoderm Mrf sequences. In (B, D), the abbreviations of 
proteins names were used as delineated in Table 1 and Appendix Fig.1. In (B,D), Bootstrap values are also indicated. Note that gnathostome Myf5, MyoD, MyoG and Mrf4(=Myf6) 
proteins form clearly distinguished groups. Also note that Myf5-MyoD and MyoG-Mrf4 form meta-groups, supported by high bootstrap values. This suggests that Myf5 and MyoD genes 





4.2.1.2 Protein motif analysis 
Having established the allocation to the four gnathostome Mrf groups, we now separately aligned 
the individual Mrf paralogs to compare similarities and differences. For the chicken, the various 
version available for a particular protein were also included. The alignments are shown in Appedix 
1; conserved features as well as differences between the chicken proteins are annotated. The 




Table 4. 1: Typical features of Mrf proteins 
Amino acids are displayed in 1-letter-code, colour code as in Appendix 1. 
Note the similarity between the Myf5/MyoD and MyoG/Mrf4 protein termini and the presence of a 
complete Myf5 domain in Myf5/MyoD only, supporting the idea that Myf5/MyoD and MyoG/Mrf4 are 
phylogenetically and functionally related. 
 
 Gnathostome Myf5 Gnathostome MyoD Gnathostome MyoG Gnathostome Mrf4  
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The alignment of the Myf5 sequences revealed a high degree of conservation for the basic 
(Appendix 1A, blue shading), helix-loop-helix (green shading) and the Myf5 domain (pink shading). 
Notably, in all animals except teleosts and lepidosaurs (Anole lizard and python), the first 5 amino 
acids are highly conserved; the consensus sequence in 1-letter-code is M-E/D-V-M-D (Appendix 
Fig.1A, black bracket). Likewise, the C-terminus typically shows the presence of T-Y-Q-A-L in birds 
(T-C-L-A-I in the zebra finch), I/V-Y-H-V-L in all other gnathostomes (Appendix Fig 1.A, arrows). 
Exception for the latter are the sequences for the budgerigar (premature stop codon), and the 
sequences for the peregrine falcon, the rock dove and crocodylians. Here the sequence 
downstream to the 2nd splice site (2nd black triangle) are highly divergent. Yet these sequences are 
currently predicted sequences only, suggesting that the 3rd exon may not yet have been properly 
identified. However, the conservation of the internal protein domains and the sequences at the 
protein termini suggested they are all functionally important and therefore, to avoid interfering 
with the activity of these domains, we decided not to tag the proteins.   
Interestingly, avian Myf5 sequences showed a few special features. This included a stretch 
enriched in prolines and charged amino acids in the centre of the basic domain (position 35-45 in 
the gapped alignment) and a stretch enriched in prolines towards the C-terminus (position 293-
295). Given that prolines can change the 3-D structure of proteins, in particular break helices, this 
features might be relevant (359). Thus, the use of chicken-derived sequences might be the safest 
option when using the chicken model. Importantly, for chicken Myf5 the RNAseq-derived 
sequences and the sequences predicted on the basis of the sequenced genome are identical, but 
differ from the curated (NP) protein sequence at 2 positions inside the Myf5 domain (Appendix 
Fig.1A, black boxes). Yet the RNAseq-derived and genomic sequences closely match the 
sequences of other amniotes. Thus, the curated sequence was deemed unreliable, and the 
RNAseq-derived/ genomic sequences were used for our construct design. 
4.2.1.2.2 MyoD 
The alignment of MyoD sequences indicated that a number of sequences were incomplete at the 
N-terminus (fly catcher, ostrich, Latimeria). Moreover, a number of sequences lacked exon 2-
encoded sequences (atlantic cod, Medaka MyoD-2) or exon 3-encoded sequences (MyoD of the 
Chinese softshell turtle, MyoD encoded by cod scaffold gs298, Medaka MyoD from scaffold 3975). 
However, we had sufficient information from all animal taxa to characterise the features of their 
MyoD proteins.  
The tetrapod MyoD N-terminus (Appendix Fig. 1B, bracket) typically encompassed the sequence 
M-E/D-L-L, which in most diapsids was followed by G-P/H. Also in tetrapods, a variation of the N-
terminal theme occurred a second time, and in non-mammalian species, this matched closely the 
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N-terminus of the actinopterygian and chondrichthyan sequences (M-E-M/V/I-T versus M-E-L-S/P 
or M-E-I-T; Appendix 1B, 2nd black bracket), suggesting an internal sequence duplication. In the 
middle of the basic domain, we found for all species an extended histidine-rich stretch with the 
exception of mammalian MyoDs. Notably, this H-rich stretch was not present in the curated 
chicken MyoD sequence. Histidine stretches are enriched in developmentally important 
transcription factors and involved in locating proteins to nuclear speckles (360). Hence, this 
difference may be significant. Further downstream, all proteins continued with the highly 
conserved basic, helix-loop-helix and Myf5 domains (Appendix 1B, blue, green, pink shading). In 
most MyoD proteins, C-terminus ended in the sequence I-Y-Q-V-L (arrows), the exception being 
the less well conserved the C-termini in the more divergent, 2nd teleost MyoD proteins. The 
conservation of the MyoD termini suggests that also in this case, an untagged version of the 
protein should be used.  
Notably, diapsid MyoD proteins, in addition to the extended stretch of conserved amino acids at 
the N-terminus, contained an expansive serine-rich stretch just before the C-terminus (position 
351-356 in the gapped aligment). Serines are prime targets for phosphorylation, and MyoD 
activity is known to be controlled by phosphorylation (206,361). Therefore, we decided to use 
chicken MyoD as this would be most adapted to the chicken system. Yet in the chicken, the 
curated MyoD not only lacked the H-stretch, but differed at 3 further positions (black boxes) from 
the RNAseq-derived sequence. The latter however matched the sequences found specifically in 
other birds. Therefore, as with Myf5, the RNAseq-derived sequence was deemed most likely to be 
the correct sequence and was consequently used in the construct design.  
4.2.1.2.3 MyoG 
The alignment of MyoG sequences revealed a highly conserved sequence at the N-terminus that 
constituted the start of the basic domain of the protein (Appendix 1C, bracket, blue shading). This 
sequences consisted of M-E-L-F/Y-E-T-N/S-A/P, the exception being quail MyoG (contained M-S-D-
F-I-L-K) and Xenopus MyoD (started with an extra M). The proteins continued with the highly 
conserved basic and helix-loop-helix domain (Appendix 1C, blue and green shading). MyoG 
proteins were shorter than Myf5/MyoD proteins and lacked the full Myf5 domain. Nonetheless, 
the C-termini (from position 269 in the gapped alignment shown in Appendix 1C) were highly 
conserved, in diapsids invariably ending with E-E-R-V/G/S-Q/H-N (arrows), again, suggesting that 
an epitope tag should not be used. Overall, sarcopterygian MyoG sequences were very similar. 
However, to be consistent, we decided to continue using the chicken sequences. The various 




Mrf4 proteins resembled MyoG proteins in that they carried a conserved N-terminus (M-M-D/E-
L/M-F-E-T/S, Appendix 1D, bracket; in half the sequences preceded by a further M) at the start of 
the conserved basic domain (blue shading), which was followed by the equally conserved helix-
loop-helix domain (Appendix 1D, green shading) and a truncated version of the Myf5 domain. In 
amniotes, the proteins ended with two acidic amino acids, followed by V/A/L-V/L/A-E-K, 
suggesting that also in this case, no epitope tags should be added. As for MyoG, sarcopterygian 
sequences were very similar, but we decided to continue using the chicken proteins. The chicken 
Mrf4 sequences were identical and matched the sequences of other birds, and hence, were also 
deemed reliable. 
4.2.1.3 Selection of the expression vector 
Having established which sequences to use to express chicken Mrf genes, we now considered 
possible expression vectors. Several expression vectors have a long standing use in the avian 
system, including pCab-GFP which contains a separate open reading frame (orf) for EGFP and 
vectors such as pCAGGS in which the EGFP orf is used as a tag, being fused to the orf of the gene 
of interest. Importantly, these vectors are typically driven by the cytomegalovirus (CMV) enhancer 
and the chicken beta Actin promoter, which fulfils our requirements for strong cis-regulatory 
transcriptional elements. However, as we did not wish to tag our constructs, the second type of 
vectors was dismissed, and pCab-GFP was used to clone the constructs for misexpression in 
chicken embryos. The features of this vector are shown in Fig. 4.2.  
Figure 4.2 (A), shows the circular map of the pCab expression vector generated by the Gene Snap 
program. On the right (Fig.4.2 B) the functional elements that facilitate expression of the gene of 
interest and the tracing of targeted cells are represented graphically; map drawn to scale. In brief, 
ubiquitous eukaryotic expression is driven by the cytomegalovirus (CMV) enhancer and the 
chicken beta Actin promoter. If a gene of interest is cloned into the multiple cloning site (MCS), 
transcription generates a bi-cistronic transcript that contains the sequences of the desired gene, 
followed by the CMV derived internal ribosomal entry site (IRES) and the coding sequence for 
enhanced green fluorescent protein (EGFP). Thus, presence of EGFP-dependent fluorescence 
indicates that the construct was transcribed in full and that translation is occurring. The inclusion 
of the chicken beta Actin-rabbit beta Globin intron downstream of the transcriptional start site 
results in a single splicing event known to stabilise the mature transcript. The rabbit beta Globin 
poly (A) signal downstream of the EGFP ORF ensures transcript polyadenylation and consequently 
stabilisation. Translation occurs simultaneously via cap-dependant initiation of the gene of 






Figure 4. 1: Properties of the pCab expression vector 
(A) Circular map of the pCab expression vector generated by the SnapGene Viewer program. (B) Graphic representation of the functional elements that facilitate expression of 
the gene of interest and the tracing of targeted cells. Ubiquitous eukaryotic expression is driven by the cytomegalovirus (CMV) enhancer and the chicken beta Actin promoter. 
If a gene of interest is cloned into the multiple cloning site (MCS), transcription generates a bi-cistronic transcript that contains the sequences of the desired gene, followed by 
the CMV derived internal ribosomal entry site (IRES) and the coding sequences for enhanced green fluorescent protein (GFP). Owing to the fused chicken beta Actin-rabbit 
beta Globin intron downstream of the transcriptional start site, the transcript is spliced once. The rabbit beta Globin poly (A) sequences downstream of the GFP sequences 
ensure transcript polyadenylation and hence stabilisation. Simultaneous translation then occurs from the sequences upstream of the gene of interest and from the IRES. 
If cells or tissues targeted with the pCab construct are being analysed by in situ hybridisation, care has to be taken to avoid unwanted hybridisation of the probe with the 
pCab-derived transcript. pCab / pCab transcripts do not contain M13-derived sequences typically included in plasmids ISH probes are generated from (B, bottom; lines markers 
by asterisks). Hence standard ISH probes pose no risk. ISH probes generated from construct intermediates cloned into pMK/pMA contain 124 nucleotides that match the 
chicken beta Actin - rabbit beta Globin sequences of the unspliced and 86 nucleotides of the spliced pCab-derived transcript, respectively (orange-pink line). Stringent 




4.2.2 Attempts to obtain the chicken Mrf open reading frames by RT-PCR 
We had been kindly provided with expression constructs for mouse Myf5 and MyoD by D. Duprez 
(337) and with constructs expressing tagged chicken Mrf by A. Münsterberg (224). In initial sets of 
experiments we electroporated these constructs into chicken somites, but did not obtain any 
phenotypes (not shown). To optimise the constructs as discussed above, we decided to generate 
constructs for untagged versions of chicken Mrf. Our expression analysis had established that 
chicken Mrf are all robustly expressed in somitic myotomes at E3. Therefore, bodies of E3 (HH20) 
were collected, total RNA was isolated and reverse transcribed to generate cDNA. To obtain the 
Mrf sequences, a nested primer approach was used. A set of primers upstream of the ATG codon 
and downstream of the stop codon were used in the first PCR, followed by a second PCR with 
primers located at the ATG and the stop codon. This second set of primers was designed such that 
restriction enzyme (RE) sites for cloning into pCab and the Kozak sequence at the translational 
start site would also be introduced. The sequences and location of these primers are shown in 
Appendix 2A-D. Our established PCR conditions (Biomix Red system employing a non-proof-
reading DNA polymerase, annealing temperature 5 degrees below the primers’ melting 
temperature) did not produce any fragments of the expected sizes, possibly owing to the high GC 
(Guanine-Cytosine) content of the chicken sequences. Therefore proof-reading enzymes, PCR kits 
optimised for GC-rich sequences and various conditions for primer annealing were used. Some 
PCRs produced fragments of the expected size, and these fragments were cloned into pCab and 
sequenced. However, none of the clones contained the correct Mrf orf; all contained small 
deletions or frame-shift mutations (not shown). Therefore, gene synthesis was outsourced and 
the desired sequences were chemically synthesised and cloned by Life Technologies (GeneArt). 
4.2.3 Gene synthesis 
Life Technologies were provided with the desired chicken Mrf cDNA sequences and the sequences 
of the pCab vector. Out of convenience, the company did not use the Cla1 restriction site that 
would link the 5’ end of the fragment to the pCab polylinker, but synthesized the Mrf orf and 
pCab upstream sequences up to the Xba1 site of the vector. The synthesized sequences were 
linked to Sfi1 restriction sites and subcloned into the company’s own vectors, pMA or pMK. These 
are simple cloning vectors with a T7 promoter upstream of the inserts and M13-derived 
sequences suitable to prime PCR and sequencing reactions from either side of the insert. 
Subsequently, the inserts were excised for pMA/pMK using Xba1-EcoR1/BamH1 as required, and 




4.2.4 Validation of synthesised constructs 
4.2.4.1  Confirmation of correct sequences by dideoxy (Sanger) sequence analysis 
To confirm that the Life technologies products indeed yielded the correct sequences, both strands 
of each construct were re-sequenced; sequences were assembled and aligned and compared with 
the desired sequences using the Bioedit software. This information is included in (Appendix Fig. 
2A-2D), and shows, that for all four Mrf constructs, the correct sequences were obtained. 
4.2.4.2 Evaluating construct activity in the heterologous frog system 
The African clawed frog (Xenopus laevis) is a well-established vertebrate model for the in vivo 
analysis of gene function. Specifically, has been used for the evaluation of the Mrf function. Co-
culture experiments showed that the early gastrula ectoderm (corresponds to the epiblast in 
amniotes) inhibits the differentiation of muscle precursors (362). However, when Xenopus Myf5 
or MyoD mRNA was injected into single blastomeres at the 1 or 2-cells stage or early morula 
stages of development, the descendants of these cells were recruited into myogenesis and 
expressed sarcomeric Myosins (334); mouse MyoD has a similar effect (A. Philpott, personal 
communication). We therefore expected that chicken Mrf construct would also be active in the 
Xenopus model. To misexpress the genes in this system, they had to be cloned into a vector from 
which in vitro translation and mRNA preparation would be possible. Thus, in collaboration with 
Professor Matthew Guille (University of Portsmouth) the open reading frames of the synthesised 
Mrfs were excised by restriction digest and cloned into the pCS2 (cuts with Cla1 and EcoR1) vector 
and sequenced (Fig. 4.3) . The genes were transcribed using the SP6 RNA polymerase, making use 
of the SP6 promoter located upstream of the insert; as control, βGal mRNA was used (see 








Figure 4. 2: Properties of the pCS2+ expression vector 
(A) Circular map of the pCS2+ expression vector generated by the SnapGene Viewer program. The vectors pCS2+ contains a strong enhancer/promoter (CMV) followed by a 
polylinker and the SV40 late polyadenlyation site. An SP6 promoter is present in the 5' untranslated region of the mRNA from the sCMV promoter, allowing in vitro RNA 
synthesis of sequences cloned into the polylinker. A T7 promoter in reverse orientation between the polylinker and the SV40 polyA site for probe synthesis, as well as a 
second polylinker after the SV40 polyA site to provide several possible sites to linearize the vector for SP6 RNA transcription. The vector backbone is from pBluescript II 
KS+ and includes the amp resistance gene. 
(B) The vector pCS2+ does not have GFP on its sequence so all the constructs that have been cloned in this vector need to be co-electroporated with pCAB to be visualised 
at the fluorescence microscope. The constructs that were cloned in pCS2+ vector are identical to the constructs cloned in pCAB. The ORF were restriction digested using 





The RNA was in vitro translated and capped, quantified, 1ng of Mrf mRNA was injected into one 
cell of 2-cell stage Xenopus embryos; 250pg of a mRNA encoding β-Gal was used as lineage tracer. 
As the first cell cleavage of Xenopus zygote separates the left and right half of the animal, one 
side of the embryo will be the experimental side and one side will be the control side as used by 
(334). In total, 30 embryos were injected per Mrf construct, 30 were injected with the lineage 
tracer alone, and 30 were left uninjected. Embryos were incubated at 18°C until they reached 
stage 26 and analysed using the MF20 antibody to detect Myosin Heavy Chains. Representative 
embryos are shown in Fig. 4.4, the data are summarised in Table 4.2. This experiment revealed 
that MyoG and Mrf4 only recruited non-myogenic cells into myogenesis. Myf5 and MyoD did not 
give us any upregulation of the Myosin staining, the phenotype was comparable with the wild 
type, and the phenotype of the injected side were comparable with the control side.  
Of the 30 uninjected embryos, all survived. 11 were analysed for sarcomeric Myosin expression 
and showed the wildtype expression pattern (Fig.4.4 A,B). Of the embryos injected with the β-Gal 
mRNA, 18 survived, indicating that the injection somewhat compromised development. However, 
all embryos showed the same, wildtype Myosin expression as the uninjected embryos (Fig.4.4 
C,D). Of the embryos injected with chicken Myf5 or MyoD mRNA, 14 and 10, respectively, 
survived. They appeared largely normal; in a few cases, we observed a slight reduction in head 
size or enlarged occipital somites (Figure 4.4 F, arrowhead). Of the embryos injected with MyoG 
or Mrf4 mRNA, only 6 or 5, respectively, survived. Of those, half (MyoG) or 4/5 (Mrf4) were 
malformed. These embryos showed widespread ectopic expression of sarcomeric Myosin on the 
injected side (Fig.4.4 J, L, asterisks). They also had failed to complete gastrulation and to close the 
blastopore (Fig.4.4 J,L, arrows). Owing to the defective gastrulation, also the uninjected side was 
truncated and head structures were reduced (Fig.4.4 I,K). However, somites showing correctly 
aligned, Myosin expressing myotubes were present. The phenotype caused by the misexpression 
of chicken MyoG and Mrf4 resembled the phenotypes obtained from misexpresison of Xenopus 
Myf5 and MyoD (334). Thus, the experiment shows that the design of our Mrf expression cassette 
(Kozak sequence followed by the Mrf open reading frame) permits high level translation in a 
heterologous system, and in the case of MyoG and Mrf4, produced biologically active protein. 
Since all Mrf constructs were designed the same way, we can infer that all can be translated. The 
reasons why chicken MyoG and Mrf4 but not chicken Myf5 and MyoD reproduced previously 









Figure 4. 3: Chicken Mrf misexpression in frogs 
A batch of Xenopus leavis embryos was subdivided into 9 groups of 30 embryos. One set was left to develop 
(A,B); of the others, one cell each was injected with Gal mRNA (C,D), or with Gal mRNA plus the Mrf RNA 
indicated on the left of the panel (E-R). Embryos were collected when the control embryos had reached st26 
and stained for sarcomeric Myosin expression (brown staining). Representative embryos were 
photographed, showing the untreated (C,E,G,I,K,M,O; rostral to the left) and treated sides (D,F,H,J.L,N,P; 
rostral to the right) in lateral views. Note that embryos injected with chicken Myf5 and MyoD appeared 
largely normal, sometimes displaying slightly reduced head sizes or enlarged occipital somites (F, 
arrowhead). Embryos injected with chicken MyoG or Mrf4 showed extensive ectopic expression of 
sarcomeric Myosin (asterisk). Owing to the recruitment of cells into myogenesis earlier on, embryos had 
failed to complete gastrulation and to close the blastopore (arrows). The experiment indicates that of the 
four chicken Mrfs, those associated with late phases of myogenesis and terminal differentiation can force 
Xenopus cells into myogenesis, those associated with myogenic commitment cannot. 






Table 4. 2: Xenopus experiments 
In each experiment, 30 2-cell stage Xenopus laevis embryos were used. They either were left to develop 
(control 1), injected with 250pg -Gal mRNA (control 2) or injected with a mix of 250pg -Gal mRNA and 1ng 
of Mrf RNA. RNAs were delivered in a total of 5nl water. Note that RNA injection reduced the survival rate by 
40%. Injection of chicken Myf5 or MyoD RNA reduced survival rates further, but surviving embryos appeared 
largely normal, sometimes displaying somewhat smaller heads (MyoD) or enlarged occipital somites (Myf5). 
When injected with chicken MyoG or Mrf4, survival rates were poor, and in half (MyoG) or most embryos 






No of survivors 
at stage 26 
WT Malformed 
- 30 30 
11 analysed, all 
wt 
0 
-Gal 30 18 18 0 
Gg Myf5+-Gal 30 14 14 0 
Gg MyoD+-Gal 30 10 10 0 
Gg MyoG+-Gal 30 6 3 3 







4.2.4.3 Evaluating construct activity in the autologous chicken system 
The misexpression of chicken Mrf constructs in Xenopous embryos revealed that MyoG and Mrf4 
are sufficient for enforcing premature myogenesis in this system. Importantly, the experiments 
also confirmed that our constructs design allows to the production of functional protein. 
Eventually, however, we wished to use the chicken Mrf constructs in chicken embryos. Therefore, 
it was important to establish the expression from these constructs directly in the chicken system.  
The aim of the study was to challenge immature paraxial mesoderm and developing muscle stem 
cells in the somitic dermomyotome with Mrf expression constructs. Hence we turned to the 
somite. Three tests were carried out: (1) Flank somites at HH15/16 were electroporated with the 
Mrf constructs or with the parental pCab-GFP vector, and, after overnight re-incubation that 
allowed the embryos to reach HH20, messenger RNA made from all the constructs was monitored 
by in situ hybridisation. (2) An electroporation time course was carried out, and the presence of 
EGFP-fluorescence was used to monitor onset and duration of transgene expression.  
The first set of experiments revealed that GFP expression was readily detectable for the pCab 
vector as well as the vectors containing Mrf orf as inserts (Fig 4.5 A,C,E,G,I). Assaying the 
electroporated embryos for the presence of the GFP orf (Fig, 4.5 B) or the Mrf orf (Fig.4.5 D,F,H,J) 
in the mRNA from the construct, we found that this was the case: strong signals were obtained in 
a pattern that matched the GFP signal (arrows). Notably, the intensity of the GFP-derived 
fluorescence and the staining obtained from the in situ hybridisation corresponded, inferring that 








Figure 4. 4: Confirmation of Mrf construct expression in chicken somites 
Lateral views of the electroporated somites in the right side of the chicken embryo 18 hours 
after electroporation; rostral is up, the dorsal midline is to the left. (A,C,E,G,I) GFP 
expression recorded immediately after fixation. (B,D,F,H,J) Same embryos as in (A,C,E,G,I), 
showing the signals obtained by in situ hybridisation with a GFP probe that recognises the 
pCab-derived transcript (B) or with Mrf probes that recognise both the transcript and the 
endogenous gene (D,F,H,J); constructs and probes are indicated on the sides of the panel, 
the corresponding somites are indicated by arrows. Note that the constructs produce readily 





In the second experiment, embryos were harvested immediately after the electroporation, 6 
hours, 18 hours and 42 hours after electroporation (Fig. 4.6). At time zero, no fluorescence was 
observed, as expected (Fig. 4.6 A). After just 6 hours from electroporation, robust fluorescence 
could be detected in the electroporated somites (Fig. 4.6 B). After 18 hours even more intense 
fluorescence was detected (Fig. 4.6 C), indicating accumulation of construct-derived gene 
products. When the centre of the somite was targeted, cells in the dermomyotome fluoresced as 
evidenced by the rounded shape of cells when photographed in a dorsolateral view. After 42 
hours (Fig .4.6 D), fluorescence was still readily detectable. Notably, now round cells atop 
elongated cells beneath were labelled, indicating that some cells had had stayed in the 
dermomyotome while others had contributed to the myotome and formed myotubes, in tune 
with the normal progress of myotome development. The time course is fully in line with a time 









Figure 4. 5: Time course for the expression from pCab vectors in chicken somites 
Epithelial somites in the right side of HH15/16 chicken embryos were electroporated with the pCab vector and analysed for GFP expression immediately thereafter (A), 6 hours later (B), 
after an overnight incubation (O/N, i.e. 18 hours later; C), or after an additional day of incubation (42 hours; D). The targeted somites are shown in dorsal (A), dorsolateral (B) and lateral 
views (C,D). Note that the construct is well expressed 6 hours after electroporation, and expression levels continue to be high during the duration of the experimental time period 
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4.2.4.4 Analysis of Mrf gene expression 
In recent years, reports of misexpression experiments of Mrf in the chicken embryo in vivo have 
been published. Sweetman in 2008 and Delfini in 2004 showed that the electroporation of one of 
the Mrfs can lead to upregulation of other Mrf family members (224,337). In both studies, the 
Mrfs were misexpressed in the neural tube and the effects were analysed with in situ 
hybridisation using Mrf probes. Both the studies used constructs based on the pCab vector. Delfini 
misexpressed the native protein of mouse Myf5 and MyoD, while Sweetman used a HA-tagged 
version of the chicken Mrfs. Expression of endogenous Mrf was analysed by in situ hybridisation 
after overnight re-incubation of the treated embryos. To validate our results and our 
experimental methods we sought to replicate the results from Sweetman 2008 and Delfini 2004, 
except in our case we misexpressed the constructs in the somites. Our constructs contained 
untagged orfs for chicken Mrf, cloned into the pCab vector. All the embryos were analysed with 
ISH after 18 hours of re-incubation at approximately HH19/20. Since our ISH probes contained the 
Mrf orf, we were not in the position to monitor the endogenous expression of the Mrf we 
introduced as a transgene. 
Embryos electroporated with the pCab vector only displayed wildtype expression for all four Mrfs 
(Fig. 4.7 Ai, Bi, Ci, Di). When Myf5 was misexpressed, MyoD, MyoG and Mrf4 were upregulated in 
the targeted somites (Fig. 4.7 Fi, Gi, Hi, arrows). The MyoD construct upregulated Myf5, MyoG 
and Mrf4 (Fig. 4.7 Ii, Ki, Li arrows). The MyoG construct upregulated Myf5, MyoD and Mrf4 (Fig. 
4.7 Mi, Ni, Pi arrows). The Mrf4 construct upregulated Myf5 and MyoD (Fig. 4.7 Qi, Ri arrows) in 
areas corrispondng to the fluorescent somites (Fig. 4.7 Q,R arrows). We however didn't detect any 





4.2: Misexpression of Mrf genes between HH16-20 upregulates transcription of other Mrf genes. 
Flank somites were electroporated at HH15/16 and embryos harvested at HH19/20 as before. GFP fluorescence was recorded and Mrf mRNA 
expression detected by in situ hybridisation. Mrf self-regulation could not be tested due to lack of probes detecting the untranslated regions (UTRs) of 
the mRNAs. Note that Myf5 upregulated the expression of MyoD (Fi), MyoG (Gi) and Mrf4 (Hi). MyoD upregulated Myf5 (Ii), MyoG (Ki) and Mrf4 (Li). 
MyoG upregulated Myf5 (Mi), MyoD (Ni) and Mrf4 (Pi). Mrf4 upregulated Myf5 (Qi) and MyoD (Ri), but did not elevate MyoG expression beyond its 









In this section, we carried out preparatory experiments that would set the stage for the 
subsequent attempts to coax muscle precursors out of their stem cell state. This included the 
design of the most appropriate Mrf constructs for the chicken system, tests that these constructs 
would deliver functional proteins, and tests for the time frame in which the constructs would be 
expressed after electroporation into chicken somites. This has been achieved. 
4.3.1 Chicken Mrf are most appropriate for expression studies in the chicken system 
After initial obstacles regarding the allocation of Mrf proteins to the correct paralog group (which 
led to the discovery of a second MyoD gene in teleost fish other than the zebrafish), we were able 
clearly assign gnathostome Mrf sequences to their cognate groups. Sequence comparison 
confirmed a high degree of conservation for the known functional groups, the basic, the helix-
loop-helix and the Myf5/ transactivating domain. Interestingly, the comparison also revealed a 
number of short sequence stretches in specifically diapsid Mrf proteins that distinguished these 
proteins from other members of their respective paralog group, including stretches enriched in 
prolines in Myf5 and a histidine-rich stretch in MyoD. Unfortunately, detailed information 
regarding the function of these regions, in terms of linear sequence, protein folding and targets 
for posttranslational modification are not available, work on motif and protein structure have 
manly be carried out using the mammalian proteins (364). In the context of proteins other than 
Mrf, the sequence variations have been shown to be relevant (364).Given the conservation of 
these sequences throughout diapsids, it is likely that they have been selected for during diapsid 
evolution and hence, may be relevant in the chicken system. This finding suggested the use of 
chicken Mrf rather than heterologous Mrf for misexpression in the chicken embryo.  
For all Mrf, various sequences have been contributed to the various sequence databases, the 
most recent being RNAseq data for whole embryos and somites published in Ensembl. The 
sequences for MyoG and Mrf4 proteins were identical however, significant differences were 
found between the curated Myf5 and MyoD sequences and the sequences derived from the 
mRNA information obtained by RNAseq. The most obvious was the presence of a histidine-rich 
stretch in the basic domain of MyoD in all non-mammalian proteins, but not in the curated 
version of chicken MyoD. Sequences for muscle genes have been found to differ between layer 
and broiler stains of chicken (365). In laboratory research, chicken tissue is frequently obtained 
from birds bred as mixed flocks, hence sequence variations may indeed occur. However, given the 
high level of conservation of sequences, and in the absence of studies that investigated the effect 
of these sequence variations, the sequence that matched the conserved pattern were used. As 
the information collected from RNAseq data shows the presence of the histidine-rich stretch in all 
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Mrf sequences, this can be taken as good evidence that this specific sequence is correctly carried 
through from the genome to the transcripts. 
4.3.2 Conserved Mrf protein termini suggest the use of untagged constructs  
When we scrutinised Mrf sequences for conserved proteins domains, we found in line with 
previous studies (156,355,366) that the basic domain, the helix-loop-helix domain, the Myf5 
domain (Myf5 and MyoD), and the shortened version of this domain in MyoG and Mrf4 were all 
highly conserved. Moreover, both the N-termini and the C-termini were conserved, with an 
extended degree of conservation found in diapsids. Previous studies showed that both the N- and 
C-terminus have a strong influence on the activity of the protein (156,367,368). This suggested 
that the use of epitope tags, both at the termini and in the centre of the protein, would likely 
interfere with protein function as shown for other proteins (350). Hence, we decided to use 
untagged proteins only. 
4.3.3 Chicken Mrf proteins are functional in the Xenopus system 
The evolution of the somites in chordates is essential to facilitate the movement of the body axis, 
and locomotion in the water. Jawless and anamniote jawed vertebrates develop via free-feeding 
larvae, this means that development of the muscle must occur very fast to allow the larvae to 
swim. If myogenic genes are expressed in the early blastula, then the transgene expression could 
upregulate the system while it is likely geared up towards myogenesis. This could explain why the 
Xenopus early blastula cells can easily be reprogrammed to enter myogenesis. 
The misexpression experiments in the chicken showed that our constructs readily produce mRNA 
and can be translated from the 2nd cistron in all cases. Why, then, can Xenopus Myf5/MyoD (334), 
and chicken MyoG/Mrf4 but not chicken Myf5/MyoD (in this study) drive Xenopus blastula cells 
into myogenesis. The data that we obtained confirmed that during the two rounds of 
gnathostome genome evolution, the Myf5/MyoD pair and MyoG/Mrf4 pair evolved. This is in line 
with earlier studies (355). The sequence of gene expression (334) and in this study, together with 
the body loss of function experiments (316,369) established that Myf5/MyoD are involved in the 
commitment to myogenesis whereas MyoG/Mrf4 are involved in the initiation of terminal 
differentiation. Mrf4 in mammals has acquired an earlier role, possibly by tapping into some of 
the cis-regulatory elements for Myf5 expression (as they are linked in the genome; (370)), MyoD 
is the gene reaching over to the differentiation genes via the feed-forward mechanism with MyoG 
(210,371). Yet depending on how much the individual Myf5/MyoD genes may diverge from the 
original, they may have lost the ability to fully activate differentiation genes. If this were to be the 
case, then chichen/bird/diapsid genes may not be able to force cells into terminal differentiation, 
while MyoG/Mrf4, being optimised for the role, can.  
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To fully explore this, one would need to co-express Myf5- or MyoD reporters with the  expression 
constructs and monitor to which extent, both in Xenopus and in the chicken, the transgenes can 
activate the reporters. It also would be interesting to test the function of chimeric, part chicken-
part Xenopus. For this study, we rely on the fact that all constructs were designed in the same 
way, all are expressed, biological activity was confirmed for MyoG/Mrf4 in Xenopus, and by 
inference, and this should be the same for Myf5 an MyoD. Another possible experiment could be 
to express the Mrf constructs via transfection in cell culture, utilising fibroblasts as a positive 
control. The results for this experiment obtained by Weintraub and colleagues in 1989 (332) were 
that MyoD expressing transfected fibroblasts became muscle cells. This experiment was not 
performed as all constructs were tested in chicken as shown in Figure 4.7. After electroporation of 
the constructs, the levels of Mrf mRNAs were shown by in situ hibridisation to be upregulated, 
confirming biological activity of the constructs. 
4.3.4 Chicken Mrf constructs are expressed within 6 hours of electroporation in the 
chicken somite 
The test electroporations revealed that the constructs are robustly expressed 6h after 
electroporation; expression persists for the next two days, in line with (363). Therefore, if the 
embryos are left to develop overnight, they will have been exposed to the proteins derived from 
the constructs for a minimum of 12 hours. If the embryos are left to develop for another day, they 
will have been exposed for a minimum of 36 hours. Somite electroporation experiments 
conducted by various groups including ours (276,372) showed that phenotypes in terms of 
changed cell behaviour and marker gene expression can be readily obtained, exposing the cells to 
the products of expression constructs overnight. Therefore, we can be confident that muscle stem 
cells will show measurable changes in their behaviour if the Mrf constructs were able to force 
them out of their stem cell state. 
4.3.5 Mrf misexpression in the somatic dermomyotome upregulates the transcription of 
other Mrf genes 
The use of the Mrf constructs in the somitic dermomyotome showed that they stimulate the 
premature transcription of the other Mrf genes, confirming that the designed constructs are 
active. The unexpected upregulation of Myf5 in response to the other constructs can be explained 
by the use of the different constructs including conserved sequences that cannot be compared 





5 Misexpression of chicken Mrf in the immature chicken paraxial 
mesoderm 
5.1 Introduction 
Mrf misexpression experiments using 2-cell stage Xenopus embryos showed that chicken MyoG 
and Mrf4 can enforce terminal muscle differentiation in early stage embryos, thereby blocking the 
completion of gastrulation on the treated side (Section 4.2.4.2). In contrast, misexpression of 
chicken Myf5 and MyoD had little effect. Given that (i) all Mrf constructs were made the same 
way, (ii) all were confirmed by sequencing, (iii) all were actively transcribed from the pCab vector 
when electroporated into chicken somites, and (iv) GFP protein was readily produced from the 
Internal Ribosome Entry Site (IRES) of the bi-cistronic mRNA transcribed from pCab vectors, we 
inferred that in principle, all constructs deliver protein and are biologically active. We thus 
reasoned that chicken Myf5 and MyoD, while controlling myogenic commitment, may have lost 
the ability to support terminal differentiation. Alternatively, the bird-specific variations in the 
Myf5 and MyoD protein sequence may have rendered these proteins non-functional in the frog. 
However, in the autologous chicken system, the proteins should be functional. To explore these 
possibilities we now turned to the avian system, aiming to misexpress the Mrf constructs in 
tissues ideally as immature as the frog cells. 
When chickens lay their eggs, the embryos are already at a late blastula stage and ready to enter 
gastrulation, i.e. the early cell divisions of the fertilised egg take place inside the hen (287). 
Therefore, it is not possible to fully recapitulate the frog experiments. However, earlier studies in 
our laboratory suggested that expression constructs similar to pCab-based constructs can be 
electroporated directly into the primitive streak (i.e. the epiblast region undertaking gastrulation) 
of the early gastrula stage embryo without disturbing the progression of development (D. 
Sobreira and S. Dietrich, unpublished observations). Moreover, this work showed that, when the 
rostral primitive streak was electroporated, cells contributing to the paraxial mesoderm were able 
to take up the construct. This was in line with past studies that had mapped the fate of 
gastrulating cells in the primitive streak (99,296,373).  
Importantly, the primitive streak is of a different length at different stages of development: it 
extends between HH2-3 in the direction of the future rostral end, has maximal length at HH4, and 
shortens in a rostral to caudal direction from HH4+ to HH10/11, when the remnant of the 
primitive streak becomes the tail bud (374). At the earliest stages of gastrulation, the primitive 
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streak delivers the definitive (gut) endoderm, at HH3-4 it delivers the head mesoderm, and from 
HH4 onwards it delivers prospective trunk mesoderm (375). When the primitive streak delivers 
mesoderm, different areas of the streak contribute different types of mesoderm, with the rostral 
tip of the streak (Hensen’s node) generating the axial mesoderm (notochord), the caudally 
adjacent area provides the paraxial mesoderm, and the further caudal areas produce the 
intermediate, lateral and extraembryonic mesoderm, respectively. The precise territory 
contributing a particular type of mesoderm changes as the streak retracts (376).  
To define the stages and regions of the primitive streak most suitable for Mrf misexpression, and 
to ensure that the electroporated cells encompass the paraxial mesoderm as this will later 
provide the myogenic cells, we first performed a series of cell labelling experiments. For this 
purpose DiI (3H-Indolium,2-[3-(1,3-dihydro-3,3-dimethyl-1-octadecyl-2H-indol-2-ylidene)-1-
propenyl]-3,3-dimethyl-1-octadecyl-, perchlorate 41085-99-8) was injected into the primitive 
streak at early stages of development (5.2.1.1). Thereafter, we performed control- 
electroporations with the pCab vector (expressing GFP only) to confirm that the electroporation 
experiments match the DiI labelling experiments (5.2.1.2.1). This was followed by test 
electroporations to determine the onset of pCab expression in this experimental setting 
(5.2.1.2.2). Finally, we electroporated the constructs for chick Mrf, using two different 
immunohistochemical methods to assay for muscle differentiation (5.2.2). These experiments 
revealed that in the chicken, none of the chicken Mrf can drive immature paraxial mesodermal 
cells into terminal muscle differentiation. 
5.2 Results 
5.2.1 Establishing the experimental approach 
Preliminary data utilising DiI labelling collected by Dr Dietrich and Mr Cardon, showed that HH4 is 
the most appropriate early chicken development stage to use for these experiments. At this stage 
the embryos are at the beginning of development showing just the primitive streak. The embryos 
labelled with DiI and incubated overnight showed a wide range of cells labelled in the lateral 
mesoderm which will give rise to the future somites. The same results were obtained when 
repeated using GFP expressing control constructs; the majority of the fluorescent cells are in the 
lateral mesoderm. Looking at this data we decided to electroporate our Mrf constructs at HH4 
and let them develop overnight to reach HH10 before analysing them with MF20 antibody 
staining. At HH10 the only myosin expressed is in the heart. The cells forming the somites are too 
young to express Mrf or any structural genes and the only relevant protein expressed at this 
moment is Pax7. 
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5.2.2 Electroporation of Mrf constructs into the HH4 rostral primitive streak 
Having established the protocol for the electroporation of the immature paraxial mesoderm, we 
now proceeded to misexpress the Mrf constructs. Given that the first myogenic cells do not 
appear before stage HH10 (the first stage that Myf5 is expressed), and given that we did not know 
which level of myogenic competence cells had earlier, we decided to let the embryos develop to 
HH10. Thus, embryos were re-incubated for 18 hours after electroporation to reach this stage. 
The experimental approach is summarised in Fig. 5.4. 
In the first series of experiments, the Mrf constructs, or as a control, the empty pCab vector, were 
electroporated. Embryos with readily detectable GFP-derived fluorescence and overall normal 
morphology were photographed and the subjected to a 3,3′-Diaminobenzidine (DAB) antibody 
staining, using the MF20 antibody to detect sarcomeric Myosins (293). This work was carried out 
in collaboration with T. Stone in the lab (5.2.2.1).  In a second series, GFP was detected by an anti-
GFP antibody and sarcomeric Myosins with MF20, subsequently detecting the primary antibodies 
with fluorochrome-coupled secondary antibodies (5.2.2.2). Since at HH10, embryos already have 
a functional primary heart, the MF20 staining of the heart served as internal control for the 
quality of the staining. We expected that embryos misexpressing the chicken Mrf constructs 
would show premature sarcomeric Myosin expression within the targeted cells, if the 
experimental system were to resemble the frog system. The results are summarised in Table 1. 
5.2.2.1 Analysis of electroporated embryos for the expression of sarcomeric Myosin, MF20-
DAB staining 
In the first collection of embryos, all showed robust expression of sarcomeric Myosins in the 
heart, as evidence by the brown staining (included in Fig. 5.5 G,H; ht). Notably, despite the high 
level of construct expression as evidence by bright GFP fluorescence (Fig.5.5, A-E), none of the 









Figure 5. 1: Time scale and schematic representation of the electroporation experiments suited to target 
the immature paraxial mesoderm and young somites 
(A) When the rostral primitive streak is electroporated with a pCab construct at stage HH4/5, this construct 
will be reliably expressed after 6 hours when the embryos have reached HH7. When analysing the embryos 
at HH9/10, the embryos will have been exposed to the construct for 12 hours. 
(B, left) To electroporate stage HH4/5 embryos, they were mounted on filter rings and placed in a custom-
made electroporation chamber, ventral side up, such that the rostral primitive streak, but not Hensen’s 
node, were on top of the negative electrode (blue dotted line). DNA was injected between the epiblast and 
the vitelline membrane (green circle). The positive electrode was placed over the rostral-most primitive 
streak and a rectangular pulse was given. This was repeated several times, each time moving the positive 
electrode to a more caudal position, until the area marked in red had been covered. (B, middle) Tbx6 
expression (red), Pax7 expression (orange) and transgene expression (green) 6 hours after electroporation. 
(B, right) Tbx6 expression (red), Pax7 expression (orange), Myf5 expression (yellow) and transgene 
expression (green) at the time of harvesting, 18 hours after electroporation. Transgene expression overlaps 
with that of the molecular markers.  




5.2.2.2 Analysis of electroporated embryos for the expression of sarcomeric Myosin using 
MF20 and anti-GFP primary and fluorescent secondary antibodies 
For a more optimal approach and to confirm the results shown in Section 5.2.2.1, we decided to 
repeat the experiments with a double-labelled immunofluorescence approach, by utilising two 
primary antibodies and two distinct fluorescently-labelled secondary antibodies. This time, as well 
as the MF20 antibody, a GFP antibody was used to mark the cells that expressed the pCab-GFP 
constructs during the electroporation. This approach enabled detection of both signals at the 
same time, reducing the errors that occurred when overlapping the fluorescence and the 
Normaski micrographs. The embryos were processed as described in the previous paragraph 
(Section 5.2.2.1). Again, while sarcomeric Myosins were readily detectable in the heart, none of 
the embryos showed upregulation of the sarcomeric Myosins in the area of the fluorescence, and 
all Mrf misexpressing embryos resembled the control embryos only carrying the pCab vector. This 
indicated that, chicken Mrf, while able to prematurely trigger myogenesis in the frog, are unable 






Figure 5. 2: Mrf misexpression in the naïve paraxial mesoderm and young somites does not trigger premature muscle differentiation (I) 
The rostral primitive streak of HH4/5 embryos was electroporated with the constructs indicated on top of the panel. 18 hours later, the GFP expression was recorded (A-E). Embryos were 
analysed for Sarcomeric Myosin expression, using the MF20 antibody and DAB staining (F-J). MF20 recognised the Sarcomeric Myosins of the developing heart (see G, H, ht). However, 
the construct expressing cells did not show any sign of Sarcomeric Myosin expression. Abbreviations: ht, heart; s1, youngest somite; sp, segmental plate. 








Figure 5. 3: Mrf misexpression in the naïve paraxial mesoderm and young somites does not trigger premature muscle differentiation (II).  
The rostral primitive streak of HH4/5 embryos was electroporated with the constructs indicated on top of the panel. 18 hours later, GFP was detected with an anti-GFP antibody (green 
fluorescence) and Sarcomeric Myosin expression was detected with the MF20 antibody (red fluorescence). Note that both in the control and in the Mrf misexpressing embryos, the MF20 
antibody recognised Sarcomeric Myosins in the heart. However, neither the control nor the Mrf expressing embryos showed Sarcomeric Myosin expression in the targeted.  




Table 5. 1: Summary electroporation experiments shown in chapter 5 
Numbers displayed as: Total: wildtype/upregulated/downregulated 
In this table we can observe the number of the electroporated embryos that were analysed during the experiments. We can observe the number of the embryos analysed with 
the immunohistochemistry for MF20 antibody detecting Sarcomeric Myosin light chain. All embryos showed no upregulation of Myosin expression. 
 
EP targeting the immature paraxial mesoderm in the segmental plate and young somites 
Specimen analysed for Sarcomeric Myosin (MF20) 
 DAB staining Fluorescent 2
nd
 antibody 
Construct   
   
pCab 4:4/0/0 3:3/0/0 
   
Gg Myf5 5:5/0/0 4:4/0/0 
Gg MyoD 5:5/0/0 3:3/0/0 
Gg MyoG 4:4/0/0 4:4/0/0 
Gg Mrf4 3:3/0/0 4:4/0/0 




5.3.1 Electroporation into the rostral primitive streak allowed targeting of the immature 
paraxial mesoderm and newly formed somites 
We previously showed that chicken MyoG and Mrf4, when misexpressed in 2-cell-stage Xenopus 
embryos, can enforce muscle differentiation (this study), as can Xenopus Myf5 and MyoD  (334) 
but not chicken Myf5 and MyoD. We thus had to test whether any of the chicken Mrf can evoke 
myogenesis in the autologous chicken system when mimicking the experimental conditions used 
in the frog. Given that it is not possible to fully recapitulate the Xenopus experiment in the 
chicken, we tried to recreate this approach at the youngest stage we could manipulate, which is a 
gastrula stage embryo. We thus established the electroporation conditions to target the 
gastrulating cells in the primitive streak, ensuring that the prospective paraxial mesoderm (i.e. 
muscle-competent cells) were included. Our experiments show that when electroporating the 
rostral primitive streak at HH4/5, the gastrulating mesoderm including the prospective paraxial 
mesoderm can be targeted. Cell targeting matched our DiI cell labelling experiments and were in 
line with earlier fate mapping studies (296). However, in our electroporation experiments more 
cells were targeted than when injecting DiI; in fact besides cells still resident in the streak, GFP 
expression was found in cells contributing to the paraxial, intermediate and lateral mesoderm as 
well as in cells contributing to the neural plate (the latter are derived from the epiblast lateral to 
the rostral streak; (302)). This is likely a result of using a custom-made electroporation chamber 
which had a 1mm-wide negative electrode embedded in the bottom of the chamber. Thus, even 
with a flame-sharpened 0.1mm tungsten needle as positive electrode, many cells were exposed to 
the electrical field. The constructs are driven from the ubiquitously active CMV enhancer/ chicken 
beta actin promoter, and DNA was injected such that the space between epiblast and the vitelline 
membrane was filled. Therefore, many cells were in the position to take up and express the 
constructs. However, given that this electroporation approach did not prevent normal 
development, and given that a more widespread misexpression gave more cell types the chance 
to respond to Mrf, we deemed this approach very suitable indeed. 
5.3.2 The constructs were active 6 hours after electroporation 
Previous studies had indicated that the efficiency of myogenic conversion depended on the level 
of Mrf expression, which in turn accounts for the speed by which Mrf protein may accumulate 
(344). It was important to know when the transgene was first expressed following the 
electroporation. Understanding the timing of expression allowed us to identify how long the 
target tissue was exposed to the transgene encoded protein. To do this, we misexpressed pCab-
GFP in HH4 embryos and analysed them for GFP-derived fluorescence after 6, 8 and 10 hours 
after electroporation. We found that GFP was readily detectable 6 hours after electroporation, 
akin to the somite system (Chapter 4 and Lours-Calet et al., 2014). Thus, when embryos are left to 
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develop for 18 hours to HH10, the stage when the first Myf5 expressing cells appear, cells will 
have been exposed to the transgene for at least 12 hours. Previously, we and others have 
observed responses to misexpression constructs in this time window (337). Therefore, this 
experimental set-up allow us to determine cellular responses to Mrf misexpression.  
5.3.3 Chicken Mrfs are unable to drive the chicken immature paraxial mesoderm into 
terminal muscle differentiation 
The aim of this section was to test whether in the autologous system, chicken Mrf can drive 
immature cells into myogenic differentiation. The limitation of the experimental set-up was that 
cells as immature (in fact pluripotent; (377)) as early Xenopus blastomeres could not be tested. 
On the other hand, when electroporating into the HH4/5 rostral primitive streak and allowing the 
embryos to develop for 18 hours to HH10, cells still resident in the streak, cells contributing to the 
mesoderm, cells incorporated into the paraxial mesoderm, cells that already have become part of 
a somite, cells in the somite that have begun to express Myf5 alongside cells in the epiblast that 
will contribute to neural tissue all will have the chance to respond to Mrf. Yet, while sarcomeric 
Myosins were readily detected in the cardiac muscle of the heart of the embryos which at HH10 is 
already beating, we found no sarcomeric Myosins in the electroporated cells, neither when using 
DAB immunostaining nor when using fluorescing secondary antibodies. Even MyoG and Mrf4, 
which were able to force Xenopus cells into muscle differentiation, did not upregulate  sarcomeric 
Myosin expression in the chicken. This suggests that Mrf did not trigger prmature skeletal 
myogenesis in immature chicken cells.  
A simple explanation for this difference may be that the chicken experiment did not recapitulate 
the experiment conducted in the frog: in the chicken, gastrulating cells were targeted whereas in 
the frog, blastomeres were exposed to Mrf. These cells have different properties, with 
gastrulating cells becoming committed to a particular germ layer while early blastomeres are still 
pluripotent. However, (334) also reported a recruitment of later stage blastomeres in to 
myogenesis which suggests that the ability to readily engage in myogenesis may be a generic 
property of early embryonic frog cells. As discussed in chapter 4, anamnia such as Xenopus 
embryos have to undergo myogenesis at an early stage to allow the tadpole to swim (145,378). In 
amniotes including birds, there is no necessity to develop skeletal muscle at such an early stage. A 
fully formed chick will hatch at 21 days of incubation, whereas a Xenopus tadpole has to be able 
to swim at stage 31 (between two to three days, depending on the temperature of incubation), 
but they are able to respond to stimulus even earlier and they can move at stage 24 (289). 
Therefore, it is possible that in Xenopus, chromatin at muscle gene loci is already in an accessible 
(poised) state, whereas corresponding chromatin in the chicken may be tightly closed. If this were 
to be the case, we would expect that close to the onset of skeletal muscle formation, i.e. when 
muscle stem cells develop from the somites, the cells will be able to respond to Mrf. If however 
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the muscle stem cell state itself is protected, the cells will not engage in premature myogenesis. 
With this in mind, we now turned to the developing muscle stem cells in the dermomyotome of 
somites. Another explanation could be the time of incubation, it could be that the constructs need 
more time to complete the process and activate muscle structural genes. In a future experiment 
we could let the embryos develop for 48 hours until HH16. The embryos could be analysed with 
MF20 antibody with immunohistochemistry and with Mrf probes with an in situ hybridisation to 





6 Misexpression of Mrf genes in the somitic dermomyotome and 
developing muscle precursor cells 
6.1 Introduction 
Our previous analyses revealed that misexpression of chicken Mrfs, when introduced into 
gastrulating cells at HH4 to target the newly formed paraxial mesoderm and somites, was 
insufficient to drive these cells to terminal muscle differentiation (see Chapter 5). These results 
differed from Mrf misexpression experiments frog embryos in which at least the late Mrfs, namely 
chicken MyoG and Mrf4, were able to convert immature cells in the early blastula and gastrula 
into terminally differentiated muscle cells (see Chapter 4). In the frog, the paraxial mesoderm 
engages in muscle formation before the somites are properly formed (145,378). Moreover, 
muscle has to be made quickly to allow the tadpole to swim (289,379,380). In contrast, amniotes 
develop directly, i.e. not via distinct larval intermediates, and they do not rely on functional 
skeletal muscle for a prolonged period of time from fertilisation. It thus is conceivable that in 
amniotes, the immature paraxial mesoderm is not yet muscle-competent, and hence Mrfs may be 
unable to enforce terminal muscle differentiation. Once the amniote somite is formed, however, 
it readily begins to engage in muscle formation. First, cells from the epithelial wall of the somite 
form the primary myotomal scaffold (134). Thereafter, cells from cells from the edges of the 
dermomyotome are recruited to participate in an extensive second wave of myogenesis. Finally, 
the dermomyotome de-epithelialises and releases a third wave of myogenic cells into the 
myotome, the embryonic muscle precursor cells. These are crucial both for fetal and juvenile 
muscle growth and for the deployment of adult muscle stem cells (55,57). Thus the 
dermomyotome has to be considered a muscle-competent tissue. Consequently, the next aim was 
to directly target the developing embryonic muscle precursor cells in the dermomyotome to test 
the effect of Mrf misexpression. 
6.1.1 The experimental paradigm 
Our test electroporations had revealed that pCab-based constructs are expressed 6 hrs after 
electroporation, both when electroporating the HH4/5 primitive streak and stage HH15-16 flank 
somites (Chapters 4, 5 and (363)). Moreover, we readily detected construct activity for 2 days 
despite the fact that the constructs, being plasmid-based and thus not replicated along with the 
host cell’s genome, must eventually become dilute as cells divide (Chapter 4 and (363)). We 
therefore had a wide window of opportunity to target the dermomyotome. Our expression 
analysis had shown that during development, somite differentiation speeds up whereas somite 
181 
 
formation proceeds at constant pace (Berti et al., 2015, see Chapter 3). This suggests that the 
later we electroporated, the closer to differentiation the targeted cells would be. The 
dermomyotome begins to release muscle precursor cells into the underlying myotome at E3-E3.5 
(135,142). Thus the electroporation cannot be so late in the development of the chicken 
otherwise we will not be able to target the muscle precursor cell, this is why we decided to use an 
earlier stage. At this point in time, a transgene electroporated in the dermomyotome would no 
longer reach the muscle precursor cells. Therefore, we had to electroporate early enough to 
target these cells and allow them to be exposed to the construct for a sufficient amount of time. 
In previous studies, we had observed changes in marker gene expression when flank somites of 
HH15/16 embryos were left to develop for 18 hours (i.e. exposure to the construct was at least 12 
hours), thereby reaching stage E3/HH19-20. Since this type of electroporation would meet our 
requirements, we initially followed this experimental paradigm. As the initial experiments in 
which Mrfs were misexpressed in dermomyotomal cells did not yield ectopic muscle 
differentiation, a second series of experiments was performed, in which we extended the re-
incubation time to 42 hours.  
The experimental strategy is summarised in Fig. 6.1. In brief, we microinjected the expression 
construct directly into the lumen of the HH15/16 flank somites, which are epithelially organised at 
this stage. The positive electrode was be placed on the dorsolateral side of the somite that we are 
targeting and the negative electrode will fed through the neural tube and placed underneath the 
somites (Fig. 6.1 B). We applied 1-2 rectangular pulses at 17 Volts. Embryos were be re-incubated 
for 18 or 42 hours, respectively. Thereafter, embryos with wildtype overall morphology and 
readily detectable fluorescence were analysed for the changes in marker gene expression, the 
unelectroporated side served as internal control side; embryos electroporated with the pCab 







Figure 6. 1: Time scale and schematic of electroporation experiments using HH15-16 flank somites. 
Embryos were injected with DiI in one of the three positions indicated in the schemes on the left. Embryos 
were re-incubated overnight (ON) for 12 hours, reaching stages HH10-11. Images on the right show 
microphotographs obtained by Nomarski optics, overlaid with images obtained by fluorescence microscopy, 
of embryos at these stages; ventral views of the trunk, anterior to the top. The numbers on the images 
reflect the injection site. Abbreviations: hn, Hensen’s node, lm, lateral mesoderm, np, neural plate, not, 
notochord, ps primitive streak, s, somite. 
Note that, as the primitive streak lays down the body sequentially from rostral to caudal, later injections 
lead to the labelling of more caudal areas in the body. This will be important for the planned 
electroporation experiments, the area of the primitive streak that contributed to the paraxial mesoderm 
becomes smaller as development proceeds.  




6.1.2 Markers to monitor Mrf effects 
The function of muscle fibres requires the presence and correct interaction of sarcomeric proteins 
(295). The MF20 antibody readily detects sarcomeric Myosins (382) and during our expression 
analysis (Chapter 3), the antibody proved to be reliable. Therefore MF20 antibody staining 
continued to be the main tool to investigate the response of electroporated somites to Mrf 
misexpression. Since we did not observe any response when the electroporated embryos were re-
incubated for 18 hours, we systematically analysed whether any of the earlier expressed genes 
would be ectopically expressed. Therefore, we analysed the experimental embryos for the 
expression of: the premyogenic/myogenic genes Six1 and Eya1, for the expression of endogenous 
Mrf genes; for the expression of Mef2c, the most likely partner of Mrfs in the somite; and for 
Tnni1, the first structural gene to be expressed. This analysis was done by in situ hybridisation, 
following the same procedures that were employed in Chapter 3. Our analysis showed that in the 
first 18 hours after electroporation, Mrf proteins can activate some genes in the early myogenic 
cascade but were insufficient to drive full muscle differentiation. 
 
6.2 Results 
6.2.1 Mrf misexpression, assaying for the premature expression of sarcomeric Myosins 
6.2.1.1 Analysis after 18 hours of re-incubation HH20 
When analysed 18 hours after electroporation, more than 90 % of the embryos were alive with 
the heart beating and overall good morphology. The embryos were analysed by MF20 antibody 
staining using DAB as described in the previous chapter; numbers of experimental specimen and 
results of the experiment are shown in Table 6.3. As shown in Figure 6.2, both sides of the 
experimental embryos were photographed and compared with both sides of the pCAb control 
embryos (Fig. 6.2 B, C). Notably, all the embryos presented the same phenotype in that the 
electroporated side didn’t present any upregulation of sarcomeric Myosin (Fig. 6.2 F, I, L, O) 
compared with the control side (Fig 6.2 E, H, K, N). The striped appearance of the stained somites 
suggested that only the myotubes expressed sarcomeric Myosin. To confirm this, embryos shown 
in Fig.6.2 were vibratome-cross sectioned. Comparison of the control sides (Bi, Ei, Hi, Ki, Ni) and 
the electroporated sides (Ci, Fi, Ii, Li, Oi) showed that indeed, in all specimen sarcomeric Myosin 







Figure 6. 2: Misexpression of Mrfs between HH16-20 is insufficient to induce Sarcomeric Myosin 
expression in the chicken dermomyotome. 
Flank somites were electroporated at HH15/16 with GFP (control) or GFP and Mrf expressing constructs as 
indicated on the left of the panel. Embryos were harvested 18 hours later at HH19/20, i.e. they were 
exposed to Mrf and/or GFP proteins for at least 12 hours. (A,D,G,J,M) Overlays of the Nomarski and 
fluorescence photomicrographs of the electroporated flanks, dorsolateral views, rostral to the top. GFP 
expression indicates that 1-3 somites were targeted (green fluorescence, arrows). (B,E,H,K,N) Nomarski 
images of the un-electroporated control sides, and (C,F,I,L,O) of the electroporated sides of the embryos 
shown in (A,D,G,J,M), assayed with MF20-DAB staining to reveal Sarcomeric Myosin expression (brown 
staining), views as in (A,D,G,J,M). The targeted somites and their un-electroporated counterparts are 
indicated by arrows. Note, the levels of Sarcomeric Myosin expression are the same on either side. 
(Bi,Ei,Hi,Ki,Ni) and (Ci,Fi,Ii,Li,Oi) Nomarski images of cross sections of the flanks shown in (B,E,H,K,N) and 
(C,F,I,L,O), respectively. Note the absence of Sarcomeric Myosin expression in the electroporated 





6.2.1.2 Analysis after 42 hours of re-incubation HH24 
The previous experiment indicated that that 18 hours after electroporation, i.e. a minimum of 12 
hours exposure to the transgene, none of the Mrf was able to drive developing muscle precursor 
cells into premature differentiation. This suggested that the myoblast state may be protected in 
these cells. To explore whether after prolonged exposure, Mrf would overcome this myoblast 
state, we electroporated embryos at HH15/16 as before, this time re-incubating the embryos for 
42 hrs. This gave the embryos time to reach approximately HH23/24 after which they were 
analysed for GFP-derived fluorescence and sarcomeric Myosin expression as before (Fig. 6.3). The 
numbers of specimen and the results are also included in Table 6.3.  
At the stage of harvesting, muscle precursor cells are in the process of populating the myotome 
with some cells producing differentiating daughter cells. Thus, as expected, some of the 
electroporated cells were still in the dermomyotome (round GFP-filled cells), others were in the 
myotome and had produced elongated myotubes (elongated fluorescing cells). Owing to the 
progress in development, the somites were much larger in size than a day earlier (Fig.6.3). Figure 
6.3 B and C shows both sides of a pCab-electroporated control embryo, which, as expected, didn’t 
show any upregulation of sacromeric Myosin. Electroporations using the Myf5, MyoG and Mrf4 
expression constructs similarly showed wild type MF20 staining on both sides (Fig. 6.3 E-F, K-L, N-
O). In contrast, MyoD induced strong upregulation of sarcomeric Myosin expression within the 
fluorescing cells (Fig.6.3 I). Comparison of the cross sections confirmed the upregulation of 
sarcomeric Myosin in the dermomyotome of the MyoD-misexpressing somites (Fig. 3.6 Ii). This 
phenotype was obtained in two of six embryos (see Table 6.3). This suggests that after the after 






Figure 6. 3: Misexpression of MyoD but not other Mrfs, induces Sarcomeric Myosin expression in the 
chicken dermomyotome between HH16-24. 
Flank somites were electroporated at HH15/16 with GFP (control) or GFP and Mrf expressing constructs as 
in Fig. 6.2 but embryos were harvested 42 hours later at HH23/24, i.e. cells were exposed to the proteins 
expressed from constructs for at least 36 hours. The location of the construct expressing cells was visualised 
by means of GFP expression and Sarcomeric Myosin expression was detected with the MF20 antibody as 
before. In the embryo electroporated with the MyoD expression construct, the area expressing the 
construct (G, arrows) shows strongly elevated Myosin expression (I, arrows). The corresponding cross 
section (Ii) shows that this elevated Myosin expression is confined to the dermomyotome of the 
electroporated somite, indicating that after prolonged exposure, MyoD is able to drive muscle stem cells 
into myogenic differentiation. The ectopic muscle is disorganised, probably because it developed without 
the scaffold of the post-mitotic myotome. The data suggest that between HH16 and HH20, the developing 
muscle stem cells are protected from premature differentiation. Abbreviations: dm, dermomytome; dml, 




6.2.2 Assaying for markers of myogenic progression after 18 hours of Mrf misexpression 
Expression of sarcomeric Myosin demarcates the terminal differentiation of muscle cells, which 
did not occur when embryos were reincubated for 18 hours and thus exposed to Mrf proteins for 
12 hours. We were wondering whether nonetheless, cells would undertake some steps towards 
myogenesis. We therefore repeated the initial 18 hour- electroporation experiments, this time 
monitoring the expression of genes which, according to our expression analysis, demarcate earlier 
steps in myogenesis. To assay for gene expression, we performed in situ hybridisation with the 
antisense RNA probes used in chapter 3. In order to minimise any binding of probe to the 
sequences derived from the pCab vector, embryos were treated with RNAse A after hybridisation. 
The results are also included in Table 6.3. 
6.2.2.1 Analysis of Six1 and Eya1 expression 
The first set of electroporated embryos was analysed for the expression of the premyogenic genes 
Six1 and Eya1. In Chapter 3, we showed that at the time of electroporation at HH15/16, both 
genes are expressed in the epithelial somites, but proteins may not act as transcriptional 
activators yet. At the time of harvesting, Six1 and Eya1 are normally expressed in the dorsomedial 
and ventrolateral dermomyotomal lips and in the myotome, together with the Mrf genes (see 
Chapter 3). Thus, if Mrf were to prematurely initiate steps towards myogenesis including Six1 and 
Eya1 activation, we would expect to see upregulated expression of these genes in the 
dermomyotome.  
In all embryos, GFP-derived fluorescence was recorded and the electroporated and neighbouring 
somites were photographed after completion of the in situ hybridisation as shown in Fig. 6.4. 
When analysing the expression of Six1, we found that all somites showed wildtype expression 
only (Fig.6.4 B,F,J,N,R). When analysing the expression of Eya1 expression, we found that the 
overall staining was unexpectedly weak and hence, results have to be interpreted with caution. 
However, an upregulation of Eya1 was also not observed (Fig.6.4 D,H,L,P,T). In contrast with the 






Figure 6. 4: Misexpression of Mrf genes between HH16-20 is insufficient to upregulate Six1 or Eya1 
transcription. 
Flank somites were electroporated at HH15/16 and embryos harvested at HH19/20 as shown in Fig. 6.2. 
Thus, the embryos were exposed to the constructs for a least 12 hours. GFP expression was recorded, and 
then the embryos were analysed for the expression of Six1 and Eya1 mRNA expression by in situ 
hybridisation as indicated on top of the panel. Normal expression of these genes was observed in the 
somitic myotomes and the dorsomedial and ventrolateral dermomyotomal lips, mirroring the expression on 






6.2.2.2 Analysis of Mef2c expression 
The four members of Mef2 family of transcription factors are important Mrf co-factors 
(189,384,385). However, we previously showed that in the context of the chicken somite, Mef2c is 
the most likely partner of the Mrf proteins, overlapping with the expression of the Mrf in the 
dorsomedial and ventrolateral dermomyotomal lips and the myotome (381). We hence 
investigated whether Mrf may upregulate the expression of Mef2c. Unfortunately, in this set of 
experiments, high levels of background staining were obtained (Fig.6.6). Yet elevated levels of 
Mef2c expression were clearly detectable in somites electroporated with the Myf5, MyoD or 










Figure 6. 5: Misexpression of Myf5, MyoD and MyoG but not Mrf4, between HH16-20 
upregulated Mef2C transcription. 
Flank somites were electroporated at HH15/16 and embryos harvested at HH19/20 as before. GFP 
fluorescence was recorded and Mef2C mRNA expression detected by in situ hybridisation. Myf5 








6.2.2.3 Analysis of Tnni1 expression 
We showed in chapter 3 that the Troponin I 1 gene which encodes for a component of the 
sarcomeric multiprotein complex is the first muscle structural gene to be expressed, labelling the 
myotome at the stage that also MyoG is expressed (chapter 3, (381). Yet we found that neither 








  Figure 6. 6: Misexpression of Mrf genes between HH16-20 is insufficient to upregulate Tnni1 
transcription. 
Flank somites were electroporated at HH15/16 and embryos harvested at HH19/20 as before. 
GFP fluorescence was recorded and Tnni1 mRNA expression detected by in situ hybridisation. 
Note that neither the pCab control plasmid nor the Mrf expression constructs were able to 







Previous sections showed that while chicken MyoG and Mrf4 can trigger premature myogenesis in 
early Xenopus blastomeres, none of the chicken Mrf was able to drive the chicken gastrulating 
mesoderm and early paraxial mesoderm into forming skeletal muscle. Aim of this section was to 
explore whether developing muscle stem cells could be driven into myogenesis as these cells are 
only one step away from myogenic differentiation. Therefore, the chicken Mrf expression 
constructs were electroporated into the developing muscle stem cells in chicken flank somites. 
Embryos were analysed to the premature expression of markers indicating myogenic progression 
and terminal differentiation. These experiments revealed that Mrf activated some of the early 
muscle regulatory genes including other Mrf family members. However, in an 18 hours time 
window, Mrf were unable to enforce terminal muscle differentiation. 
6.3.1 Mrf misexpression in the somitic dermomyotome leads to the premature activation 
of some myogenic genes 
When electroporated into the somite, chicken Mrf can activate the expression of other Mrf family 
members and of Mef2c within 18 hours, with Myf5, MyoD and MyoG being the most potent 
activators. These findings indicate that our constructs are biologically active. They are in in line 
with the initial in vitro studies that once established that all Mrf can evoke skeletal muscle 
differentiation, and the in vitro studies that showed that MyoD can activate MyoG and Mef2 
family members (386). This is also similar to misexpression experiments conducted in the chicken 
neural tube in vivo which showed that mouse Myf5 and MyoD can activate chicken MyoD and 
MyoG (Mrf4 not tested), and that a tagged version of chicken Myf5 can activate MyoD, MyoG, 
Mrf4, tagged MyoD can activate MyoG and Mrf4, tagged MyoG can activate MyoD and Mrf4 and 
Mrf4 can activate MyoG (224,337). The differences that were observed in the chicken 
experiments may be due to a somewhat different type of expression construct used, as well as 
the fact the in the neural tube, the range of genes accessible to Mrf proteins may be different to 
the range available in the somite (summarised in Table 6.1). Nevertheless, the experiments all 
indicated Mrf can upregulate the expression of transcription factors needed for the subsequent 
expression of myogenic genes.  
Remarkably, Tnni1, a muscle structural gene normally expressed simultaneous with MyoG and 
before Mrf4, was not activated by any Mrf, suggesting that in contrast to experiments in vitro and 
experiments in the frog, chicken Mrf were unable to force cells into terminal differentiation. This 
was corroborated by the absence of any premature expression of sarcomeric Myosins in the 
electroporated cells. This suggests that Mrf activate genes associated with readying the cells for 
myogenesis but in the contexts of the developing muscle stem cells, do not force premature 





Table 6. 1: Comparison of results obtained in this study (Berti) with those obtained in previous studies (Delfini or Sweetman) 
Mrf electroporations analysed by in situ hybridisation or by immunohistochemistry from this study are summarised and evaluated alongside those of two other important published 
papers (224,337). Data is colour-coded by study (Delefini-Blue, Sweetman-Red and Berti-Green). The observed upregulation of a gene is represented by a tick in the corresponding colour. 
The results of all three works are mostly in agreement but differ in some experiments. 
 Marker 
 Myf5 MyoD MyoG Mrf4 Pax3 Pax7 FgfR4 Id1 miR1 miR206 Six1 Eya1 Mef2c Tnni1 Mox2 Notch1 Serrate1 
Sarcomeric Myosin 
(MF20 staining) 
Construct                   
pCab 
control 
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Figure 6. 7: Summary of changes in marker gene expression induced by Mrfs in the flank dermomyotome 
in 18 hour timeframe between HH16-20. 
Schematic representation of the onset of marker gene expression in chicken somites at HH20 as revealed by 
the expression analysis in Chapter 3. The immature paraxial mesoderm is shown on the left, the oldest 
somites are shown on the right; somites are numbered consecutively from youngest to oldest. The Mrf that 
was misexpressed is indicated on the left. Genes that are normally expressed in the myotome and that 
become upregulated in the dermomyotome upon 12 hour exposure to the Mrfs are shown in green. Note 




6.3.2 The precursor/ stem cell state of cells in the somitic dermomyotome is likely 
protected 
Our experiments showed that when electroporated embryos were re-incubated overnight such 
that developing muscle stem cells were exposed to Mrf for a minimum of 12 hours, Mrf did not 
trigger premature expression of muscle structural proteins. However, when embryos were left to 
develop for additional 24 hours, then a third of the embryos electroporated with a MyoD 
expression construct showed ectopic sarcomeric Myosin expression in the dermomyotome. This 
indicates that after prolonged exposure specifically to MyoD, muscle stem cells can undertake 
complete muscle differentiation. This finding is in line with the experiments conducted in the 
chicken neural tube, where it took 3-4 days of exposure until some limited myogenic conversion 
of cells was obtained (337). Cells in the neural tube are not normally geared up to engage in 
myogenesis, thus, the reluctance of neural cells to express muscle genes is perhaps not surprising. 
Developing muscle stem cells however are set up for myogenesis. Moreover, Mrf are able to 
activate a number of co-factors essential for the efficient activation of muscle genes. Therefore, 
the delay in muscle differentiation of Mrf misexpressing embryonic muscle stem cells is, at first 
sight, surprising. We hypothesised at the outset of this study that the muscle stem cells state 
might be protected from premature differentiation. We summarise in Table 6.2 the expected 
results if the muscle stem cell state were to be protected. Our results are compatible with the 
idea that the muscle stem cells state is protected from premature differentiation. Moreover, our 
result suggest a time frame for the protection of the stem cell state between HH15/16 and 
HH23/24, when the first terminally differentiated cells appear in the targeted dermomytomes. 
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Table 6. 2: Expected and obtained outcomes of in vivo misexpression in chicken Mrf 
The experiments conducted in early Xenopus embryos suggested different roles for Myf5/MyoD and MyoG/Mrf4 genes. They are however also compatible with (i) a possible difference in 
the myogenic competence of immature cells in amniotes and anamnia or (i) with species-specific differences between chicken and frog Mrf. The experiments conducted in the chicken 
suggest that the immature paraxial mesoderm and the developing muscle stem cells are protected from precocious differentiation. 
 
 Results obtained in this study when misexpressing chicken Mrf 
Scenario 
Expected result following 
Mrf misexpression in 
muscle precursor or muscle 
stem cells in vivo 
In 2-cell stage 
Xenopus embryos, 
targeting pluripotent 
cells (chapter 4) 
In gastrula stage chicken 
embryos, targeting the 
immature paraxial 
mesoderm and young 
somites (chapter 5) 
In chicken somites, 
targeting the 
developing muscle stem 
cells; 18h incubation 
(chapter 6) 
In chicken somites, 
targeting the 
developing muscle stem 
cells; 42h incubation 
(chapter 6) 
      
All Mrf are sufficient to drive myogenesis all will drive muscle 
precursor/ muscle stem 
cells into differentiation 
    
Mrf have different roles, with Myf5 
controlling myogenic commitment, MyoD 
prepares for the entry into differentiation, 
and the late expressed MyoG and Mrf4 
control terminal differentiation 
only MyoG and Mrf4 will 
drive cells into terminal 
differentiation     
MyoD triggers myogenesis via a feed 
forward mechanism 
MyoD, alone or together 
with MyoG will drive 
terminal differentiation 
    
The precursor/ muscle stem cell state is 
protected 
Mrf will not be able to 
enforce myogenic 
differentiation 




6.3.3 Possible explanations for the protection of the precursor/ stem cell state 
6.3.3.1 Insufficient levels of MyoD and MyoG to activate late-phase myogenic genes 
After close analysis of the previous results we decided to dedicate more time to investigate why 
the cells are in such a protected state and how we could achieve differentiation of the muscle 
stem cells. We therefore agreed that the first step towards this analysis was to try a co-
electroporation of MyoD and MyoG. MyoD has always been considered one of the main guides of 
myogenesis and thought to push the muscle stem cells to leave the cell cycle and start 
differentiating. Alternatively MyoG is considered responsible for the final differentiation and the 
formation of the myofibers. We hypothesised that the presence of both the constructs in the 
same electroporation at HH16 will likely be the key to obtaining the final differentiation of the 
muscle stem cells (see Chapter 7).  
6.3.3.2 Insufficient levels of Mef2 cofactors 
As described in Section 6.2.1, Mef2C was chosen as the most likely co-factor involved in 
myogenesis in chickens. During myogenesis, Mrf have been found to interact with Mef2 proteins, 
and neighbouring binding sites for these factors have been found in the promoters of muscle 
genes (387). Mef2 misexpression per se has been shown to be insufficient to initiate myogenesis, 
but the presence of Mef2 proteins accelerates this process, absence of Mef2 prevents it (388). We 
showed that in the chicken somite, Mef2c is the first Mef2 gene to be transcribed in the somite, 
followed be Mef2a (381). Misexpression of Myf5, MyoD and MyoG led to upregulated Mef2c 
mRNA expression. However, we had no means to establish whether sufficient Mef2c protein was 
made to accompany the Mrf proteins, and it is possible that Mef2c (or Mef2a) proteins levels 
were too low to support efficient myogenesis. Therefore, we tested in chapter 8, whether 
elevation of both, Mrf and Mef2c levels would overcome the protection of the muscle stem cell 
state. 
6.3.3.3 Absence of Six1 
Six1 was chosen because it was believed to be the most closely related of the Six family genes to 
muscle formation in chickens. We decided to analyse the expression of Six1 mRNA after the 
misexpression of the Mrfs. The results of the in situ hybridisation showed that there was no 
detectable changes in the mRNA levels. The role that Six1 plays is somewhat controversial as 
previous research has shown that it is also active further downstream in myogenesis hence, their 
description as “pre-myogenic” genes may be somewhat misleading (182).  We theorised that it 
would be important to test the misexpression of Six1 itself and as a co-electroporation with 
MyoD. It could be possible that high levels of a premyogenic gene could activate the molecular 
cascade of myogenesis causing myogenic differentiation (see Chapter 9). 
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6.3.3.4 Persistence of muscle differentiation inhibitors 
In the intricate network of myogenesis, we don’t find just genes that trigger the muscle cell 
division or differentiation but there are a lot of molecules that contribute to maintaining the 
important balance between proliferation and stem cell state. Pax7 is one of the most important 
markers involved in the control of the stem cell state. Additionally the micro RNA miR206 has 
been defined as an important factor in somite development since loss of miR206 is correlated 
with loss of expression of MyoD (389). We will therefore analyse the expression of both of these 
genes following electroporation of the Mrf constructs. We formulated the hypothesis that 18 hrs 
after electroporation, the expression of Pax7 could be downregulated whilst in contrast, the 
expression of miR206 will be upregulated (Chapter 10).  
6.3.3.5 Failure to withdraw from the cell cycle 
A possible explanation for the failure of the upregulation of Myosin could be related to lack of cell 
cycle withdrawal. Cells that need to differentiate have to leave the cell cycle to reach the final 
stage of development into a muscle fibre. We reasoned that an important step would be to 
investigate which Cyclin-dependant kinase (Cdk), activators and inhibitors play an important role 
in myogenesis. We will analyse the mRNA levels in the somites and then we will focus our 
attention on choosing the best candidate for misexpression/co-misexpression experiments using 
electroporation. MF20 antibody staining with DAB will be performed to test the level of the 
Sarcomeric Myosin expression in the electroporated somites (Chapter 11). 
6.3.3.6 Inhibiting phosphorylation of MyoD 
The heterodimerisation of MyoD and E proteins is an essential step in binding to the chromatin 
during myogenesis. The process of heterodimerisation is facilitated in part by E protein 
phosphorylation through P38 MAPK. This kinase has been demonstrated as an essential 
component in myogenesis and the regulation of MyoD/E47 heterodimerisation (390). Conversely, 
phosphorylation of MyoD by cyclin dependant kinases (CDKs) has been demonstrated to target it 
for rapid degradation by the ubiquitin pathway (206). A phosphorylation-site mutant construct of 
the mouse MyoD gene will be used to further investigate whether phosphorylation of the 
transgene encoded MyoD could be inhibiting its activity in the chicken (Chapter 12).  
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               Table 6. 3: Summary electroporation experiments shown in chapter 6 
 Numbers displayed as: Total: wildtype/upregulated/downregulated  
Summary of the number of electroporated embryos that were analysed with ISH using antisense probes, or with immunohistochemistry using MF20 antibody, together with the 
number of altered phenotypes observed. Blue boxes highlight when upregulation was observed in mRNA or Myosin levels. The asterisk in the final column highlights that the 
upregulation results were observed in multiple sets of electroporation experiments.  
EP targeting the embryonic muscle stem cells in the somitic dermomyotome 
specimen analysed for Six1 mRNA Eya1 mRNA Myf5 mRNA MyoD mRNA MyoG mRNA Mrf4 mRNA Mef2c mRNA Tnni1 mRNA Sarcomeric Myosin (MF20) 
 18h 42h 
pCab 3:3/0/0 2:2/0/0 3:1/0/0 2:1/0/0 2:1/0/0 2:1/0/0 3:2/0/0 2:1/0/0 4:4/0/0 4:2/0/0 
           
Gg Myf5 3:3/0/0 2:2/0/0  2:0/2/0 3:0/3/0 4:1/3/0 3:1/2/0 2:2/0/0 5:5/0/0 5:5/0/0 
Gg MyoD 3:3/0/0 2:2/0/0 3:0/3/0  2:1/1/0 2:0/2/0 2:0/2/0 1:1/0/0 3:3/0/0 6:4/2*1/0 
Gg MyoG 2:2/0/0 2:2/0/0 2:1/1/0 2:0/2/0  2:0/2/0 2:0/2/0 2:2/0/0 3:3/0/0 3:3/0/0 
Gg Mrf4 1:1/0/0 2:2/0/0 2:0/2/0 2:0/2/0 2:2/0/0  2:2/0/0 1:1/0/0 5:5/0/0 2:2/0/0 
 
*1
 from two separate EP sessions 
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Chapter 7  
7 Combined misexpression of MyoD and MyoG 
 
7.1 Introduction  
The tissue culture experiments conducted in the nineteen eighties established that all Mrf have 
the capacity to drive myogenic and some non-myogenic cell types into muscle differentiation 
(332,391). Our experiments conducted in the chicken embryo in vivo however showed within a 
time window of 18 hours, Mrf genes were unable to enforce skeletal muscle differentiation, not 
even from developing muscle precursors. Only when left to develop for another day, and only 
when treated with MyoD, then 1/3 of embryos showed signs of ectopic muscle deployment. 
Expression analyses including the analysis conducted here showed that in vivo, Mrf are expressed 
sequentially in the order Myf5-MyoD-MyoG-Mrf4 (exception mouse, where Mrf4 is expressed 
earlier; (370,392)). Phylogenetic analyses including the one conducted here revealed that during 
the two rounds of gnathostome genome duplication, Myf5 and MyoD pair arose from one, MyoG 
and Mrf4 from the other gene generated during the first duplication round. Since then, both the 
bHLH and the Myf5/transactivation domains diversified (393) such that to date Mrf proteins have 
overlapping but also distinct target genes they bind to (394). Significantly, Myf5 and MyoD are not 
only expressed early, they also preferentially bind to genes activated at the onset of myogenesis 
(395). MyoG on the other hand, in addition to being expressed late, it specifically activates muscle 
structural genes and genes that promote cell cycle exit (200). In line with this observation, 
removal of Myf5 and MyoD function blocks myogenesis early since it prevents the formation of 
myoblasts; this phenotype cannot be rescued by an earlier activation of MyoG. Removal of MyoG 
however prevents the formation of myocytes and terminal differentiation (57), underlining that 
for myogenesis to be completed, MyoG is essential. 
In vitro studies showed that once MyoD is activated, it enhances its own expression and activates 
MyoG. Both genes together then activate the subsequent set of muscle genes. This constitutes a 
feed-forward mechanism, and suggests that once a cell has invested into the onset of myogenesis, 
it will eventually complete the differentiation process (57,395). Our experiments showed that 
misexpression of MyoD led to the upregulation of endogenous MyoG, and misexpression of MyoG 
led to the upregulation of endogenous MyoD, suggesting a similar, self-perpetuating mechanism 
in vivo. However, terminal differentiation of developing muscle precursor was only achieved after 
prolonged exposure to MyoD. 
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In vitro misexpression studies for MyoD indicated that the myogenic conversion rate of tissue 
culture cells correlates with the levels of MyoD expression, and hence, the accumulation of MyoD 
protein (57,396). We thus wondered whether the same may hold true for MyoG, and whether 
simultaneous, high level misexpression MyoD and MyoG would be required to obtain fully 
differentiated muscle from developing moblasts. We therefore planned a series of co-
electroporation experiments. However, it was not known whether simultaneously electroporated 
constructs would enter the same cell. We therefore first performed a set of test-electroporations 
using pCab-GFP and pCab-RFP (Red Fluorescing Protein). These electroporation experiments were 
conducted by S. Dietrich and confirmed dual construct uptake. Thereafter, we co-electroporated 
the MyoD and MyoG expression constructs. We found, however, that combined MyoD-MyoG 
expression did not accelerate myogenesis from muscle precursor. 
7.2  Results 
7.2.1 Co-electroporations to test for dual construct uptake 
As explained previously we hypothesised that the simultaneous delivery of MyoD and MyoG 
expression constructs may overcome the stem cell state of developing muscle precursor and drive 
these cells into immediate muscle differentiation. As the constructs act cell-autonomously, they 
would have to be taken up by the same cell. We therefore tested whether this is the case. In the 
first experiment, two pCab vectors were used, containing different fluorescent proteins: GFP 
(green fluorescent protein) and RFP (red fluorescent protein). The two vectors were 
electroporated into two adjacent flank somites. Embryos were harvested after 18 hrs of re-
incubation at approximately HH19/20 and analysed with Normarski, fluorescence and confocal 
microscopy. This experiment showed that GFP- and RFP-dependent fluorescence can clearly be 
distinguished (Fig. 7.1 D, E, F). In the second part of the experiment the two constructs were co-
electroporated into the same somite. The concentrations of the two constructs were adjusted to 
be equal.  In this case, RFP and GFP expression occurred in the same cells (Fig. 7.1, compare H-I 
and K- L) creating a yellow appearance upon overlay of the individual images (G-J). This confirmed 
that two constructs co-electroporated into somites can enter the same cell and this cell will be 









Figure 7. 1: Constructs co-electroporated into somites enter the same cell. 
(A-F) To test whether GFP and RFP generated by two distinct pCab vectors can be distinguished, these 
constructs were electroporated individually into neighbouring somites at HH15. Embryos were harvested at 
HH19 and subjected to Normarski and fluorescent microscopy (A-C) and confocal microscopy (D-E). Both 
microscopical methods detected red fluorescence only in the RFP expressing somite and green fluorescence 
in the GFP expressing somites, indicating that the contribution from each vector can be distinguished. 
(G-L) Both the GFP and the RFP encoding vectors were electroporated simultaneously at HH15. At HH19, 
embryos were analysed by Normarski and fluorescent microscopy (G-H) and confocal microscopy (J-L) as 
before. This analysis showed that RFP and GFP were co-expressed in the same cells (compare H,I and K,L), 
hence the combined signal appears yellow (G,J). Thus, when constructs are co-electroporated into somites, 
they enter the same cell, and this cell will be exposed to the products of both constructs. 




7.2.2 Co-electroporation of MyoD and MyoG expression constructs 
Previous data confirmed that two constructs can be co-electroporated into the same somites and 
they will be taken up by the same cells. We now co-electroporated HH15/16 embryos with equal 
concentrations of the expression constructs for MyoD and MyoG (2μg/μl each); embryos were re-
incubated for 18 hours to reach HH19/20 or for 42 hours to reach HH23/24. 
Immunohistochemistry using MF20 antibody/DAB staining and vibratome sectioning was 
performed as before. A comparison of specimen obtained here with specimen electroporated 
individually with MyoD and MyoG constructs (at 4μg/μl) is shown in Fig.7.2; results are 
summarised in Table 7.1. We found that 18 hours after co-electroporation of both, the MyoD and 
MyoG expression constructs, the morphology of the electroporated somites was normal. Notably, 
as with the earlier MyoD and MyoG misexpression experiments, no upregulation of sarcomeric 
Myosin was observed (Fig. 7.2 B-C, E-F, H-I). When left to develop for 42 hours, in 2 out of 2 
embryos, ectopic sarcomeric Myosin expression was found. In one embryo, the GFP expressing 
cells were found in a small confined domain, resembling the phenotype found in the MyoD 
expressing embryo at that stage (Fig.7.2 J-Li and not shown). In the second, more cells had taken 
up the construct, and hence, misexpression was more widespread (Fig.7.2 P-Ri). Sarcomeric 
Myosin expression was found throughout the targeted cells, and extensive ectopic muscle had 
formed. The ectopic muscle appeared disorganised, probably because the differentiation of cells 
occurred outside the scaffold of the myotome. Taken together, MyoD and MyoG expression 
constructs electroporated together can promote myogenesis in muscle precursor as can the 
MyoD construct alone. However, MyoD-MyoG co-electroporation did not bring muscle formation 








Figure 7. 2: MyoD and MyoD-MyoG co-electroporation did upregulate Myosin light chain in the 
electroporated somites 
Flank somites were electroporated at HH15/16 with pCAB-GFP (control) or GFP and Mrf expressing 
constructs as indicated on the left of the panel. Embryos were harvested 18 hours later at HH19/20, or 
42hrs at HH23/24 i.e. They were exposed to Mrf and/or GFP proteins for at least 12 hours or 36 
respectively (A,D,G,J,M,P). Overlays of the Nomarski and fluorescence photomicrographs of the 
electroporated flanks, dorsolateral views, rostral to the top. GFP expression indicates that 1-3 somites were 
targeted (green staining, arrows). (B,E,H,K,N,Q) Nomarski images of the un-electroporated control sides, 
and (C,F,I,L,O,R) of the electroporated sides of the embryos shown in (A,D,G,J,M,P), assayed with MF20-
DAB staining to reveal sarcomeric Myosin expression (brown staining), views as in (A,D,G,J,M,P). The 
targeted somites and their un-electroporated counterparts are indicated by arrows. Note, the levels of 
sarcomeric Myosin expression are the same on either side in the pictures for (B-C, E-F, H-I,N-O). The 42 hrs 
developed embryos electroporated with MyoD (K-L) and co-electroporated MyoD-MyoG (Q-R) showed 
upregulation of Myosin staining in the area of the fluorescence. (Bi,Ei,Hi,Ni) and (Ci,Fi,Ii,Oi) Nomarski 
images of cross sections of the flanks shown in (B,E,H,N) and (C,F,I,O), respectively. Note the absence of 
sarcomeric Myosin expression in the electroporated dermomyotomes. The cross sections (Ki-Li and Qi-Ri), 
of the flanks somites (K-L and Q-R), respectively. Note the upregulation of the Myosin expression in the 
electroporated dermomyotome.  





7.3.1 These electroporation conditions allowed the simultaneous uptake of several 
molecular constructs into one cell 
In this chapter we aimed to misexpress two individual transgenes together in the same cells in 
order to test their combined effect separate to their individual effect. This strategy has been 
employed previously and therefore should be appropriate to our specific application (315,397). 
This strategy was initially tested with two constructs that express RFP and GFP, respectively. 
Electroporation of the individual constructs in adjacent somites and analysed by fluorescence 
microscopy showed that the fluorescence from each construct could be visualised and clearly 
distinguished. Subsequently, both constructs were co-electroporated into the same somite and 
analysed by fluorescence microscopy as before which showed overlapping of green and red 
fluorescence, appearing yellow, indicating cells were expressing both fluorescent proteins. We 
therefore used identical experimental parameters in future experiments to ensure simultaneous 
uptake of multiple constructs in order to specifically observe their additive effect. 
7.3.2 Co-expression of MyoD and MyoG does not overcome the protection of the muscle 
stem cell state in the time window between HH15/16 and HH19/20 
The co-electroporation of MyoD and MyoG was important to test whether the simultaneous 
expression of MyoD and MyoG allows not only the activation of genes that prepare cells for 
myogenesis, but also activates muscle structural genes, thereby driving developing myoblast into 
terminal muscle differentiation.  We obtained a phenotype similar to the misexpression of MyoD 
alone. The embryos analysed showed premature differentiation of muscle precursor located in 
the dermomyotome, but specimen numbers are too low to establish whether the rate of 
myogenic conversion obtained with combined MyoD-MyoG misexpression is significantly different 
to the rate of conversion obtained after misexpression of MyoD alone. The important finding 
however was that even in the presence of both MyoD and MyoG, developing muscle precursor 
did not engage in muscle differentiation any earlier than when exposed to MyoD alone, 
supporting the idea that in the 18h time window between HH15/16 and HH19/20, embryonic 
muscle precursor are safeguarded against premature differentiation. 
7.3.3 Muscle ectopically developing in the dermomyotome is disorganised 
Amniote muscle development begins when cells from the medial wall of the somite form the 
primary myotome. This provides a scaffold into which the second wave of muscle cells intercalate 
when they detach from the four dermomyotomal lips (141,398). This secondary myotome serves 
as a scaffold for the muscle precursor that enter when the dermomyotome centre de-
epithelialises (66,399). The process is aided by Wnt11 in the dorsomedial dermomyotomal lip 
which controls the directed elongation of differentiating myotubes (276). Myf5 in the early 
myotome is required for maintaining alpha6-beta1 integrin expression on myogenic precursor 
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cells. alpha6-beta1 integrin is necessary for myotomal laminin matrix assembly and cell guidance 
into the myotome. Engagement of laminin by alpha6-beta1 integrin also plays a role in 
maintaining the undifferentiated state of cells in the dermomyotome prior to their entry into the 
myotome. Conversely, cells away from the alpha6-beta1 laminin matrix express MyoG and 
continue differentiation (Bajanca et al., 2006). During 2nd and 3rd myotome formation, N-cadherin-
mediated adhesion maintains the epithelial configuration of the dermomyotome domains and 
also promotes the onset of MyoD transcription and the translocation of cells into the myotome 
(Cinnamon et al., 2006). The receptor Robo and its ligand Slit drive directional migration of 
pioneer myoblasts (Halperin-Barlev and Kalcheim, 2011). Wnt11 function in the dorsomedial lip of 
the dermomyotome, via the PVP pathway, controls the organisation and elongation of 
myocytes/myotubes and the failure of Wnt11 expression leads to disorganisation of myotomes 
(Gros et al., 2009). 
After the primary myotomal scaffold formed, cells use this scaffold to contribute to the myotome 
and elongate in the same direction as the cells deployed earlier. The requirement of this scaffold 
is particularly obvious in the hypaxial domain where the absence of the primary myotome 
prevents the formation of an organised hypaxial myotome.  When in our experimental set up 
muscle precursor eventually differentiate, they do this within the dermomyotome and in the 
absence of a primary myotomal scaffold, and this may be the reason why muscle is disorganised. 
However, cells in the dermomyotome normally express genes associated with the formation of 
somitic boundaries. Yet in one of our embryos obtained after MyoD-MyoG misexpression, we did 
observe myotubes that spanned more than one somite. Since the embryo was not seen at an 
earlier stage, it cannot be decided whether or not the somite had been injured during 
electroporation, leading to a disturbance of somite boundaries. Since the focus of this study is to 
discover conditions for premature initiation of the muscle formation from muscle precursor, we 






   Table 7. 1: Summary of N.numbers for electroporation experiments of chapter 7 
   Key - total:wild type/upregulated/downregulated 
  Summary of the number of electroporated embryos that were analysed for Myosin levels using immunohistochemistry with MF20 antibody detection and DAB  
 staining, together with the number of altered phenotypes observed. The misexpression of MyoD and the combination of MyoD and MyoG caused upregulation 
of the Myosin level in the electroporated somites after 42hr of incubation (blue shade). The asterisk highlights that the upregulation results were observed in 
multiple sets of electroporation experiments 
EP targeting the embryonic muscle precursor in the somitic dermomyotome 
Specimen analysed for Sarcomeric Myosin (MF20) 
 18h 42h 
Gg MyoD 3:3/0/0 6:4/2*1/0 
Gg MyoG 3:3/0/0 3:3/0/0 
Gg MyoD+MyoG 3:3/0/0 2:0/2/0 





8 Combined misexpression of MyoD or MyoG with Mef2 genes 
8.1 Introduction  
As described in Section 1.5.10, there are four Mef2 genes in vertebrate species: Mef2a, b, c, and 
d. Mrf proteins are expressed exclusively in skeletal muscle and have not been detected in the 
heart, despite the fact that many of the genes that they regulate are expressed in both skeletal 
and cardiac muscle (146,384). 
Mef2 DNA-binding activity is upregulated during differentiation of established muscle cell lines 
and can be induced in non-muscle cells by MyoG and MyoD (400,401), consistent with the notion 
that Mef2 lies in a regulatory pathway downstream of these myogenic factors. However, there is 
also evidence that Mef2 participates in the regulation of the Mrf genes. A Mef2 site in the 
promoter of the MyoG gene, for example, is essential for MyoG transcription in cultured skeletal 
muscle cells (402); mutation of this site also alters the expression of reporter genes linked to the 
MyoG promoter in the somites and in the limb buds of transgenic mouse embryos (191,291). 
Mef2 has little ability to trigger myogenesis alone, but the absence of Mef2 genes caused defects 
in muscle development and regeneration (403). This is due to the fact they bind to target 
sequences found in close proximity to Mrf binding sites, thereby enhancing the efficiency of Mrf 
to drive muscle formation (404,405). Our expression analysis (Chapter 3) showed that chicken 
Mef2c was the first Mef2 family member to be transcribed in the chicken somite, followed by 
Mef2a. This was in line with observations in the mouse (146,406). We also found that Mef2c, 
while being expressed along the rostral and caudal dermomyotomal lips before cells leaving these 
lips express Mrf, expression in the dorsomedial and ventrolateral lips and in the myotome 
commenced just after that of MyoD. We therefore reasoned that Mef2c may be the main Mrf 
partner during the somitic myogenesis, possibly followed by Mef2a.  
Binding studies have established that MyoD and MyoG proteins upregulate Mef2 genes, with 
Mef2 proteins operating a positive feedback mechanism, enhancing the expression of Mrf. In line 
with this observation, when misexpressing Mrf in the chicken somite, we found that Mef2c was 
transcribed in the targeted cells. However, within a time window of 18 hours, muscle structural 
genes were not activated and cells did not reach a fully differentiated state. This suggests that 
possibly, Mef2c (or 2a) protein levels are still not high enough to support myogenesis initiated by 
the Mrfs. To test this possibility, Mef2c and Mef2a expression constructs were electroporated 
into chicken flank somites as before, either alone or in combination with MyoD or MyoG 
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expression constructs. However, these experiments revealed that, again, within the 18 hour time 
interval after electroporation, no premature myogenesis occurred. 
8.2 Results 
To misexpress Mef2c and Mef2a genes, expression constructs were made using the same 
approach as for the Mrf constructs. The Kozak sequences and the open reading frames of chicken 
Mef2c and Mef2a were synthesised and cloned into the pCab vector as before. The constructs 
were then verified by sequencing. They were electroporated into chicken flank somites at 
HH15/16 as before, either alone (at 4μg/μl) or in combination with MyoD or MyoG expression 
constructs (at 2μg/μl each). 18 hours later, embryos with readily detectable GFP-derived 
fluorescence were analysed for the differentiation of the targeted cells into contractile skeletal 
muscle, assaying for the presence of sarcomeric Myosin using the MF20 antibody and DAB 
staining. Embryos were bisected along the midline of the neural tube, to allow the comparison of 
the control side and the electroporated side. Results are summarised in Table 8.1. 
8.2.1 Misexpression of Mef2c alone or in combination with MyoD or MyoG in chicken 
somites 
When Mef2c was misexpressed alone, analysis of the fluorescence micrographs revealed that the 
anatomy of the electroporated somites were comparable to the non-electroporated somites, 
confirming that the structure of the tissue wasn’t compromised by the electroporation (Figure 8.1 
A, arrowed somites). The MF20 antibody staining revealed that in the treated somites, no 
upregulation or ectopic expression of sarcomeric Myosins had occurred (Figure 8.1 B,C). When 
Mef2c was misexpressed together with MyoD (Fig. 1.8 D-F) or MyoG (Fig. 1.8 G-I), the anatomy of 
the electroporated somites appeared again unaffected by the experiment and comparable with 
the rostrocaudally adjacent non-electroporated somites or the somites in the control side. 









Figure 8. 1: Mef2c does not enhance the ability of MyoD or MyoG to induce premature differentiation 
of muscle precursor between HH16 and HH20 
HH16 embryos were electroporated (as shown in Chapter 6) with Mef2c individually (A-C), co-
electroporated with MyoD (D-F) or co-electroporated with MyoG (G-I). Embryos were re-incubated to 
develop for a further 18 hours until HH19/20. GFP fluorescence was imaged to locate the successfully 
electroporated somites (arrows), followed by antibody staining for sarcomeric Myosins with the MF20 
antibody (brown staining). Comparison of control vs. electroporated somites revealed no change in 
staining for Mef2c (compare B with C), Mef2c with MyoD (compare E with F) or Mef2c with MyoG 











8.2.2 Misexpression of Mef2a alone or in combination with MyoD or MyoG in chicken 
somites 
After the first set of experiments we focused our attention on the Mef2a gene. The Mef2a 
expression construct was electroporated individually and with MyoD or MyoG expression 
constructs; successfully electroporated somites were located by fluorescence microscopy (Fig. 8.2 
A, D and G). Subsequent MF20 antibody staining revealed that the individual misexpression of 
Mef2a did not lead to premature sarcomeric Myosin expression (Fig. 8.2 B and C). Similar results 
were obtained from co-electroporation experiments using Mef2a together with MyoD constructs 








Figure 8. 2: Mef2a does not enhance the ability of MyoD or MyoG to induce premature 
differentiation of muscle stem cells between HH16 and HH20 
HH16 embryos were electroporated (as shown in Chapter 6) with Mef2a individually (A-C), co-
electroporated with MyoD (D-F) or co-electroporated with MyoG (G-I). Embryos were re-incubated 
to develop for a further 18 hours until HH19/20. GFP fluorescence was imaged to locate the 
successfully electroporated somites (arrows), followed by antibody staining for sarcomeric Myosins 
with the MF20 antibody (brown staining). Comparison of control vs. electroporated somites 
revealed no change in staining for Mef2a (compare B with C), Mef2a with MyoD (compare E with F) 





8.3.1 Co-expression of Mrf and Mef2 genes did not overcome the protection of the muscle 
stem cell state in the time window between HH15/16 and HH19/20 
Given the tight relationship specifically of Mef2c and Mef2a and MyoD and MyoG (307,384,404), 
we hypothesised that the simultaneous misexpression of these Mef2 genes with one of the two 
Mrfs would be sufficient to drive muscle precursor out of their stem cell state and into terminal 
muscle differentiation, visible as upregulated, ectopic expression of sacromeric Myosins in the 
electroporated dermomyotomes. On the other hand, given that Mef2 genes have little myogenic 
function by themselves (58,188,388), we expected that the Mef2 genes alone would not be 
sufficient to drive myogenesis from muscle precursor. Indeed, the results showed that individual 
electroporation of either Mef2c or 2a constructs into chicken somites was not sufficient to cause 
premature sarcomeric Myosin expression. However, the co-expression of Mef2 genes with either 
MyoD or MyoG also proved insufficient to upregulate sarcomeric Myosin expression, thus 
indicating that, again in contrast to experiments performed in tissue culture (188), the muscle 
precursor or muscle stem cell state cannot easily be overcome in vivo. 
Binding studies showed that Mrf and Mef2 proteins are present at the promoters of muscle genes 
before chromatin is opened and transcription of these genes starts (407,408). Chromatin opening 
is facilitated by Six proteins. However, when Mrf were misexpressed, Mef2c expression was 
upregulated as seen with in situ hybridisation while Six1 and its activator Eya1 did not show any 
upregulation (see Chapter 6). We therefore decided to investigate a possible requirement for Six1 





Table 8. 1: Summary electroporation experiments shown in chapter 8 
Numbers displayed as: Total: wildtype/upregulated/downregulated 
Summary of the number of electroporated embryos that were analysed for Myosin levels using immunohistochemistry with MF20 antibody 
detection with DAB staining at 18h of incubation. 
EP targeting the embryonic muscle precursor in the somitic dermomyotome 
Specimen analysed for Sarcomeric Myosin (MF20) 
 18h 
Gg Mef2c 6:6/0/0 
Gg Mef2c + MyoD 4:4/0/0 
Gg Mef2c + MyoG 4:4:0/0 
Gg Mef2a 7:7/0/0 
Gg Mef2a + MyoD 3:3/0/0 




9 Combined misexpression of Six1, MyoD and Mef2c genes 
9.1 Introduction 
Our study has revealed that MyoD, alone or in combination with MyoG, may overcome the stem 
cell state of developing muscle precursor in vivo, provided cells were exposed to the transgenes 
for 36 hours. In the time frame of 18 hours after construct electroporation (a minimum of 12 
hours exposure), Mrfs were able to activate a few other genes that set the cell up for myogenesis. 
However, in this time window, neither Mrfs alone, nor MyoD in combination with MyoG, nor Mrfs 
in combination with Mef2 proteins were able to drive muscle precursor into terminal 
differentiation. Mrf and Mef2 proteins have been shown to occupy their binding sites in the 
promoters of muscle genes long before these genes are being transcribed (384,408). Thus, we 
reasoned that further cofactors might be required to drive muscle precursor into terminal muscle 
differentiation. 
In Chapter 1, we introduced Six proteins and their Eya cofactors as multifunctional regulators of 
myogenesis. During amniote development, Six (exception optix homologs) and Eya genes are 
expressed in the paraxial mesoderm as early as the pre-myogenic genes Pax3/7 and Paraxis 
((169,297,314,328); this study). Six proteins, when turned into transcriptional activators with the 
aid of Eya phosphatases (Li et al., 2003), have been shown to upregulate Pax3 and Myf5 in mouse 
limb muscle precursors (164,179). In the somite, at least in mouse mutants devoid of Myf5, 
Six1/4/2 contribute to the activation of MyoD (180). Together, this has suggested that Six genes 
are pre-myogenic genes.  
Our expression analysis has shown that when muscle forms, the expression of Six and Eya genes is 
downregulated in the somitic dermomyotome but persists in the dorsomedial and ventrolateral 
dermomyotomal lips and the myotome (83). (Fougerousse et al., 2002) showed that in the human 
somite, Six proteins are only detectable in the nuclei of cells and hence able to act as transcription 
factors, when the cells begin to express sarcomeric Myosins. Binding studies in tissue culture cells 
showed that Six1 contributes to the activation of MyoG, binding to a target sequence next to the 
binding sites of MyoD and Mef2 proteins (181). Similarly, in activated satellite cells, Six proteins 
do not regulate Myf5 but MyoG (183). Six proteins also bind to the promoters of muscle structural 
genes and genes encoding enzymes essential for the establishment of a fast-twitch muscle 
phenotype, in fact Six proteins can enforce a muscle fibre-type switch from slow to fast (409). This 
suggests a myogenic rather than pre-myogenic function of Six-Eya protein complexes. 
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When Six proteins or complexes of Six and its co-repressor Dach are phosphorylated by Eya 
proteins, they are able to open chromatin and to recruit the CBP co-activator and RNA 
polymerase II, which then starts the transcription of target genes (Li et al., 2003). We found that 
when Mrfs were misexpressed in the somite, endogenous MyoG expression was initiated but 
expression of Six1 and Eya1 was not, indicating that in the context of muscle precursor, the 
regulation of MyoG was not Six-Eya dependent. However, we reasoned that, in order to promote 
the completion of myogenesis in developing myoblasts, Six function may be required in addition 
to the function of Mrf and Mef2 proteins to activate muscle structural genes. We thus set out to 
misexpress Six1 alone, or in combination with MyoD and Mef2c. 
9.2 Results 
9.2.1 Six1 expression constructs 
Owing to time constraints, we were unable to generate chicken-specific Six1 expression 
constructs. However, constructs to misexpress various wildtype and mutant versions of mouse 
Six1 were kindly provided by Dr. Pascal Maire (Institut Cochin, University Descartes, Paris). Of 
these constructs, we chose to use a construct encoding a Six1-GFP fusion protein and a construct 
encoding a fusion protein between the Six1 protein and the VP16 transactivation domain 
(182,410). VP16 is formed of 490 amino acids and two important functional domains: a core 
domain in the central region and the carboxy-terminal transactivation domain. The core domain is 
important for indirect DNA binding (411,412). By comparison GFP, a commonly used fusion 
protein within this study, is 238 amino acids long (413). 
We expected the Six1-GFP protein to act like wildtype Six1. Thus, in the central dermomyotome, 
where Groucho and Dach co-repressors are present and the Eya co-activators are absent 
(165,245,414), the protein should not be able to activate Six targets. The Six1-VP16 protein 
however should be independent from activating phosphorylation by Eya proteins and hence be a 
constitutive transcriptional activator all the time. Constructs were based on the pCR3 vector, 
which, similar to pCab, uses the CMV (cytomegalovirus) promoter and enhancer to drive strong 
transgene expression (415). Therefore, the constructs should be expressed at levels comparable 
to pCab. The pCR3 vector however does not encode for a cell lineage tracer. Therefore, when 
testing Six1-VP16 function alone, we electroporated the construct together with pCab. The Six-
GFP protein fluoresces on its own account, and we exploited this to determine whether the 
proteins would translocate to the nucleus – a prerequisite to act as transcription factor. We found 
that indeed, the Six1-GFP protein was present in the nucleus. Unexpectedly, however, the Six1-
GFP protein was able to drive premature expression of sarcomeric Myosins in developing 
myoblasts. In contrast, Six1-VP16, neither alone nor in combination with MyoD and Mef2c, was 




9.2.2 Six1-GFP triggers an unexpected upregulation of sarcomeric Myosin expression 
The aim of these experiments was to explore whether Mrf proteins, when accompanied by Mef2 
and Six cofactors, might be able to force developing myoblasts into premature differentiation. To 
test this, we used two mouse Six1 constructs. In one, the Six1 open reading frame was linked with 
the coding sequences for the VP16 transactivation domain. Thus, Six1-VP16 should be 
independent from activating phosphorylation by Eya1 and act as a constitutive transcriptional 
activator. 
Recent data showed that the use of a transactivation domain can have the opposite effect to the 
activation, causing negative feedback and repressing transcription. The use of VP16 can have 
negative effects on cells in which they have been injected (416). Ryu and colleagues developed a 
system Gal4-VP16, transactivator component assembled through the fusion of the DNA binding 
domain of Gal4 with the VP16transactivation domain. When the Gal4-VP16 transactivator was 
expressed at high levels it was shown to inhibit transcription by binding and titrating out 
transcription factors. This could explain why we could not see any upregulation of Myosin 
expression with the use of the Six1-VP16 and the co-electroporation. The presence of the VP16 
transcriptional activator could have a feedback mechanism which influences the role of 
transcription factors, forcing them to be inactivated.  
The other electroporation construct used was the fusion of Six1 protein with the lineage tracer 
GFP. This protein was expected to require activating phosphorylation by Eya proteins. In the 
somite, the Six co-repressors Dach and Groucho are expressed in the dermomyotome, while Six 
and Eya proteins become confined to the dorsomedial and ventrolateral lips of the 
dermomyotome and the myotome (169,417). We therefore expected that Six1-VP16 was more 
likely than Six-GFP to change gene expression when misexpressed in the myoblast that develop 
from the dermomyotomal centre (169). To our surprise, however, Six1-GFP but not Six1-VP16 
triggered upregulation of sarcomeric Myosin expression in the targeted cells. Six1-GFP 
fluorescence was also found in patterns that indicated nuclear localisation whereas when Six1-
VP16 electroporated together with pCab-GFP, only showed disperse fluorescence consistent with 
cytoplasmatic localisation of the independently translated GFP. Therefore, a 
biological/biochemical explanation was more likely (Fig. 9.1). In Figure 9.1, a comparison of the 
fluorescence between Six1-GFP and pCAB-GFP is shown. Fluorescence micrographs of both 
embryos are shown at 10 × and 20 × magnification. The morphology of the fluorescence visible in 
the Six1-GFP expressing embryo (Fig. 9.1A, B) appeared concentrated to small areas, presumably 
localised to the nucleus of the cells (Fig. 9.1B white rectangle). In comparison, the fluorescence 
visible in the pCAB-GFP expressing embryo (Fig. 9.1Ai, Bi) appeared more disperse, presumably 
localised in the cytoplasm of the cells (Fig. 9.1 Bi white rectangle).  
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Addition of proteins tags, especially large tags such as the GFP protein, have been shown to alter 
protein function (350). Given that Six proteins interact with a number of co-factors (173,409), it is 
possible that the presence of GFP severely disrupted normal protein-protein interactions and may 
even have facilitated new, artificial interactions. This in turn may have changed both the 
recognition of target promoter sequences as well as the ability to transrepress or transactivate 
targets. Six1-GFP may also more strongly interact with some partners, thereby sequestering them. 
As a result, Six1-GFP protein may not function identically to the native protein inside the cell. 
Further experiments such as RNAseq could reveal how cells misexpressing Six1-GFP are affected 
when compared to normal cells undergoing myogenesis. 
While the phenotype obtained by Six1-GFP misexpression is likely an artefact, it is nonetheless 
interesting. Following the electroporation of the Six1-GFP construct, the cells showing elevated 
sarcomeric Myosin expression were located in the myotome and were oriented in the same 
direction as normal myotubes. This was distinct from the cells that differentiated into a 
disorganised array of myotubes in the dermomyotome when exposed to MyoD or MyoG for a 
prolonged period of time. This suggests that Six1-GFP protein accelerated recruitment of cells into 
the earlier myotomal scaffold. Moreover, the Six1-GFP misexpressing cells showed a larger 
diameter than normal myotubes, suggesting that overall sarcomeric protein production was 
enhanced. Quantitative assays such as Western blotting would be useful to further elucidate this 
phenotype. Finally, it has to be considered that Six proteins activate genes required for the 
establishment of fast-twitch, anaerobic muscle fibre and override slow-twitch, aerobic muscle 
fibre (409). In the early embryo, myotomal muscle has a slow-twitch fibre type (418). Use of 
antibodies that discriminate between fast and slow Myosin Heavy Chain proteins would reveal 
whether Six1-GFP may have triggered a cascade that bypassed normal myotomal differentiation 






Figure 9. 1: Six1-GFP fluorescence compared with control pCAB-GFP fluorescence reveals specific 
localisation of the fusion protein 
Six1-GFP fluorescence (A and B) is compared with pCAB-GFP fluorescence (Ai and Bi). Photographs are 
shown at 10 × magnification as standard (A and Ai). At 20 × magnification (B and Bi), pCAB-GFP fluorescence 
appears disperse presumably localised in the cytoplasm (Bi, white box). Comparably, Six1-GFP fluorescence 
appears localised to specific areas, presumably localised within the nuclei of the cells (B, white box). 
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9.2.3 MyoD in combination with Mef2c and Six1-VP16 is still unable to drive muscle 
precursor into terminal muscle differentiation 
Binding studies have shown that muscle gene promoters are loaded with MyoD and Mef2 
proteins, but may require activated Six proteins for the chromatin to open, the transcriptional 
machinery to be recruited and gene transcription to start (reviewed in (193)). We therefore 
reasoned that our earlier attempts to force embryonic muscle precursor into terminal 
differentiation failed because activated Six1 was lacking. However, when misexpressing MyoD, 
Mef2c and the constitutively active Six1-VP16, we did not observe sarcomeric Myosin expression 
any earlier than when misexpressing MyoD alone. Cumulative evidence suggest that our 
constructs are active given the data showed in Chapters 6 and 4. Having established that mouse 
Six1 protein can translocate to the nucleus of the targeted chicken cells, we now systematically 
explored whether Six1, alone or in combination with MyoD, Mef2c, or both MyoD and Mef2c, 
could accelerate terminal muscle differentiation in developing muscle precursor in HH15/16 flank 
somites. To test this, we electroporated a DNA mixture made of combinations of multiple 
constructs together. The contribution of each construct becomes smaller, as more constructs are 
added. However, we previously observed that when the MyoD expression construct was “diluted” 
with the MyoG expression construct, the ability of MyoD to enforce muscle stem cell 
differentiation after 42 hours of embryo re-incubation was not diminished; it may even have been 
enhanced (Chapter 7). Moreover, all constructs are driven by strong promoters/enhancers. 
Therefore, it is likely that protein levels are sufficient to in principle activate target promoters. 
This could be tested, co-electroporating a reporter construct that contains a MyoD-Mef2-Six-
dependent promoter such as the MyoG promoter (181). Yet our results suggest that it is not the 
mere absence of Mrf, Mef2 and Six-Eya proteins that prevents premature differentiation of 
muscle precursor.  
Embryos were harvested 18 hours after electroporation and assayed for sarcomeric Myosin 
expression using MF20-DAB staining as before. Results are summarised in Table 9.1. When the 
Six1-GFP construct was used (Fig. 9.2 A-C), the electroporated somites showed stronger MF20-
DAB staining than the neighbouring somites or the somites on the contralateral control side. The 
strong staining was in elongated cells located in the myotome and orientated rostrocaudally as 
myotubes would be at this stage. Moreover the strongly stained cells appeared thicker in 
diameter than the myotubes in neighbouring somites. This suggests that either Six1-GFP recruited 
additional dermomyotomal cells to contribute to the myotome or Six1-GFP expressing myotubes 
expressed higher level of sarcomeric proteins than usual, or both. When the Six1-VP16 construct 
was electroporated, no upregulated expression of sarcomeric Myosins was found (Fig. 9.2.D-F). 
Likewise, no change in the levels of sarcomeric Myosin production or the size of myotubes was 
observed when misexpressing Six1-VP16 together with MyoD (Fig. 9.2 G-I), with Mef2c (Fig. 9.2.J-
234 
 
L) or with both, MyoD and Mef2c together (Fig. 9.2.M-O). Moreover, no ectopic sarcomeric 
Myosin expression was found in the dermomyotome, indicating that the three factors were 








Figure 9. 2: Misexpression of Six1VP16 alone and in combination with MyoD and Mef2c as well 
as Six1-GFP alone 
Embryos were electroporated with Six1-GFP (A-C), or co-electroporated with Six1VP16+GFP (D-
F), MyoD+Six1VP16 (G-I), Mef2c+Six1VP16 (J-L), MyoD+Mef2c+Six1VP16 (M-O). Embryos were 
left to develop for 18 hours as before. GFP expression was recorded (electroporated somites 
indicated by the white arrows), followed by antibody staining for sarcomeric Myosins with the 
MF20 antibody (brown staining). (C) Six1-GFP alone induces premature Sarcomeric Myosin 
expression in the 18 hour time window between HH15/16 and HH19/20 (The black arrows are 
indicating the correspondent electroporated somites). The strong staining of the Myosin 
reflected the area of the fluorescence. The Six1VP16 construct combined with pCAB, MyoD, 
Mef2c and MyoD and Mef2c together did not induce any premature sarcomeric Myosin 





9.3.1 The muscle stem cell state may be actively maintained 
Even providing MyoD, Mef2c and Six1 with our electroporations and co-electroporations, muscle 
precursor situated in the dermomyotome would not undergo terminal muscle differentiation. 
The Six1-GFP misexpression experiment suggests that the protein enters the nucleus. The 
experiments conducted in the chicken somite indicate that the Mrf constructs readily lead to 
upregulation of genes involved in setting the cell up for myogenesis. The experiments in the frog 
and the experiments in the chicken where the muscle precursor were exposed to Mrf for a longer 
time indicated that the Mrf constructs are able to drive myogenesis. Therefore, biologically active 
proteins are being made. Yet in the 18 hour time window between HH15/16-HH19/20, Mrf, even 
in combination with Mef2c and Six1-VP16 were unable to drive the muscle precursor into 
terminal differentiation. This indicates it is not the mere absence of myogenic regulators that 
prevents premature differentiation of muscle precursor. Rather, there are factors that actively 
preserve the stem cell state. 
In the myogenic cascade, the premyogenic Pax genes have been shown to ready the cells for 
myogenesis, to activate Myf5, and when Myf5 is absent, to contribute to the activation of MyoD 
(419,420). However, the Pax genes keep cells in a proliferative state (unless additional factors 
enforce adoption of a quiescent state) and they prevent muscle differentiation (297). When cells 
commit to myogenesis, they express microRNAs such as miR-206 which target the Pax mRNAs, 
thereby clearing the cell of inhibitors of muscle differentiation (229,230). We therefore reasoned 
that Mrf may not be able to drive muscle precursor into immediate differentiation because Pax 
gene expression has not been stopped. This will be explored in the next Chapter. 
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           Table 9. 1: Summary electroporation experiments shown in Chapter 9 
Numbers displayed as: Total: wildtype/upregulated/downregulated 
Summary of the number of electroporated embryos that were analysed for Myosin levels using immunohistochemistry with MF20 antibody detection and 
DAB staining, together with the number of altered phenotypes observed. We observed upregulation of Myosin levels with the use of Six1-GFP construct 







EP targeting the embryonic muscle precursor in the somitic dermomyotome 
Specimen analysed for Sarcomeric Myosin (MF20) 
 18h 42h 
Mm Six1-GFP 4:2/2/0  
Mm Six1-Vp16 + pCab 3:3/0/0  
Mm Six1-Vp16 + Gg MyoD 3:3/0/0  
Mm Six1-Vp16 + Gg Mef2c 2:2/0/0  




10 Prolonged expression of Pax7 may contribute to the in vivo 
protection of the muscle stem cell state 
10.1 Introduction  
Misexpression experiments suggested that the muscle stem cell state of developing muscle 
precursor in vivo is actively protected. Hence, factors have to be considered that are associated 
with myogenic competence but at the same time, prevent differentiation. Such a factor is Pax7 
and its paralog Pax3.  
The two Pax genes arose from a common ancestor during vertebrate evolution (72). Gene 
function diversified somewhat, with Pax3 but not Pax7 being crucial for the development of 
migratory limb muscle precursors (421). However, both vertebrate Pax genes have redundant 
roles in the early embryo and without them, no myogenic cells form (89).  
In adult muscle precursor (satellite cells) and C2C12 myoblasts in vitro, misexpression of a 
dominant-negative form of Pax7 or Pax3 prevented muscle differentiation and led to cell death by 
apoptosis. Constitutive expression of Pax7 or Pax3 resulted in increased proliferation and 
decreased cell size as well as significant delay of differentiation. This occurred despite the Pax 
genes upregulating expression of Mrf genes such as Myf5 and MyoD (318,422), indicating that the 
Pax genes provide myogenic competence but support the undifferentiated stem cell state.  
When muscle precursor differentiate, both in vivo or in vitro, they downregulate Pax7 (317,423). 
This is facilitated by regulatory miRNA molecules: differentiating cells have been shown to express 
microRNAs including miR1, miR206 and miR486 (424,425). Specifically, miR206 and miR486 target 
sequences in the 3’ untranslated region (UTR) of the Pax7 mRNA, promoting its degradation 
(229,230). Notably, loss of this regulation by microRNA inhibition causes differentiation to be 
delayed, whilst a microRNA-resistant form of Pax7 inhibits differentiation (230). Thus, microRNAs 
are a key mechanism to clear differentiating cells of Pax7 (and Pax3) gene products, thereby 
ensuring that differentiation can proceed. 
Notably, in mice mutant for Myf5 (but not MyoD), expression of miR1 and miR206 is lost (224). In 
myoblasts in vitro, MyoD upregulated the expression of miR206 and miR486 (230). When (tagged 
versions) of chicken Mrf proteins were misexpressed in the chicken neural tube, they were able to 
trigger miR1 (Myf5 and MyoD) and miR206 expression in this tissue (all Mrfs, (224). This points to 
a molecular mechanism by which Mrf, by means of miRNA expression, remove the differentiation-
inhibiting muscle stem cell factors.  
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When misexpressing (untagged) chicken Mrf in developing muscle precursor in vivo, we found 
that only a selection of early myogenic genes were upregulated, and cells were unable to 
differentiate for another day. We thus wondered whether the Mrf were unable to activate 
miRNAs and to remove Pax7 gene products. Thus, we misexpressed Mrf once again, this time 
assaying for the expression of Pax7 protein, Pax7 mRNA and miR206 (the miRNA that can be 
activated by all Mrf,(224). The in situ hybridisation assaying for miR206 expression required 
special reagents and was therefore carried out in collaboration with D. Sweetman (University of 
Nottingham, UK). Results are summarised in Table 10.1. 
10.2 Results  
10.2.1 Analysis of Pax7 protein expression after misexpression of Mrf genes 
Chicken embryos were electroporated with the Mrf constructs and pCAB vector as a negative 
control, then, stained for Pax7 protein as seen in computationally combined images of 
dorsolateral views. The embryos electroporated with pCAB construct appeared somewhat 
subdued in the electroporated region (Fig. 10.1, Bi-iii). However, closer inspection revealed that 
the subdued staining occurred in the targeted as well as the surrounding cells (Fig.10.1, Bii, Biii; 3rd 
somite from the top). Analysing the entire z-stack of images obtained for this specimen, we 
realised that Pax7 protein was readily detectable throughout the dermomytome (not shown). The 
cross sections confirmed that in the targeted cells in the dermomyotome, Pax7 protein was at the 
same level as in the surrounding, un-electroporated cells (Fig. 10.1, Ci-iii). This suggested the 
computational combination of images obtained from the z-stack may lead to wrong conclusions. It 
also indicated that individual images obtained in the z-stack and cross sections would have to be 
carefully analysed. This was done for all specimens, but for space constraints, only the combined 
dorsolateral views and a single cross-sectional view are shown. 
When analysing specimens electroporated with Mrf expression constructs, we found that in 
dorsolateral views, Pax7 protein was detectable in the targeted cells at the same level as in the 
surrounding cells, even though in the combined image, at times expression levels appeared lower 
(Fig.1.10, E,H,K,N i-iii). Inspection of cross sections confirmed that Pax7 protein was present in the 
electroporated cells in the dermomyotome (Fig. 10.1.C,F,I,L,O i-iii). At first sight, the specimen 
electroporated with the Myf5 construct seemed to be an exception: here, Pax7 expression 
appeared reduced on the electroporated side compared to the contralateral control side (Fig. 
10.1.Fi-iii). However, this section unfortunately is oblique, and hence, different somitic areas are 
represented on both sides. When closely analysing the targeted, GFP-expressing cells (green 
fluorescence) and the neighbouring GFP-negative cells, they display the same red fluorescence 
obtained from the Pax7 antibody.  
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Taken together, our results suggest that Pax7 protein was present when muscle precursor in the 






Figure 10. 1: In the 12 hour time window between HH16-20, just MyoD and Myf5 proteins may partially downregulate Pax7 protein 
expression. 
Flanking somites were electroporated at HH15/16 with the pCab control construct or with Mrf expressing pCab constructs as indicated on 
the left. Embryos were harvested at HH19/20 and GFP expression was recorded (A,D,G,J,M,P). Embryos were then subjected to fluorescent 
immunohistochemistry, using an anti-GFP antibody (green fluorescence) and an anti-Pax7 antibody (red fluorescence). The position of the 
fluorescent signals was analysed using confocal microscopy; flattened z-stacks of dorsolateral views are shown in (B,E,H,K,N,Q i-iii). 
Thereafter, somites were cross-sectioned on a vibratome and analysed by confocal microscopy (C,F,I,L,O,R i-iii). Note that targeted cells 
contributed to the myotome and formed myotubes when the electroporated side encompassed the rostral or caudal dermomyotomal lips. 
This contribution was irrespective of the construct that was used (see Eiii, arrowheads). Relevant electroporations were those where the 
centre of the dermomyotome was targeted (see Hiii) since this is where the muscle stem cells developed. Here, electroporated cells 
remained in the dermomyotome. Weaker Pax7 staining in the treated compared to the untreated dermomyotome was observed after 
electroporation with Myf5 and MyoD and MyoG (F, I, L i-iii) but we hypothesised in this case analysis of the sections was influenced by the 




10.2.1. Analysis of Pax7 mRNA and miR206 expression after Mrf misexpression 
So far we have focused our attention on Pax7 protein, because this is the functionally relevant 
Pax7 gene product. However, Pax7 protein turnover may be low. Moreover, in differentiating 
myoblasts, the main mechanism of Pax7 removal is the degradation of Pax7 mRNA involving Mrf-
induced miRNAs (230). Therefore, we electroporated embryos with Mrf constructs as before, this 
time analysing for the expression of Pax7 mRNA and miR206, using in situ hybridisation. 
Embryos were electroporated at HH16 and reincubated for 18 hrs to reach HH20. We 
misexpressed the Mrf members and used the pCAB as a negative control. Successfully 
electroporated cells were located by fluorescence microscopy (Fig. 10.2 A-Q) and all embryos, 
control and electroporated somites alike, displayed normal Pax7 mRNA expression in the somitic 
dermomyotome, including the typical upregulated expression in the dermomyotomal centre (Fig. 
10.2 B-R and Bi-Ri). A second group of embryos was electroporated with Mrfs constructs and 
analysed for miR206.  Successfully electroporated cells were located by fluorescence microscopy 
(Fig. 10.2 C-S). The embryos showed probe staining in the somitic myotome as shown by (224) 
and no ectopic expression of miR206 was observed in the electroporated somites (Fig.10.2 D-T 







Figure 10. 2: In the 12 hour time window between HH16-20, Mrf misexpression did not change levels of 
Pax7 mRNA or miR206 expression. 
Flanking somites were electroporated at HH15/16 with the pCab negative control or with Mrf expressing 
pCab constructs. Embryos were harvested at HH19/20 and GFP expression was recorded as before 
(A,E,I,M,Q and C,G,K,O,S). The expression of Pax7 and miR206 was analysed by in situ hybridisation (blue 
staining). No differences in expression levels were observed when comparing the electroporated somites 
and the corresponding somites on the untreated control side (arrows). Both sets of embryos analysed for 




10.3 Discussion  
10.3.1. mRNA levels of Pax7 and miR206 are unaffected after Mrf misexpression  
The misexpression of the Mrfs constructs did not influence the expression levels of Pax7 protein 
in the dermomyotome in the electroporated somites. This would explain the reason why we did 
not see any upregulation of Myosin expression after the electroporation of Mrfs as shown in 
Chapter 6. The level of Pax7 protein is still stable after 12 hrs of incubation from the 
electroporation, this means that the cells in the dermomyotome are still undifferentiated and 
these data are in line with other studies that describe Pax7 as essential for the maintenance of 
the muscle stem cell state (89,229,230). Recent studies have underlined the importance of 
microRNAs during muscle proliferation and differentiation, controlling an elevated number of 
transcription factors and signalling molecules  (424,149). miR-206 is activated during the myoblast 
differentiation and stimulates muscle differentiation by directly targeting and downregulating 
Pax7 protein and mRNA (230). Expression of microRNAs in myoblasts accelerates differentiation, 
whereas inhibition of these microRNA causes persistence of Pax7 protein and inhibits 
differentiation (230). Our experiments showed that the levels of miR-206 were not influenced by 
the electroporation of the Mrf constructs. These data support the results of Pax7 protein 
expression. The presence of undifferentiated cells which do not enter into myogenic 
differentiation even after transgene electroporation are unchanged and consequently still show 
high levels of Pax7 protein. A future experiment could be the analysis of Pax3 gene expression. As 
Pax3 is also regulated by muscle specific mircoRNAs in somites and it would be interesting to see 
if the expression level of this gene decreases with the misexpression of Mrf constructs and if 
mir206 levels increase after the electroporation. This experiment could also be carried out in cell 
culture.  
Experiments conducted in vitro by Dey and colleagues in 2011, showed that Pax7 expression 
levels in C2C12 cells was comparable with that of mouse primary myoblasts when analysed by 
qRT-PCR. After the withdrawal of serum, Pax7 protein levels decreased followed by the increase 
of Myosin expression, indicating that the cells were differentiating. The decrease in Pax7 protein 
started from day 1 with levels going below detection by day 4 (230). The experiments conducted 
in vivo by Sweetman and colleagues in 2008 which showed upregulation of miR-1 and miR-206 in 
the neural tube as a result of Mrf construct electroporations could potentially be explained by 
lesser protection of myogenic fate control in the cells of the neural tube due to the alternative 
fates of those cells. This hypothesis could explain the results observed in this Chapter.  
Alternatively, the time frame used in our experiments between the electroporation and the 
analysis of the Pax7 may have been insufficient to observe the eventual decrease in protein levels 
as compared with that used in the study of Dey and colleagues. It would be interesting to further 
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investigate the expression levels of Pax7 protein after Mrf construct electroporation, but with an 
experimental time frame extended up to 4 days.  
If our hypothesises proves correct we would expect to see a decrease in Pax7 expression in the 
electroporated somites coupled with the upregulation of miR-206 levels. 
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   Table 10. 1: Summary electroporation experiments shown in chapter 10 
   Numbers displayed as: Total: wildtype/upregulated/downregulated 
 Summary of the number of electroporated embryos that were analysed for protein levels of Pax7 and RNA levels of Pax7 and miR-206 after 18h of incubation. 
 
EP targeting the embryonic muscle precursor in the somitic dermomyotome 
specimen 
analysed for 
Pax7 mRNA Pax7 protein 
miR-206 
 
   18h 
pCab 3:3/0/0 5:5/0/0 3:3/0/0 
    
Gg Myf5 3:3/0/0 3:3/0/0 4:4/0/0 
Gg MyoD 3:3/0/0 4:4/0/0 3:3/0/0 
Gg MyoG 4:4/0/0 3:3/0/0 3:3/0/0 
Gg Mrf4 4:4/0/0 3:3/0/0 2:2/0/0 





11 Requirement of cell cycle withdrawal for the terminal 
differentiation of muscle precursor 
11.1 Introduction  
In the previous chapters, we showed that in a time window between HH15/16 and HH19/20, the 
stem cell state of developing myoblasts was protected from premature differentiation. Moreover, 
we showed that in this time window the pre-myogenic and muscle stem cell factor Pax7 persisted 
when Mrf genes were ectopically expressed. Pax7 provides myogenic competence but delays 
differentiation. Moreover, when misexpressed in adult muscle stem cells or in C2C12 myoblasts, 
PAx7 supported cell proliferation. When myoblasts enter terminal differentiation and become 
myocytes, however, they withdraw from cell cycle (230). This is concomitant with (i) the 
downregulation of cell cycle promoting Cyclins (426), (ii) upregulation of members of the 
p21/p27/p57-Cdkn1 family and the p16-Ink4-Cdkn2 family of Cyclin dependent kinase inhibitors 
which block cell cycle in G1 (reviewed in (Sherr and Roberts, 1995), and (iii) the hypo-
phosphorylation of the retinoblastoma protein pRb which both inhibits DNA synthesis and 
promotes the activation of muscle genes (427,428) . Misexpression of Cyclin D1 (Ccn D1) or of 
CcnA/E together with the Cyclin dependent kinase Cdk2 inhibited myogenesis (426,429), while 
misexpression of p16/Cdkn2a and p21/Cdkn1a in myoblasts supported some muscle-specific gene 
expression even in growth medium (430) . On the other hand, when in amniote muscle fibres pRb 
or p53 together with Cdkn2a/ARF was removed, cells re-entered cell cycle, expressed Pax7 and 
dedifferentiated (431,432), mimicking muscle dedifferentiation that occurs in the context of 
salamander limb regeneration(433). Therefore, cell cycle control is a key step in the terminal 
differentiation of myogenic cells. 
Given that the misexpression of Mrf in chicken muscle precursor did not lead to a downregulation 
of Pax7, we wondered whether the cells were still in a mitotically active state, preventing their 
differentiation. We therefore decided to investigate expression levels of Cdkn genes. We also 
decided to misexpress Cdkn genes alone or in combination with MyoD or MyoG. Yet the number 
and expression of cell cycle regulators in the chicken was not fully characterised. Specifically, it is 
controversial whether birds have the Cdkn2a member of the p16/Ink4/Cdkn2 family, whether 
they have an alternative upstream Cdkn2a exon that is translated in an alternative reading frame 
(hence this Cdkn2a isoform is also referred to as ARF) (434) . In a combined effort of S. Wöhrle 
and S. Dietrich in the lab and F. Pituello at Université P. Sabatier, Toulouse, France, we used 
bioinformatics to determine the members of the Cdkn gene families in the chicken, and we 
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analysed their expression in comparison to that of Cdk and Cnn genes by in situ hybridisation. This 
analysis revealed chicken Cdkn1b as the most likely regulator of cell cycle withdrawal during early 
chicken myogenesis. The subsequent functional analyses suggested however that Cdkn1b was 
unable to promote terminal differentiation in developing myoblasts. 
11.2 Results  
11.2.1. Identification of avian Cdkn genes 
In mammals, the Cdkn1, Cdkn2 and the small Cdkn3 family of cell cycle suppressors are well 
characterised (87,435). Information on Cdkns in other vertebrate species is fragmentary. In order 
to establish which Cdkn would be a likely regulator of cell cycle exit during early chicken 
myogenesis, we searched the NCBI, Xenbase and Ensembl databases for Cdkn sequences, using 
the same approach as for the Mrf genes (see chapter 4). This work was carried out by S. Wöhrle 
and S. Dietrich, the data are summarised in (Table 11.1). In placental mammals, the Cdkn1 gene 
family encompasses the Cdkn1a, Cdkn1b and Cdkn1c genes. However, in the marsupial opossum, 
in all bird species analysed and in lepidosaurs (lizards and snakes), Cdkn1c was not found. Given 
that Cdkn1c was present in alligators and turtles which are more closely related to birds than 
lizards and snakes, our data suggest that during evolution, Cdkn1c was lost independently in some 
amniote lineages. In teleost on the other hand, duplicates of Cdkn1c and, in zebrafish, duplicates 
of Cdkn1b, were found, in line with the three rounds of genome duplication that occurred during 
teleost evolution (436,437). Interestingly, in actinopterygians (exception: spotted gar) as well as in 
birds, alligators, turtles, lizards/snakes, and Latimeria, a fourth Cdkn1 family member, called 
cdkn1d in teleost and Cdkn1a or d in birds, was found. Comparison of protein sequences 
suggested that the so far unknown sarcopterygian Cdkn1 family member was similar to teleost 
cdkn1d. These data suggest that in most vertebrates, cell cycle control may involve a further 
Cdkn1 member, which has been lost in mammals. The synteny analysis revealed that, where the 
new Cdkn1 gene was present, it was linked to Cdkn1b. This analysis also revealed that extensive 
rearrangements between Cdkn1 gene loci had occurred. Therefore a full phylogenetic analysis will 
have to be carried out to establish the relationship of the new Cdkn1 gene with the known Cdkn1 
paralogs. However, the fact that different vertebrate species have different complements of Cdkn 
genes is quite important: Studies in mammals showed that Cdkn1b is required for adult muscle 
stem cell (satellite cell) self-renewal including the suppression of differentiation and the return to 
quiescence, whereas Cdkn1a is required for cell cycle arrest when myoblasts enter terminal 
differentiation (438). In zebrafish however, it is cdkn1c that assists myod during myogenesis in the 
cells to differentiate first, the adaxial cells (435). This suggests that after the generation of Cdkn1 
genes during the two (teleosts: three) rounds of gnathostome genome duplication, distinct sub-




The search for Cdkn2 family members revealed that placental mammals have four paralogs, 
Cdkn2a,b,c,d. Moreover, they have an alternative first exon for Cdkn2a which, when spliced to the 
2nd exon of Cdkn2a, creates an alternative reading frame and hence produces a distinct protein, 
Cdkn2a-ARF (439). Homologs of mammalian Cdkn2b and c we found in all osteichthyan (“bony”) 
vertebrates analysed. In contrast, Cdkn2d was absent in birds and possibly also in turtles. Cdkn2a 
as well as Cdkn2a-ARF was missing in marsupial and monotreme mammals, Xenopus, Latimeria 
and in all actinopterygians. The information we were able to obtain for diapsids is incomplete 
because the loci where, according to our synteny analysis, we expected Cdkn2a/ARF to be 
situated, are not fully sequenced. Nevertheless, we detected evidence for Cdkn2a-ARF in galliform 
(chicken, turkey), anseriform (duck) and passeriform (zebrafinch, flycatcher) birds, but not in 
turtles or lizards/snakes. When performing a BLAST-search using mouse sequences, we obtained a 
hit for ARF, followed by a 2nd hit for ARF and a hit for the 2nd exon of Cdkn2a at a location on 
chromosome Z where genes typically linked to Cdkn2a/ARF were found. We furthermore found 
evidence for Cdkn2a in passeriform birds and the budgerigar, as well as for turtles and the 
Burmese python, suggestion that Cdkn2a is present in diapsid animals. 
 To complete the analysis, we searched for Cdkn3 genes and we found that all vertebrates with 
the exception of Xenopus had a single Cdkn3 gene, located in a conserved environment, 
suggesting immediately after the two round of genome duplication, all duplicates with the 












Table 11. 1: Presence of Cdkn genes in osteichtyans  
Table showing cross reference of Cdkn genes with species investigated.  
Cdkn1a, b, c, d and Cdkn2a ARF, a, b, c, d and 3 have been summarised. Columns 1 to 4 dictate the classification of the species investigated. Remaining columns dictate 
the genes being investigated. The colour code indicated the data base sources (dark green Ensemble, light green NCBI) and light beige see annotation at the bottom 
row. N/A indicates non availability of the data. The yellow boxes underline where we are have fragments of the sequences.  
Some of the sequences have gaps and we have just fragmented information. Few of the sequences have the corresponding Cdkn sequence but just in one exon. And in a 




   species investigated  Cdkn1a Cdkn1b Cdkn1c Cdkn1d  Cdkn2a-ARF Cdkn2a Cdkn2b Cdkn2c Cdkn2d  Cdkn3 
Sarcopterygians                 
 Mammals Placentals Human, mouse     -         
  Marsupials Opossum    - -  -       
  Monotremes Platypus  N/A N/A N/A N/A  - N/A N/A N/A N/A  N/A 
 Birds Galliformes  Chicken, turkey    -   Gg  for ex1 Gg ? Gg   -   
  Anseriformes 
(waterfowl) 
Duck   (blast 
hit) 
-   - -   -   
  Passeriformes Zebrafinch, flycatcher 
(Tibetian ground tit, white 
throated sparrow) 
   - -  Blast hits for 
ex1 
   -   
  Parrots Budgerigar    - -     N/A N/A  N/A 
 Alligators, 
crocodiles 
 Chinese and American 
alligator 
   ()   N/A N/A N/A N/A N/A  N/A 
 Turtles  Chinese softshell turtle 
(painted turtle, green sea 
turtle) 
 (gaps)     - (blast hit)   ?   
 Lizards and 
snakes 
 Anole lizard (Burmese 
python) 
   -   -       
 Amphibians  Xenopus tropicalis, 
Xenopus laevis 
    -  - -     - 
 Coelocanths  Latimeria       - -      
Actinopterygians                 
 Holosts  Gar     -  - -      
 Teleosts Cypriniformes  Zebrafish        - -      
  Gadiformes Atlantic cod     -  - -      
  Beloniformes Medaka   -    - - (gaps)     




    - -      
  Gasterosteiformes Stickleback    (blast hits)   - -      
                 
        Bird & lizard gene upstream of 
Cdkn1b. Gene is similar to 
teleost cdkn1d; but could also be 
a duplicated Cdkn1a 
 where present, 
Cdkn2a/ARF is 
downstream of Cdkn2b 




11.2.2. Expression analysis for chicken cell cycle regulators 
Having identified the Cdkn family members present in the chicken genome, we next examined 
which of them are expressed during somitic myogenesis. Moreover, we analysed the expression 
of Cyclin (Ccn) genes, Cdk genes and Cdc25 genes that promote cell cycle and hence, might be 
expressed in developing myoblasts. The analysis was performed by in situ hybridisation of 
HH13/14 embryos. Fabienne Pituello kindly provided us with her collection of in situ probes (see 
Materials and Methods), all other probes were synthesised according to the sequences we 
extracted from the databases. Since we were unable to find the sequences for Cdk4 in the 
chicken, we instead used the sequences we found for Pseudopodoces humilis (Tibetian ground tit) 
and the American alligator. Since the Cdkn2 sequences we found in the chicken were very short, 
we used the sequences for zebrafinch Cdkn2a instead. This zebrafinch probe was also tested on 
stage-matched zebrafinch embryos. Moreover, we used a CcnB2 sense probe as negative control. 
The results are shown in Fig.11.1 and 11.2, with images sorted according to the phase of the cell 
cycle in which the proteins are active. 
Amongst the Cyclins, we found that Ccn D1, B2 and B3 were strongly expressed in the somites and 
in the neural tube, Ccn D2, E and E2 had similar expression patterns but at lower expression 
levels. Ccn A1 and A2 were expressed throughout the embryo and in blood islands, the latter also 
showed expression of Ccn D3 (which interestingly can act as positive regulator of differentiation; 
(440)); for Ccn O, no expression was detected. For Cdk4 we were unable to detect any specific 
expression, which may be due to the fact that we only had heterologous probes. Cdk6 was 
strongly expressed in the neural tube and lateral mesoderm, but not in the somites. In contrast, 
widespread expression that also encompassed the somites was found for Cdk2 and Cdk1, with 
expression levels of Cdk1 being higher than those of Cdk2. Both Cdc 25 genes were expressed in 
the neural tube, somites and lateral mesoderm. Amongst the Cdkn genes, widespread expression 
encompassing the somites was found for Cdkn1a, Cdkn2c and Cdkn3. Widespread expression not 
including somites was found for Cdkn2b, no signal was detected for Cdkn1d, Cdkn2a, ARF. 
However, a specific signal in the somites that began in the medial-most area and then spread 
laterally was observed for Cdkn1b. This expression pattern was similar to that of myogenic genes, 
suggesting that specifically Cdkn1b might be involved in cell cycle exit during somitic myogenesis. 
Finally, the Ccn B2 sense probe did not produce any staining as expected, indicating that any 
staining we obtained was trustworthy. In summary, somites expressed Ccn D1, D2, E, E2, A1, A2, 
B2, B3, Cdk2, Cdk1, Cdc 25a, Cdc25b, low levels of Cdkn1a, 2c, 3. Moreover they expressed 




Since the Cdkn1b staining resembled that we obtained with myogenic genes analysed in chapter3, 
we in more detail investigated the dynamics of Cdkn1b expression in comparison with that of 
Myf5 and MyoD (Fig. 11.3). At HH4-5, the expression of Cdkn1b was visible along the primitive 
streak (Fig. 11.3 A). At HH8 Cdkn1b staining was observed in the early rostral neural plate in the 
developing cardiac cells and the youngest two somites (Fig.11.3 B). At both stages, the two Mrf 
genes were not expressed (Fig.11.3 G,H,M,N). At HH10, Cdkn1b and Myf5 were transcribed 
throughout the 10 somites present, but Cdkn1b was also expressed in the neural tube, the cardiac 
mesoderm and the primitive streak (Fig. 11.3 C,I). MyoD was not expressed yet (Fig.11.3, O). At 
HH13/14 Cdkn1b was expressed in the dorsomedial edge of the somites, spreading laterally as 
somites matured (Fig.11.3 D). A similar expression pattern was observed for Myf5. However, Myf5 
was consistently expressed in the condensing somite whereas Cdkn1b was not (Fig. 11.3 J). MyoD 
expression commenced in somewhat more mature somites, somites 4-5 (Fig.11.3.P). A similar 
patterns was observed at HH15/16, with MyoD expression beginning already in somites1/2 
(Fig.11.3 E,K,Q). At HH20, the overall blue staining of the embryo hybridised with the Cdkn1b 
probe suggested more widespread expression. In the somites, however, Cdkn1b, Myf5 and MyoD 
were expressed in similar pattern (Fig.11.3 F,L,R). To verify the similarity of Cdkn1b and Mrf 
expression, the flank regions of HH20 embryos stained for the expression of Myf5, MyoD, MyoG, 
Mrf4 and Cdkn1b were vibratome-cross-sectioned (Fig. 11.4). This analysis showed that Myf5 was 
expressed in the dorsomedial and ventrolateral lips of the dermomyotome, whereas the other 
Mrfs and Cdkn1b were expressed in the myotome. Taken together, our data suggest a close link 
between Cdkn1b and myogenesis. In terms of timing of expression, Cdkn1b appeared after that of 
Myf5 and before that of MyoD, which is earlier than the withdrawal of myogenic cells from cell 
cycle. However, we do not currently have information on the emergence of Cdkn1b protein. In 
addition, no other Cdkn gene showed an expression pattern that would link it to myogenesis. 







Figure 11. 1: Expressions of positive cell cycle regulators at HH14: 
Analysis of the expression of cell cycle promoters in different phases of the Mitosis. Embryos analysed at HH13-14 (19-22 somites). In this 
experiment, it was observed which cell cycle promoter have more possibility to be involved in the Myogenesis. From A to J, the cyclins 
have been analysed with in situ hybridisation (see Material and Methods).  Ccn D1, CCn A2, Ccn B2, Ccn B3 (images A, H. I, J) are the cyclins 
that showed the best mRNA signal in somites. From figure K to O, Cyclin-dependent kinase have been analysed, finding that Cdk1 showed 
the best expression in the somite. Finally P and Q represent the Cdk activators where just Cdc 25b showed strong staining in the somites. 








Figure 11. 2: Expression of negative cell cycle regulators 
Cdk inhibitors have been analysed. From figure A to C show; Cdkn1=Cip/Kip family analysed with in situ 
hybridisation.  Cdkn1b (B) showed strong expression in the somites. On the Cdkn2=Ink4 family, Cdkn2C (H), 







Figure 11. 3: Comparison of Cdkn1b, Myf5, MyoD expression, time course 
The strong staining of the mRNA after ISH treatment gave strong information of the similar staining of the Cdkn1b compare to Myf5 
and MyoD. In this template stages HH4-5 to 20-21 have been compared to see the affinity and the resemblance of the 3 pattern. A 
to F, Cdkn1b looks appear earlier of the other two genes. This gene was express in HH4 and 8, there was not any record for Myf5 
and MyoD for this early expression. At the HH10, Cdkn1b has still a strong where it is detect for the first time the appearance of 
Myf5 (figure C and I), Myod is not appearing at this early stage. Myf5 has a strong expression in the somites from HH10 to 20-21, 
where MyoD appears at HH-13-14 in the oldest somites until somites 5 (s5) from the primitive streak. All three the genes had a 
strong expression in mRNA levels the HH15 -16 until HH20. The staining appeared to have a different distribution in the somites 





Figure 11. 4: Comparison of Cdkn1b, Myf5, MyoD expression, time course 
The strong staining of the mRNA after ISH treatment gave strong information of the similar staining of the Cdkn1b compare to Myf5 and MyoD. 
In this template stages HH4-5 to 20-21 have been compared to see the affinity and the resemblance of the 3 pattern. A to F, Cdkn1b looks 
appear earlier of the other two genes. This gene was express in HH4 and 8, there was not any record for Myf5 and MyoD for this early 
expression. At the HH10, Cdkn1b has still a strong where it is detect for the first time the appearance of Myf5 (figure C and I), Myod is not 
appearing at this early stage. Myf5 has a strong expression in the somites from HH10 to 20-21, where MyoD appears at HH-13-14 in the oldest 
somites until somites 5 (s5) from the primitive streak. All three the genes had a strong expression in mRNA levels the HH15 -16 until HH20. The 





Figure 11. 4: Analysis somite-expressed Mrf in comparison with Cdk1b 
(A) Schematic representation of the images displayed in B-F (lateral view of flank somites on the right of the embryo, rostral to the top, lateral to the 
right) and Bi-Fi (cross section to flank somites, dorsal to the top, lateral to the right; section (Si) is from the forelimb- flank boundary as indicated in S). 
Markers are indicated as before. The Mrf genes and Cdk1b show overlapping expression in the myotome, with the late commencing markers still 






11.2.3. Analysis of Cdkn1b expression after Mrf misexpression  
The analysis of Cdkn1b expression suggested that a close link with of this gene with the process of 
myogenesis. Yet expression emerged after that of Myf5, suggesting the possibility that Cdkn1b 
could be regulated by Myf5 and, if generic E-Box sequences were to be located in the Cdkn1b 
promoter, by other Mrf proteins. To test this, HH15/16 embryos were electroporated with the 
pCab control vector, with the various Mrf expression constructs or with both MyoD-MyoG 
constructs. The embryos were re-incubated for 18 hours to reach HH19/20 and analysed by in situ 
hybridisation for the expression of Cdkn1b (Fig.11.5). The results are summarised in Table. 11.2.  
The experiment revealed that electroporation of the pCab vector did not change the expression of 
Cdkn1b (Fig. 11.5 A,B). In contrast, any of the Mrf and MyoD and MyoG together caused a 
significant upregulation of Cdkn1b in the electroporated cells (Fig. 11.5 C-N), the weakest effect 
having been obtained with Mrf4 Fig.11.5, I,L). These results indicate that Mrf are sufficient to 








Figure 11. 5: Mrf Misexpression of Mrf genes, analysis of Cdk1b expression 
Embryos were electroporated with plasmids encoding the factor shown and GFP and grown to HH20. 
Fluoresce was visualized at the microscope (figure from A to M). Embryos were analised with ISH to 
detect mRNA for Cdk1b. The misexpression of the Mrf upregulate Cdk1b, localized in the area of the 





11.2.4. Misexpression of Cdkn1b in chicken somites 
11.2.1.1 Effect on cell cycle 
To investigate whether Cdkbn1b or any of the Mrf indeed facilitate cell cycle exit of myogenic 
cells, a Cdkn1b expression constructs was generated. Chicken embryos at HH15/16 were 
electroporated with Cdkn1b or Mrf expression constructs, harvested after 18 hours, cross-
sectioned on a cryostat and analysed for the presence of Histone H3 phosphorylated at Serine 10, 
using immunohistochemistry. The anti-pH3 antibody detects cells with compacted chromatin 
ready for or undertaking mitosis (361). Simultaneously, sections were stained with an anti-GFP 
antibody to trace the targeted cells and with DAPI (4',6-diamidino-2-phenylindole, dilactate) to 
reveal cellular nuclei (Fig.11.6,7). Overall, the number of cells that could be stained with the pH3 
antibody was low, possibly owing to the fact that cell-cycle is not fast. We therefore were unable 








Figure 11. 6 Misexpression Mrf and Cdk1b genes; analysis for cell cycle withdrawal (pH3 staining). 
Embryos were electroporated with plasmids encoding the factor shown and GFP and grown to HH20. Fluorescence was visualised at the 
microscope. Embryos were treated in OCT (see material and methods) and section at the cryostat at 15 µm. The sections were treated with 
fluoresce immunohistochemistry for pH3 (anti-phospho-Histone H3) anti GFP and DAPI. Analysis of the EP embryos doesn’t show any significant 






  Figure 11. 7:Misexpression Mrf and Cdk1b gens; analysis for cell cycle withdrawal (pH3 staining) 
(detail lip of the somite) 
Embryos were electroporated with plasmids encoding the factor shown and GFP and grown to 
HH20. Fluoresce was visualised and the microscope. Embryos were treated in OCT (see material and 
methods) and section at the cryostat at 15 um. The sections were treated with fluoresce 
immunohistochemistry for pH3 (Anti-phospho-Histone H3) anti GFP and DAPI. DAPI (A-F), pH3 (Ai-
Fi), GFP (Aii-Fii) and overlapped images (Aiii-Fiii). Pictures were taken a higher magnification for the 
lip of the somites to have more detailed images of the staining. The analysis of the immune staining 
doesn’t show any significant change 
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11.2.1.2 Effect on myogenesis 
To test whether Cdkn1b, alone or in combination with Mrf might be able to accelerate 
myogenesis in developing muscle precursor, we misexpressed Cdkn1b alone and in combination 
with MyoD and MyoG, re-incubated the embryos for 18 hours and performed a MF20-DAB 
antibody staining (Fig.11.8; results are summarised in Table 11.2). , no upregulation or changes 
were observed (Fig. 11.8 B,C). Yet, none of the embryos displayed ectopic expression of 









Figure 11. 8: Misexpression of Cdk1b alone or with Mrf; analysis for sarcomeric Myosin expression 
Embryos were electroporated with plasmids encoding the factor shown and GFP and grown to HH20. GFP 
was visualised (arrowed in A, D, G) and sarcomeric myosin expression detected by antibody staining with 
DAB. No changes in sarcomeric myosin levels were detected when the control and electroplated sides were 





11.3.1. Cdkn1b is a likely regulator of cell cycle exit during early chicken myogenesis  
The differentiation of the muscle stem cell is strictly related to the cell cycle control 
(333,426,441). Muscle precursor have to leave the cell cycle to differentiate and develop from 
myoblast to myocytes giving rise to muscle fibres. We hypothesised that this was the key step for 
cells to move forward into the differentiation. We decided to focus our attention on the 
expression of the Cyclin Dependent kinase, cyclin activators and inhibitors in chick embryos and 
see which one could be considered the best candidate to carry on our studies and find the best 
one that could be expressed in the somites push the cell to leave the cell cycle. 
We realised that Cdkn1b showed an impressive resemblance during the in situ hybridisation 
comparable to Myf5 and MyoD. We therefore decided to focus our attention on this particular 
Cyclin inhibitor. We electroporated Mrfs constructs and analysed hybridising the antisense probe 
for Cdkn1b. All Mrfs constructs caused an upregulation of Cdkn1b mRNA levels. The analysis of 
the embryos electroporated with Mrfs constructs with the antibody against the Phosho Histone 
H3 Serine 10, show that we could not detect a satisfying quantity of data from the cryostat 
sections and we could not see any difference between the electroporated and the non 
electroporated sides. Due to time constraints an insufficient number of repeat experiments were 
performed to make a conclusive analysis. Also, proper quantification by cell counting was not 
possible to provide a robust quantification. Given more time, these experiments would be 
repeated to provide more conclusive analysis. In Figure 10.6-7 Bi-iii, antibody staining can be seen 
in the electroporated area. Again, as the number of repeats was too low, the significance of this 
observation and its validity cannot be commented on with complete certainty.  
Future experiments would require comparison with a positive control for Ph3, the most common 
one is the immunostaining in mouse or human carcinoma cells. These cells have a high rate of 
division so the antibody would detect mitotic phosphorylation of H3 Thr3 in prophase and its 
dephosphorylation during anaphase (442). 
Cell counting could be performed using the program CellProfiler (cellprofiler.org) or ImageJ 
(imagej.net). These programs efficiently create boundaries between the cells visible in the image 
to ensure that cells in close proximity aren't excluded. The programs can be set for specific 
fluorescence wavelengths and will repeat the counting process several times giving an average 
number of the cells. These programs can be used both for cultured cells and in sectioned tissues.  
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11.3.2. Cdkn1 gene misexpression does not advance myogenesis from developing muscle 
precursor 
When we compare the staining of the Mrfs mRNA levels with Cdkn1b, we realised that from the 
sections we could confirm that the staining of this cyclin inhibitor is very similar to Myf5 and 
MyoD and MyoG. The staining is along the line of the myotome and it is reaching the dorsomedial 
and the ventrolateral lip. We decided to misexpress Cdk1nb in the somites and to use the co-
electroporation technique to expresses the cyclin inhibitor with MyoD and MyoG. If we were able 
to force the cell to leave the cell cycle, may be Cdkn1b alone would be enough to give an 
upregulation in the Myosin staining, and the co-electroporation with MyoD and MyoG would have 
caused the cell to leave the cycle and in the same time to push the cell to differentiate. In all three 
cases we did not see any changes in the Myosin staining, all the somites, are showing the same 
pattering comparable with the control. The N.number (Table 10.2) of the experiments are 
confirming the results obtained and the reproducibility of the experiment itself. We hypothesised 
that even in this case there is a time frame in which the muscle precursor are highly protected 
and the use of cyclin inhibitors does not influence the exit from the cell cycle. In a forming 
embryo, the cells must replicate to ensure a high number of cells to create a new tissue, but at 
the same time they have to ensure to renew the stem cell pool. This is an important step in 
embryogenesis. The stem cell pool is essential for renewing or substituting damaged tissue in 
adulthood, and consequently its control and maintenance is important. Therefore in the embryos 
the myoblasts cannot leave the cell cycle too early because they have to make sure to renew the 
stem cell pool. We hypothesised that there could be another mechanism of control which 
contributes to the protection of the stem cell state. Looking at the literature we found that MyoD 
protein could be inactivated by phosphorylation of specific residues (207,443). MyoD contains 
several consensus cyclin-dependent kinase (CDK) phosphorylation sites which if mutated can 
protect the MyoD protein from phospho-regulated degradation (444). In line with these findings, 
we decided to use murine phospho-incompetent MyoD constructs for studying its misexpression 
in HH16 chicken somites. The mutated mouse MyoD should be constitutively activated because it 
is protected from phosphorylation and therefore is hypothesised to cause upregulation of Myosin 




Table 11. 2: Summary N. number of the experiments in Chapter 11. 
Numbers displayed as:   total: wildtype/upregulated/downregulated 
The table summarises the N.number of the experiments shown in Chapter 11: immunohistochemistry, in 
situ hybridisation and electroporation. We saw upregulation of mRNA levels with the electroporation of Mrf 
constructs (Myf5, MyoD, MyoG and Mrf4) analysed with the antisense probe for Cdkn1b after 18hr of 
incubation. (Blue shade). 
EP targeting the embryonic muscle precursor in the somitic dermomyotome 
specimen analysed for sarcomeric Myosin (MF20) Cdkn1b mRNA pHistone3 
 18h 
pCab 4:4/0/0 2:2/0/0 3:3/0/0 
    
Gg Myf5  3:1/2/0 2:2/0/0 
Gg MyoD  3:0/3/0 2:2/0/0 
Gg MyoG  2:0/2/0 2:2/0/0 
Gg Mrf4  3:1/2/0 1:1/0/0 
Gg MyoD+MyoG  3:1/2/0  
    
Gg Cdkn1b 3:3/0/0  3:3/0/0 
Gg Cdkn1b + MyoD 4:4/0/0   




12 Inactivation of MyoD by phosphorylation  
12.1 Introduction  
In chapters 5-9, we systematically explored whether chicken Mrf genes, either alone, or in 
combination with other Mrf, with Mef2c and with Six1, could drive premature paraxial mesoderm 
(chapter 5) or developing muscle promoter (chapters 6-9) out of their stem cell state and into 
myogenesis. Our data indicated that Mrf were able to activate a small collection of early myogenic 
genes, but were not able to enforce terminal differentiation. This suggested that it is not the 
absence of myogenic factors but rather a more active mechanism that protects the muscle stem 
cell state. In Chapters 10 we investigated whether the continued presence of the premyogenic 
and muscle stem cell factor Pax7 might contribute to the protection of the muscle stem cell state, 
and found that indeed was the case. Since Pax7 promotes proliferation, we in Chapter 11 
explored whether the continued ability of cells to undertake mitosis might prevent terminal 
differentiation. However, this was not the case. We were therefore left with: (i) Mrf can initiate 
the transcription of a few myogenic genes and (ii) Mrf are unable to activate the full complement 
of myogenic genes that ensures expression of muscle structural genes and removal of 
premyogenic/ stem cell factors. This suggested that possibly, the efficacy of Mrf as transcription 
factors mighty be limited. 
A number of molecular studies have established that MyoD protein activity can be negatively 
regulated. MyoD can be inactivated through sequestration by the basic-helix-loop-helix protein 
association with proteins Id or when interacting with the histone deacetylases HDAC4 and HDAC5 
(385,387). MyoD may also be subjected to inactivating phosphorylation executed by Cyclin 
Dependent Kinase (Cdk) activity, specifically Cdkn1 and 2 (443,445). In proliferating C2C12 mouse 
myoblasts in vitro, high levels of phosphorylated MyoD are found which gradually decrease during 
muscle differentiation. Moreover, mouse MyoD contains a Cdk consensus site comprising of a 
serine at position 200 which is phosphorylated in vivo in myoblasts and in vitro by Cdk1 and Cdk2. 
Phosphorylation of MyoD by Cdks has been shown to target the protein for rapid degradation by 
the ubiquitin pathway (206). When serine 200 was changed to a non-phoshorylateable alanine 
(S200A mutation), the mutant protein showed great ability to convert 10T1/2 fibroblast to muscle 
cells (206,443,445). Our expression analysis for cell cycle regulators revealed that Cdk1 and 2 are 
expressed in somites (see chapter 9). Moreover, experiments conducted in Xenopus 2-cell stage 
embryos suggested that the S200A mutation of mouse MyoD has a stronger myogenic effect that 
wildtype mouse MyoD, and this effect was enhanced when additional amino acids were rendered 
non-phosphorylateable (A. Philpott and L. Harwick, personal communication). We thus wondered 
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whether also in chicken muscle promoter, MyoD phosphorylation might prevent MyoD from 
activating genes required for terminal differentiation. 
To explore this possibility, Professor Anna Philpott and Dr. Laura Harwick kindly provided us with 
3 constructs, expressing a variant of wildtype mouse MyoD, mouse MyoD with the S200A 
substitution, and a penta-mutant construct with 5 substitutions S(200, 262, 277, and 298)A; 
T296A, which protects against MyoD hyperphosphorylation (personal communication with S. 
Dietrich). These constructs were cloned in the pCS2+ vector, allowing transcription of mRNA from 
a sp6 promoter and misexpression in amniote cells from the CMV promoter (see chapter 4). We 
injected the in vitro transcribed mRNAs in Xenopus 2-cell stage embryos to confirm their 
biological activity. We then electroporated the constructs into chicken HH15/16 flank somites and 
once more, analysed for the premature expression of sarcomeric Myosins after 18 hours of re-
incubation. We found that in contrast to the frog blastomeres, developing chicken myoblasts 
could not be forced into differentiation. 
12.2 Results  
12.2.1 Misexpression of mouse MyoD mutant constructs in Xenopus embryos 
To test the biological effect of the constructs we decided to use the mouse MyoD constructs in 
the Xenopus system, following the strategy initially used when validating the chicken constructs in 
Xenopus embryos (Chapter 4). The three mouse MyoD constructs were transcribed in vitro to 
obtain mRNA for injection into 30 2-cell stage Xenopus embryos, utilising βGal as a lineage tracer. 
Embryos were harvested at stage 26 and analysed using the MF20 antibody to detect sarcomeric 
Myosin. Embryos were compared to those obtained by injection of βGal mRNA or RNA for βGal 
and chicken MyoD. The results are summarised in Table 12.1. 
When mRNA encoding the lineage tracer (Fig. 12.1 A-B) alone or with an mRNA for chicken MyoD 
was injected (Fig. 12.1 C-D), no ectopic expression of sarcomeric Myosins was observed on the 
injected side. When mRNA for mouse MyoD was injected, survival rates of embryos was lower 
that survival rates of embryos injected with chicken MyoG or Mrf4 mRNA. Of the 3 surviving 
embryos, 2 showed ectopic expression of Myosin expression and gastrulation defects akin to 
those obtained with chicken MyoG and Mrf4 (Fig. 12.1 E-F, compare with Fig. 4.7 I-L). When the 
S200A mutant of mouse MyoD was used, 13 of 30 embryos survived, with 12 showing ectopic 
MF20 staining and gastrulation defects (Fig. 12.1 G-H). Upon injection of the penta-mutant mRNA, 
2 embryos with normal Myosin expression survived. The remaining 28 embryos were too 
malformed to reach stage 26. Thus, when arranging the constructs with respect to the severity of 
phenotypes they cause, the order from weaker to stronger is: mouse S200A MyoD, chicken 








Figure 12. 1: Misexpression of WT and phosphorylation-incompetent mutant mouse MyoD proteins 
in xenopus embryos causes upregulation of Myosin expression between two-cell and stage 26 
A batch of Xenopus leavis embryos were subdivided into 9 groups of 30 embryos. One set of embryos 
was left to develop as normal (A,B); of the other embryos, one cell each was injected with Gal mRNA 
(C,D), or with Gal mRNA plus the Mrf RNA (E,F,G,H). Embryos were collected when the control 
embryos reached stage 26. Representative embryos were photographed, showing the untreated 
(C,E,G; rostral to the left) and treated sides (D,F,H; rostral to the right) in lateral views. Embryos 
injected with mouse MyoD appeared largely normal (E,F). Embryos injected with the S200A mutant of 
mouse MyoD showed similar survival rates (G,H), but most embryos had ectopic MF20 staining (asterix 
F,H) and truncated bodies, the latter suggesting a gastrulation defect (arrowed F,H). Upon injection of 
the RNA encoding the S(200, 262, 277, 298)A; T296A mutant of mouse MyoD, only two, healthy-
looking embryos survived, suggesting that most embryos became too malformed to develop beyond 





12.2.2 Misexpression of mouse MyoD and MyoD mutants in chicken somites 
Given that we were able to confirm the biological activity of the mouse constructs, we next 
electroporated them in the chicken system. Since the pCS2+ vector containing the mouse 
sequences does not encode the GFP lineage tracer, these constructs were co-electroporated with 
pCAB-GFP vector. The pCS2+ vector not carrying any insert was co-electroporated with pCAB-GFP 
vector as a negative control. Electroporation of HH15/16 embryos was performed in a consistent 
manner with previous experiments; embryos were harvested after 18 hours of re-incubation as 
before (see Chapter 2 for Methods). Electroporated cells expressing p-Cab-derived GFP 
fluorescence were located with fluorescence microscopy; embryos were analysed with 
immunohistochemistry using the MF20 antibody to detect sarcomeric Myosins and re-
photographed as before (Fig.12.2). The results are summarised in Table 12.2. This analysis 
revealed that in control and experimental somites, sarcomeric Myosins were expressed in the 
myotomes, as expected. However, no upregulated or ectopic expression ever occurred. Thus, 
different to the frog system, phosphorylation-resistant mouse MyoD was unable to advance 








Figure 12. 2: Misexpression of WT and phosphorylation-incompetent mutant mouse MyoD proteins in 
the chick somites is insufficient to upregulate Myosin expression between HH16 and HH20 
Embryos were electroporated with plasmids encoding the factor pCS2, MyoD+pCAB, MyoD 
S200A+pCAB, MyoD, 5 Mut+ pCAB. After electroporation, the embryos were reincubated until HH20. 
GFP was visualised (arrows in A,D,G,J) and sarcomeric Myosin expression detected by antibody staining 
by immunohistochemistry. The embryos were dissected following the line of the neural tube from the 
caudal to the rostral part of the embryos, this allowed the comparison between the two sides of the 
neural tube, the control and electroporated (B-C, E-F, H-I, K-L). No changes in sarcomeric Myosin levels 






12.2.3 Comparative analysis of putative phosphorylation sites in gnathostome MyoD 
protein sequences 
The misexpression of the phosphorylation-resistant mouse MyoD constructs in chicken somites 
did not lead to premature entry of muscle precursor into differentiation. However, during our 
initial analysis of Mrf sequences, we had noticed differences between gnathostome Mrf proteins 
(see Chapter 4). We therefore wondered whether the amino acids mutated in mouse MyoD might 
not be conserved, and hence, avian MyoD function might not be controlled in the same fashion as 
that of mouse MyoD. To extend this analysis, we comparatively analysed which and how many 
amino acids in could be subjected to phosphorylation in mouse (curated and variant version), 
diapsid (chicken, python), Xenopus, zebrafish, and elephant shark MyoD, using the Netphos 2.0 
server to computationally predict phosphorylation sites. Fig. 12.3 shows an alignment of chicken 
and zebrafinch MyoD sequences, the mouse MyoD sequence obtain from the Ensemble and NCBI 
data bases, the variant version of MyoD that was used as control in A. Philpott’s and L. Harwick’s 
constructs, and the two mutant MyoD proteins derived from that. This alignment shows that S200 
of mouse MyoD is located at the N-terminus of the Myf5 domain, and this region is strongly 
conserved also in the avian MyoD proteins. However, of the remaining four amino acids mutated 
in the S(200, 262, 277, and 298)A; T296A of mouse CAA3836.1 MyoD, only two are conserved in 
the avian MyoDs and hence may not be relevant for MyoD activity in birds. Interestingly, in birds, 
the C-terminus of MyoD contains many more serines, including a serine also conserved in the 
mouse protein. This suggests that inactivating phosphorylation of the misexpressed MyoD 
proteins may well be possible. Indeed, when analysing gnathostome MyoD proteins for potential 
phosphorylation sites, these serines were predicted as phosphorylation targets with high 
statistical significance (Fig. 12.4). Counting potential phosphorylation sites (Table 12.3), we found 
little difference in the number of potential threonine and tyrosine phosphorylation sites but a 
significant difference with respect to possible serine phosphorylation sites, with the mouse having 
14, elephant shark 16, zebrafish 17, but Xenopus 21, chicken 22 and python 26. This suggests that 









Figure 12. 3: Alignment of chicken (Gg), zebrafinch (Tg) and mouse (Mm) wild type MyoD protein 
sequences with mouse (Mm) phosphorylation-incompetent mutant MyoD sequences  
Protein sequences shown in one-letter code. Blue shading: the alpha-helical basic domain involved in DNA 
binding; the Pbx/Meis binding motif N-terminal of the core basic domain indicated by a red line, the 
conserved tryptophan indicated by an asterisk. Green shading: the helix-loop-helix domain; amino acids 
required for protein dimerisation were marked with “o”, amino acids required for DNA binding with “X”, 
and the amino acid determining binding specificity to the CANNTG-E-box was marked with a black frame. 
Pink shading: the Myf5 domain involved in gene activation/ transactivation; core amino acids 246-258. The 
tyrosine at position 157 that, when phosphorylated, stabilises MyoD indicated by a green box. The serine at 
position 200 targeted by Cdk1 and Cdk2 and converted to an alanine in the S200A mutant was highlighted 
in yellow. Also highlighted in yellow: the four serines and the threonine converted to alanines in the S(200, 
262, 277, 298)A; T296A mutant. Note: the mouse sequences used to generate the MyoD mutants shows 
slight variations in amino acid sequence to the previously annotated sequences at positions 53, 66 and 234. 
Also note: with the exception of the serine in position 262 and the threonine in position 296, the targeted 
serines were conserved in amniotes (black asterisks; see also Chapter 4 Appendix Fig.1B). Yet the high 
serine content in the chicken and zebrafinch MyoD C-termini (and in other diapsid and anapsid proteins) 








Figure 12. 4: Alignment and prediction of phosphorylation sites in gnathostome MyoD proteins 
Serine (S), threonine (T) and tyrosine (Y) phosphorylation sites predicted by the NetPhos 2.0 Server (http://www.cbs.dtu.dk/services/NetPhos/) as above the 
threshold score of 0.5 were shown for a collection of gnathostome MyoD proteins, the value of the phosphorylation is indicated by the colour code, from magenta 
with the higher score and more likely to be phosphorylated to blue shade with a low value. 
We also showed the mouse protein prediction of the constructs kindly provided by A.Philpot. The prediction of the phosphorylated serine is significantly higher in 
chicken, python and Xenopus tropicalis whereas the mouse proteins have the lowest number of phosphorylation sites.  





12.3 Discussion  
12.3.1 Mouse MyoD and phosphorylation-independent versions of mouse MyoD promote 
myogenesis from Xenopus early blastomeres 
The injected of the mouse MyoD constructs showed a strong phenotype in Xenopus embryos at 
stage 26. The use of the mouse wild type showed upregulation of the Myosin at ectopic level, 
while the mouse construct with the single mutation of serine 200 to alanine, caused change a 
drastic change in the morphology of the embryos influencing even the control side. Mouse MyoD 
has fewer sites that might be subject to inactivating phosphorylation, providing an explanation as 
to why mouse MyoD but not chicken MyoD could force myogenic differentiation of blastomeres. 
The position of the serine in the MyoD sequence of these three species could be the key to 
understand why we could not see any changes in the Myosin expression after the MyoD chicken 
injection. We hypothesise that the chicken MyoD could have been recognised and 
phosphorylated before it could have any effect in the xenopus system. While on the other hand, 
the presence of fewer phosphorylation sites in the mouse MyoD may be insufficient to allow post-
translational silencing and consequently allowed ectopic expression of Myosin in xenopus. In this 
case the MyoD has not been recognised by the host system and it is permitted to affect myogenic 
development. The 5x mutations but not the S200A mutation aggravated this phenotype. The 4 
additional mutations were all located at the C-terminus, underlining our suspicion that the C-
terminus is an important functional domain (see chapter 4). 
It would be interesting to carry on further the experiments and misexpress elephant shark MyoD 
or zebrafish or combining chicken with frog MyoD with the mouse C-terminus, to test whether 
the lower number of phosphorylation sites renders the protein biologically active.  
 
12.3.2  Mouse MyoD and phosphorylation-independent versions of mouse MyoD do not 
drive terminal muscle differentiation from developing chicken muscle precursor 
The larvae of a frog develop via free-feeding and the time of development is a lot faster if 
compared to another vertebrate like a chick. A tadpole of a frog is able to swim or anyway move 
and respond to stimulus at a young stage of formation, around st26 (378). This means that the 
tadpole has already a muscle structure to allow the larvae to move and of course the formation of 
the first myogenic cells begin very early in development. This could be link at the results that we 
obtained after the electroporation of the mouse constructs. It could be that in frog there may be 
less protection against premature myogenesis. Another possibility is that in blastomeres, since 
they normally do not encounter MyoD, they are may be little protection against the activity of 
specific differentiation genes, whereas in myoblasts, since there only one step away from 
differentiation, this has to be tightly controlled. The experiments that mimic the misexpression of 
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MyoD in blastomeres cannot be done in chicken. However, once the Pax7 promoter is available 
from the frog, it should be possible to misexpress Mrf specifically in frog myoblasts. It would be 
interesting to see whether to not they enter myogenesis as easily as blastomeres.  
12.3.3 Promoters of MyoD target genes may be closed. 
In undifferentiated myoblasts, the unscheduled activation of the differentiation program is 
precluded by recruitment of histone deacetylases (HDACs) on the chromatin of muscle genes 
(446). Class I HDACs preferentially associate with MyoD (and possibly other muscle bHLH 
proteins), while class II HDACs are dedicated repressors of MEF2-dependent transcription. These 
interactions prevent the local hyperacetylation on the regulatory elements of muscle genes. 
During muscle differentiation, HDACs are displaced from muscle bHLH and MEF2 proteins by 
distinct mechanisms, thereby allowing productive interactions with acetyltransferases p300 and 
PCAF. Histone methyltransferases belonging to the SET-domain containing families are other 
critical mediators of muscle gene repression in myoblasts. For instance, Suv39 h1-mediated 
methylation of H3 lysine 9 and Polycomb-mediated trimethylation of H3 lysine 27 are essential 
epigenetic modifications that restrict the temporal expression of muscle genes in myoblasts. The 
enzymatic component of the Polycomb complex (PcG), the H3-K27 methyltransferase Ezh2, is 
recruited to the chromatin of muscle regulatory regions via interaction with YY1 binding site and 
its interaction with HDAC1 forms a repressive complex (193,447).  
Data showed that in primary myoblasts, Snail-HDAC1/2 repressive complex binds and activate 
excludes MyoD from its targets. Snail binds E-box motif that are G/C rich in their central 
diucleotides and such sites are almost exclusively associated with genes expressed during 
differentiation (448). But in contrast Snail does not bind the A/T-rich E-boxes associated with 
MyoD targets in myoblasts. The complex Snail1-HDAC1/2 prevents MyoD occupancy on 
differentiation-specific regulatory elements and the change from Snail to MyoD binding often 
results in enhancer switching during differentiation. All these results underlined a regulatory 
paradigm that directs distinct gene expression programs in progenitors versus terminally 







Table 12. 1: Injected Xenopus with mouse MyoD showed upregulation of ectopic Myosin and malformation during development 
In each experiment, 30 2-cell stage Xenopus laevis embryos were used. These embryos were either left to develop (control 1), injected with 250 pg -Gal mRNA 
(control 2) or injected with a mix of 250 pg -Gal mRNA and 1 ng of Mrf RNA. RNA was delivered in a total of 5 nl of water. Note that the RNA injection reduced the 
survival rate by 40%. Injection of chick Myf5 or MyoD RNA reduced the survival rates further, but surviving embryos appeared largely normal, sometimes displaying 
smaller heads (MyoD) or enlarged occipital somites (Myf5). Embryos injected with the S200A mutant of mouse MyoD showed similar survival rates, but most 
embryos had ectopic MF20 staining and truncated bodies, the latter suggested a gastrulation defect. When injected with chicken MyoG, chicken Mrf4 or variant 
mouse MyoD RNAs, survival rates were poor, and most embryos were malformed. Upon injection of the RNA encoding the S(200, 262, 277, 298)A T296A mutant of 
mouse MyoD, only two, healthy-looking embryos survived, suggesting that most embryos became too malformed to develop beyond gastrulation. 
Construct No of experimental embryos 
No of survivors 
at stage 26 
WT Malformed 
- 30 30 11 analysed, all wild type 0 
-Gal 30 18 18 0 
Gg Myf5+-Gal 30 14 14 0 
Gg MyoD+-Gal 30 10 10 0 
Gg MyoG+-Gal 30 6 3 3 
Gg Mrf4+-Gal 30 5 1 4 
Mm MyoD+-Gal 30 3 1 2 
Mm MyoD S200A mutant+-
Gal 
30 13 1 12 
Mm MyoD S(200, 262, 277, 
298)A; T296A mutant+-Gal 





Table 12. 2: Number of electroporation in chicken embryos of the chapter 12 
Numbers displayed as:  total: wildtype/upregulated/downregulated 
All the data collected from the electroporated mutant mouse constructs were summarised in this table. None of the 
electroporations showed upregulation of the Myosin.  
EP targeting the embryonic muscle precursor in the somitic dermomyotome 
Specimen analysed for Sarcomeric Myosin (MF20) 
 18h 
pCS2+ pCab* 5:5/0/0 
Mm MyoD + pCab* 4:4/0/0 
Mm MyoD S200A + pCab* 6:6/0/0 




Table 12. 3: Number of predicted phosphorylation sites in gnathostome MyoD proteins 
The number of serine (S), threonine (T) and tyrosine (Y) phosphorylation sites predicted by the NetPhos 2.0 Server (http://www.cbs.dtu.dk/services/NetPhos/) as above the threshold 
score of 0.5 are shown for a collection of gnathostome MyoD proteins. The number of sites in the mouse proteins expressed from the constructs kindly provided by A. Philpott are also 
shown. Note that the number in particular of predicted serine phosphorylation sites significantly higher in chicken, phyton and Xenopus tropicalis whereas the mouse proteins have the 
lowest number of phosphorylation sites. This suggests that mouse MyoD might be less prone to inactivating phosphorylation than the MyoD proteins of other species. 
Animal species Abbreviation S T Y 
     
Mouse Mm 14 5 3 
Chicken Gg 22 5 5 
Phyton Pybi 26 6 6 
Xenopus tropicalis Xt 21 8 5 
Zebrafish Dr 17 8 6 
Elephant shark Cm 16 8 5 
Mouse Mm CAA4336 14 5 3 
Mouse Mm S200A 12 5 3 







13.1 The stem cell state of developing muscle stem cells is temporally protected in 
vivo and the expression of Mrfs is insufficient to overcome this protected state 
A critical step in muscle development is the transition from the fate-committed but proliferating 
muscle stem cell to the non-proliferating myocyte (125,126,135,145). The Mrf genes have long 
been established as regulators of this process due to their ability to drive muscle differentiation in 
non-myogenic cells in culture (450). Yet, it is not clear if Mrf expression is sufficient to start 
muscle differentiation in muscle precursor, or whether in vivo the muscle stem cell state is 
protected. The first aim of this study was to provide, in the avian model for somitic myogenesis, a 
side-by-side analysis of the key markers associated with the progression from an immature state 
of the paraxial mesoderm to myogenic commitment and, eventually, to myogenic differentiation. 
Our study also provided novel insight into the process of skeletal muscle formation (Chapter 3).  
We misexpressed Mrfs and/or known cofactors in different avian embryonic stages and analysed 
the effects of genes expression by various molecular techniques such as in situ hybridisation and 
immunohistochemistry. The lack of Myosin upregulation following the misexpression of the Mrf 
constructs in HH4 embryos indicated that terminal muscle differentiation does not occur, 
therefore the protection of the stem cell state in the paraxial mesoderm is not overcome (Chapter 
5). Co-misexpression of the Mrfs with cofactors in HH16 embryos did not overcome the muscle 
stem cell state protection but did show upregulation of Mef2c and Mrf family member 
transcription in the first 18hr of incubation after the electroporation. The misexpression of MyoD 
and the combination of MyoD and MyoG showed upregulation of Myosin protein levels after 
42hrs of incubation, but these were the only combinations shown to be sufficient to change the 
phenotype of the targeted cells (Chapter 7). The reason for the observed lack of muscle 
differentiation was hypothesised to be due to the absence of myogenic co-factors. This 
hypothesis was tested with the misexpression of Mef2a and c and the use of Six1-GFP and Six1-
VP16 fusion constructs. Upregulation of Myosin levels were only seen following Six1-GFP 
individual misexpression however, this unexpected result could be qualified as an artefact due to 
altered function of the fusion protein. Previous reports have highlighted the role of Pax7 in the 
maintenance of muscle precursor (91,451). Normally, Pax3/7-positive skeletal muscle progenitor 
cells, which are derived from the central dermomyotome region of the somites (141,142), are 
either activated to differentiate into skeletal muscle fibres through the myogenic regulatory 
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genes, or remain as a proliferating reserve cell population within the muscle mass (142,297,451). 
The lack of induced differentiation could therefore be explained by immunohistochemistry results 
that show Pax7 protein levels persist after the electroporation of the Mrf constructs. If the cells 
are under tight control to the premature differentiation, the level of Pax7 protein must remain 
high until the correct moment, whereupon the cells would be able to differentiate. Additionally, 
miR-206 microRNA, which represses Pax7 translation levels at the point of muscle stem cell 
differentiation (230,452), was shown by in situ hybridisation not to be upregulated after the 
misexpression of the Mrfs. Together, this data confirming that high Pax7 protein levels persist 
after the electroporations could be explained by the active protection of precursor against 
immature differentiation.  
To evaluate the possible strategies for overcoming the protection of the muscle stem cell state we 
analysed the literature and found extensive data describing how the expression levels of cyclin 
inhibitors increase during differentiation of muscle precursor (438,427). Cyclin inhibitors force 
muscle precursor to withdraw from the cell cycle and differentiate into muscle cells (453). The 
analysis of Cdkn1b transcript levels in wild type HH14 embryos showed surprisingly strong levels 
of expression in the somites comparable with that of Myf5 and MyoD. We later discovered that 
misexpression of the Mrf constructs upregulated Cdkn1b mRNA levels. Consequently, we 
electroporated Cdkn1b individually and in collaboration with MyoD or MyoG but no combinations 
showed upregulation of Myosin expression levels.  
 
13.2 Mrfs may be negatively phosphoregulated to inhibit differentiation and/or 
require additional signals to promote differentiation 
The results so far reinforce the theory that muscle precursor present strong protection of their 
stem cell state that is difficult to overcome. Consideration of the literature for possible 
mechanisms of protection highlighted the importance of MyoD activation in growing Myoblasts 
through stabilisation by cyclin inhibitors (454). Conversely, phosphorylation by CDKs has been 
shown to inactivate MyoD (443,455). Kitzmann and colleagues showed that MyoD 
phosphorylation was higher in proliferative C2 Myoblasts but decreases during muscle 
differentiation. MyoD was subsequently shown to be phosphorylated at Serine 200 in vitro by 
Myoblast-derived Cdk1 and Cdk2 (443,456). Following this, a phospho-incompetent MyoD mutant 
(S200A) demonstrated great ability to convert 10T1/2 fibroblasts into muscle cells (443).  
The data in the literature therefore suggested that use of the phospho-incompetent murine 
constructs would upregulate muscle differentiation due to the constitutively active MyoD protein. 
Our results however, did not corroborate this hypothesis in vivo. This result could be explained by 
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the fact that our experiments were performed in vivo in contrast to the in vitro studies shown in 
the literature. Alternatively, the use of a heterologous host in our experiments (mouse proteins in 
chicken host) could mean that there is incompatibility between the murine and chicken phospho-
regulation of MyoD. Misexpression of the mutated murine MyoD construct was insufficient to 
enforce differentiation in chicken muscle precursor, but same experiment performed in xenopus 
showed ectopic expression of Myosin in the injected side. This could be explained by the fact that 
anamniote embryos require differentiated muscle cells early in development to allow the larvae 
to swim. This characteristic could allow the mouse constructs to easily upregulate the level of 
Myosin protein.  
The inability of the Mrfs to force myogenic differentiation in vivo may be due to the added 
complexity given by extrinsic signalling from neighbouring tissues not present in cell culture 
experiments. The Mrfs do not act alone but in collaboration with numerous genes and signalling 
cascades in which many include protein kinases, phosphorylating enzymes. Little is known about 
kinase activity in Myogenesis and the signalling pathways that regulate satellite cell quiescence 
and activation as well as myocyte fusion but it is likely that numerous kinases could be involved in 
regulation of the Mrfs. 
Kinase activity in Myogenesis is known to play a part in the formation of the myotube from a 
population of embryonic precursor cells or satellite cells (457,458). It has been shown that the 
presence of specific Wnt genes (Wnt1, Wnt7) can induce the activity of Protein Kinase A (PKA) 
thereby committing myogenic precursors to form a pool of dividing myoblasts (459). The presence 
of growth factors and other extrinsic components activate ERK1/2, Akt1 and cyclin D/CDK2, 4 and 
6 to promote proliferation which act together with PKA to block differentiation (459). Intrinsic cell 
cycle signals regulate the level of cycles A, B and E which together with the respective CDKs 
promote cell cycle progression, inhibiting differentiation. While myoblasts expand, their cell-cell 
contacts can switch off ERK which will silence cyclin D/CDK2,4 which inhibits additional 
proliferation (460). At this point, cell-cell contacts can activate p38 promoting differentiation. The 
activity of p38 is relocalised to the cytoplasm where it promotes differentiation (73,390,461). 
As MyoD is known to be phosphoregulated, detailed phosphorylation site mapping will need to be 
performed in order to fully understand the stoichiometry of the phosphoregulation and to reliably 
identify novel phosphosites. Such an approach would involve tandem mass spectrometry analysis 
of transgenic protein extracts (462). Verification of novel sites can then be performed by site-
directed mutagenesis on Mrf constructs to introduce phospho-incompetent or phosphomimetic 




13.3 Myogenesis of muscle stem cells in vivo may be under stronger epigenetic 
control than previously appreciated  
MyoD has been defined as a strong transcription factor able to bind the chromatin and induce 
transcription in the cell (332,337). This may be true in vitro but the data described in the previous 
chapters suggests that the same theory may not apply in vivo. Transcription activation requires 
remodelling of the strictly controlled chromatin structure which can only happen when a specific 
remodelling complex is formed ready to allow access to otherwise masked cis- acting elements 
(341,463).  
Kinases can directly regulate the chromatin-modifying complex (CMCs), by phosphorylating the 
individual components. p38 activity can be triggered in active satellite cells and has an important 
role in regeneration (80,464). p38 directly mediates the phosphorylation of E47 and the 
heterodimerisation between E47 and muscle proteins (390,465). Heterodimerisation of muscle 
proteins is required to facilitate binding to the E-Box sequence in the regulatory region of muscle 
genes. Phosphorylation of the Mef2 proteins causes the activation and recruitment of the protein 
Trithorax (TrxG) to the chromatin of the muscle genes thus promoting trimethylation of histone 3 
lysine-4 (H3K4me3) and subsequent transcription (466–468). The proteins Trithorax (TrxG) and 
Polycomb (PcG) have been shown to play an essential role in the control of chromatin remodelling 
and histone modification. Trithorax promotes the transcription of Pax7 in stem cell asymmetric 
division by the methylation of lysine 4 on histone 3 (H3K4me3), whilst Polycomb represses the Mrfs 
by methylation of lysine 27 on histone 3 (H3K27me3). During muscle formation, Polycomb and 
Thrithorax proteins help silence or activate various genes (467,468). 
Chromatin remodelling may be a limiting step in the progression of cell differentiation as the Mrfs 
cannot overcome the protection of the chromatin structure due to the unavailability of p38 at the 
early stage of muscle precursor differentiation (469).  
One of the most important chromatin remodelling complexes in muscle differentiation is the 
SWI/SNF complex (470,471). During differentiation, phosphorylated MyoD/E protein 
heterodimers together with the phosphorylated Mef2 will activate muscle-specific promoters. 
The SWI/SNF complex will recruit HATs and Trithorax which help the demethylation of the DNA 
and the chromatin is acetylated and consequently 'opened'. We hypothesise that this complex is 
not present in muscle precursor. Experimentally, this could be tested utilising Chromatin Immuno-
Precipitation (ChIP). An antibody against one of the subunits of the SWI/SNF complex, BAF60c 
could be used to isolate the DNA associated with these modification events (472,473). 
Unfortunately there is not an antibody available that we could use in chicken. 
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Investigation into the state of the chromatin by using (ChIP) would help reveal the state of the 
chromatin associated with the muscle genes and other genes of interest by utilising antibodies 
specific to modifications known to be associated with active/repressed genes. This protocol could 
be applied to differentially evaluate the chromatin state as a result of construct misexpression. 
Additionally, a similar strategy of co-immunoprecipitating misexpressed proteins could be used to 
ascertain which if any of their target promoters they are binding to. During the electroporations 
at HH16, we know that Pax7 protein is expressed in the somite but none of the Mrf genes are 
present at this stage. Analysis of the chromatin state associated with muscle-specific genes could 
be performed in order to understand which genes are likely expressed at this stage of 
development. Experimentally, this would involve dissecting somites and performing ChIP 
experiments using antibodies against histone modifications associated with open or closed 
chromatin states. We could use a antibody raised against  H3K4me3 this will indicate the open state 
of the chromatin while the closed state will be analyse with an antibody detecting H3K27me3. We 
hypothesise that the myosin and troponin1 structural genes are likely to be associated with closed 
chromatin given that misexpressed Mrf proteins were shown to be unsuccessful in upregulating 
these genes. 
We hypothesise that the individual misexpression of Polycomb and Trithorax constructs in HH16 
somites, or with MyoD or other cofactors like Six1 of Mef2C could induce a change in the 
structure of the chromatin. Unfortunately, the use of these affinity orientated protocols requires 
an antibody or similar affinity molecule to allow enrichment of the target protein from cell 
extracts. As discussed before, there are currently no available antibodies for chicken Mrfs. We 
also decided to avoid the use of epitope tags for affinity recognition to avoid any inadvertent 
modulation of activity, especially as we have predicted a potential C-terminal protein domain for 
phosphoregulation present in MyoD (Chapter 12). Therefore, before employing these protocols 
antibodies would have to be raised by injecting purified protein/peptide into mammals and 
extracting the antiserum. Alternative approaches include the use of phage display for generating 
synthetic antibody fragments (474) or the use of SELEX (systematic evolution of ligands by 
exponential enrichment) for generating high affinity aptamers, also shown to be useful in protein 
detection in tissues (aptahistochemistry,(475)). 
13.4 Negative feedback mechanisms: premature presence of Mrfs may upregulate 
the Notch-Delta system of lateral inhibition 
The stem cell state protection may not be confined to just the somites themselves but may be 
regulated by a universal signal that controls and maintains stem cells. As described in Chapter 1, 
Notch and Delta signalling control the premature differentiation of myoblasts. In mouse C2C12 
myoblast cell lines, constitutively activated Notch delays the expression of the myogenic 
302 
 
differentiation markers MyoD and MyoG (476). The forced activation of Notch in vivo using 
chicken caused the overexpression of Delta that delayed muscle stem cell differentiation (119). 
Other experiments have shown that the activation of Notch can cause the downregulation of 
MyoD, detected in cells which are withdrawing from the cell cycle, but not Pax7 or Myf5, 
expressed in proliferating myogenic precursor cells (96). The presence and activity of Notch-Delta 
could influence the misexpression of the Mrf genes in the somites. We hypothesised that the 
electroporation of the myogenic factors in young somites could cause a feedback mechanism 
activating the Notch Delta signalling that detect premature expression of the myogenic genes, and 
subsequently repressing them. This could provide further explanation of why we didn't observe 
any change in Myosin expression during the time frame between development stages HH16 to 
HH20 in vivo. To test if this is indeed the case, Mrf misexpression coupled with loss of function 
experiments by the application of morpholino antisense oligonucleotides to knock down the 
Notch-Delta system may recover the Mrf activity (477) 
13.5 Summary 
In our study we found that muscle precursor are actively protected from prematurely entering 
differentiation. The misexpression of Mrfs in vivo individually or with other co-factors does not 
influence the expression levels of Myosin in the first 18hrs of incubation after electroporation. 
Surprisingly the expression of MyoD and the co-electroporation of MyoD and MyoG were shown 
to have an effect on Myosin expression after 42hrs of incubation. The time frame of protection 
that we observed appeared to diminish as we were able to change the Myosin expression levels in 
the later stages of development only. 
A possible explanation for this observed time frame is that there is insufficient time for the Mrf 
transgenes to induce early MF20 expression. This could be evidenced by the absence of MF20 
expression after 18 hrs whilst there is expression after 42 hrs. However, this is not likely to be the 
case as the Sx1-GFP experiment demonstrated that it is possible to induce early MF20 expression 
in the 18hr time frame. We therefore hypothesise that the likely reason that Mrf transgenes do 
not induce early MF20 expression after 18hrs is that the cells are protected from premature 
differentiation by Mrfs.  
 It is possible that at the more mature stages of somite development, Trithorax and Polycomb 
proteins allow the transcription factor MyoD to bind the chromatin and induce transcription, 
causing upregulation of Myosin in the area of transgene expression.  
We hypothesise that the main genes that keep the cells in an undifferentiated state are those 
involved in chromatin remodeling such as SWI/SNF, Polycomb and p300. All of these complexes 
have been shown to be regulated by the retinoblastoma protein pRb, which is not present at this 
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stage of muscle development. pRb is therefore also a potential candidate for inhibiting cells from 
progressing in differentiation.  
Future work is needed to investigate this time frame hypothesis further and to verify other 
aspects of our hypotheses including the state of the chromatin and the extrinsic factors 
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12 Appendix 1. A-E Chordate Mrf protein alignments. 
(A-D) Protein alignments of gnathostome Mrf proteins and (E) alignment of selected gnathostome proteins together with further deuterostome Mrf proteins, proteins 
are displayed in one letter code. The basic domain is shaded blue, the helix-loop-helix domain green and, where a Myf5 domain is present, this is shaded in pink. The 
position of exon boundaries are indicated by arrowheads on top of the set of sequences. Conserved amino acids at the N-terminus are indicated by brackets, 
conservation of the C-terminus is indicated by arrows. 







Appendix 1. A Gnathostome Myf5 proteins. 
Protein alignment of gnathgostome Myf5 proteins. Note that for chicken Myf5, the RNAseq-derived and genomic sequences differ from the curated protein sequence at 2 positions (black 
boxes), with the RNAseq-derived and genomic sequences matching the sequences of other amniotes. Thus, the curated sequence was deemed unreliable, and the RNAseq-derived/ 
genomic sequences were used for construct design. 
Also note the conserved N-terminus that yields the start of the basic domain and the conserved C-terminus (arrows). To not interfere with the function of these sequences, we designed 
















Appendix 1. B Gnathostome MyoD proteins. 
Protein alignment of gnathostome MyoD proteins. Note that the teleost MyoD sequences fall into two groups, which are consistent with their location at either the first or second MyoD 
locus. The currently available chicken MyoD sequences differ at 7 positions (black boxes); most notably the conserved proline and the histidine-stretch in the centre of the basic domain is 
represented in the RNAseq and genome- derived, but not the curated MyoD sequence. The protein termini are conserved (N-terminus: bracket; C-terminus: arrows). We thus decided to 










Appendix 1. C Gnathostome MyoG proteins. 
Protein alignment of gnathostome MyoG proteins. Note the proteins do not have a Myf5 domain. The C-termini differ from those of Myf5 and MyoD, but are nevertheless highly 
conserved in diapsid (saurian) amniotes. The N-termini are also conserved. The chicken MyoG sequences we found were identical and matched the related amniote sequences. Thus, 









Appendix 1. D Gnathostome Mrf4 proteins. 
Protein alignment of gnathostome Mrf4=Myf6 proteins. Note also these proteins do not have a Myf5 domain, but their N-termini (bracket) and in amniotes also their C-termini (arrows) 




























Appendix 1. E Select gnathostome, agnathan and deuterostome invertebrate Mrf proteins. 
Note the high degree of conservation of the basic and helix-loop-helix domains. A Myf5 domain is only present in Myf5 and MyoD proteins. However, the C-terminus of this domain is 
also recognisable in gnathostome MyoG and Mrf4, in agnathan Mrf and the Mrf of the deuterostome invertebrates shown here. The typical gnathostome Mrf N-terminus is present in the 
hagfish Mrf sequences and possibly in the Ciona sequence (depending on the actual translational start site; the predicted start site is further upstream). A variation of the C-terminal 
sequence typical for gnathostome Myf5/MyoD is present in the hagfish Mrf protein, suggesting that this sequence was secondarily lost in gnathostome MyoG and Mrf4. Interestingly, the 
first splice site shifted significantly in Myf5/MyoD compared to MyoG/Mrf4, possibly contributing to the subfunctionalisation of the proteins. 
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Appendix 2. A Myf5 cDNA, primers and synthesis products. 
Alignment of the chicken Myf5 UTR sequences extracted from Ensembl, the RNAseq sequence on which the 
construct is based, the open reading frame (orf), the orf equipped with the Kozak sequence, the cloning 
primers and the re-sequenced Life Technology product cloned into pCab, indicating that the desired 














Appendix 2. B MyoD cDNA, primers and synthesis products. 
Alignment of the curated chicken MyoD cDNA, the RNAseq sequence on which the construct is based, the 
open reading frame (orf), the orf equipped with the Kozak sequence, the cloning primers and the re-














Appendix 2. C MyoG cDNA, primers and synthesis products. 
Alignment of the chicken MyoG 5’UTR sequences extracted from Ensembl, the curated and RNAseq derived 
cDNAs that all produce the same open reading frame (orf), the orf alone and equipped with the Kozak 
sequence, the cloning primers and the re-sequenced Life Technology product cloned into pCab. The desired 











Appendix 2. D Mrf4 cDNA, primers and synthesis products. 
Alignment of the chicken Mrf4 5’UTR sequences extracted from Ensembl, the curated and RNAseq derived 
cDNAs that all produce the same open reading frame (orf), the orf alone and equipped with the Kozak 
sequence, the cloning primers and the re-sequenced Life Technology product cloned into pCab. The desired 
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